Vorinostat (SAHA)

Name: Vorinostat (SAHA)
Brand: Selleck Chemicals
SKU: S1047
Rating: 5 (318 reviews)

For research use only.

Catalog No.S1047 Synonyms: MK0683

318 publications

CAS No. 149647-78-9

Vorinostat (suberoylanilide hydroxamic acid, SAHA, MK0683) is an HDAC inhibitor with IC50 of ~10 nM in a cell-free assay. Vorinostat abrogates productive HPV-18 DNA amplification.

Selleck's Vorinostat (SAHA) has been cited by 318 publications

Nat Biotechnol, 2020, 10.1038/s41587-019-0388-4

PubMed: 31959954 ( click the link to review the publication )

Cancer Cell, 2020, 13;37(4):599-617 e7

PubMed: 32243837 ( click the link to review the publication )

Cell, 2019, 176(1-2):198-212

PubMed: 30503211 ( click the link to review the publication )

Cell, 2019, 36(2):179-193

PubMed: 28162770 ( click the link to review the publication )

Cancer Cell, 2019, 36(2):179-193

PubMed: 31378681 ( click the link to review the publication )

Cell, 2018, 174(3):536-548.e21

PubMed: 29961578 ( click the link to review the publication )

Cell Metab, 2018, 5;27(6):1294-1308.e7

PubMed: 29754954 ( click the link to review the publication )

Nature, 2017, 551(7679):247-250

PubMed: 29088702 ( click the link to review the publication )

Cancer Discov, 2017, 7(12):1450-1463

PubMed: 28963352 ( click the link to review the publication )

Cancer Cell, 2016, 29(3):311-323

PubMed: 26977882 ( click the link to review the publication )

Nat Biotechnol, 2015, 10.1038/nbt.3130

PubMed: 25751058 ( click the link to review the publication )

Nat Med, 2015, 21(10):1163-71

PubMed: 26390243 ( click the link to review the publication )

Nat Med, 2015, 10.1038/nm.3855

PubMed: 25939062 ( click the link to review the publication )

Cell, 2014, 28;158(5):989-999.

PubMed: 25131989 ( click the link to review the publication )

Nature, 2011, 10;471(7337):235-9.

PubMed: 21390130 ( click the link to review the publication )

Nat Biotechnol, 2011, 29(3):255-65

PubMed: 21258344 ( click the link to review the publication )

Nucleic Acids Res, 2020, 10.1093/nar/gkaa088

PubMed: 32107550 ( click the link to review the publication )

EMBO Rep, 2020, 21:e50162

PubMed: 32314873 ( click the link to review the publication )

J Immunother Cancer, 2020, 8(1)

PubMed: 31940587 ( click the link to review the publication )

Theranostics, 2020, 1;10(3):1433-1453

PubMed: 31938073 ( click the link to review the publication )

Cancer, 2020, 1;126(9):2024-2033

PubMed: 31999837 ( click the link to review the publication )

PLoS Pathog, 2020, 16;16(3):e1008341

PubMed: 32176725 ( click the link to review the publication )

Clin Epigenetics, 2020, 12(1):13

PubMed: 31941522 ( click the link to review the publication )

Br J Cancer, 2020, 27

PubMed: 32336756 ( click the link to review the publication )
Front Cell Dev Biol, 2020, 17;8:158

PubMed: 32258036 ( click the link to review the publication )

J Neuroinflammation, 2020, 22;17(1):125

PubMed: 32321538 ( click the link to review the publication )

ACS Infect Dis, 2020, 29

PubMed: 32347704 ( click the link to review the publication )

Mol Cancer Res, 2020, 10.1158/1541-7786.MCR-19-0669

PubMed: 32238439 ( click the link to review the publication )

Front Oncol, 2020, 10:296

PubMed: 32195191 ( click the link to review the publication )

J Virol, 2020, 4;94(10) pii: e01923-19

PubMed: 32161174 ( click the link to review the publication )

Biochem Pharmacol, 2020, 3;178:114067

PubMed: 32504550 ( click the link to review the publication )

Cancer Cell Int, 2020, 19;20:58

PubMed: 32099531 ( click the link to review the publication )

BMC Microbiol, 2020, 20(1):28

PubMed: 32028887 ( click the link to review the publication )

PLoS One, 2020, 15;15(5):e0232985

PubMed: 32413049 ( click the link to review the publication )

Sci Rep, 2020, 10(1):12864

PubMed: 32733053 ( click the link to review the publication )

Oncol Lett, 2020, 19(1):460-468

PubMed: 31897159 ( click the link to review the publication )

Sci Adv, 2020, 6(29):eaba1941

PubMed: 32832623 ( click the link to review the publication )

Colloids Surf B Biointerfaces, 2020, 188:110753

PubMed: 31884084 ( click the link to review the publication )

Acta Pharm Sin B, 2020, 10(4):615-627

PubMed: 32322466 ( click the link to review the publication )

Cancer Sci, 2020, 111(7):2374-2384

PubMed: 32391602 ( click the link to review the publication )

Oncogene, 2020, 10.1038/s41388-020-01394-w

PubMed: 32709923 ( click the link to review the publication )

Oncogene, 2020, 10.1038/s41388-020-01408-7

PubMed: 32733069 ( click the link to review the publication )

Mol Cancer Ther, 2020, 19(2):637-649

PubMed: 31784455 ( click the link to review the publication )

Genes Dev, 2020, 34(5-6):428-445

PubMed: 32001510 ( click the link to review the publication )

Cancer Manag Res, 2020, 12:4429-4439

PubMed: 32606937 ( click the link to review the publication )

Biomater Sci, 2020, 10.1039/d0bm00119h

PubMed: 32706009 ( click the link to review the publication )

Cell Cycle, 2020, 1-16

PubMed: 32807015 ( click the link to review the publication )

Life Sci, 2020, 248:117469

PubMed: 32109485 ( click the link to review the publication )
Chin Med J (Engl), 2020, 5;133(11):1304-1311

PubMed: 32452893 ( click the link to review the publication )

Pharm Biol, 2020, 58(1):231-238

PubMed: 32202448 ( click the link to review the publication )

Nat Commun, 2019, 10(1):4192

PubMed: 31519896 ( click the link to review the publication )

J Pineal Res, 2019, 66(3):e12556

PubMed: 30648757 ( click the link to review the publication )

Haematologica, 2019, 10.3324/haematol.2018.211110

PubMed: 30846494 ( click the link to review the publication )

Haematologica, 2019, 104(11):2225-2240

PubMed: 30819918 ( click the link to review the publication )

Theranostics, 2019, 9(2):540-553

PubMed: 30809292 ( click the link to review the publication )

Cancer Res, 2019, 79(7):1658-1670

PubMed: 30737231 ( click the link to review the publication )

Cell Rep, 2019, 27(11):3331-3344

PubMed: 31189115 ( click the link to review the publication )

Elife, 2019, 8

PubMed: 30652970 ( click the link to review the publication )

Mol Ther, 2019, 27(5):1039-1050

PubMed: 30852137 ( click the link to review the publication )

Cancers (Basel), 2019, 11(4)

PubMed: 30935067 ( click the link to review the publication )

Clin Epigenetics, 2019, 11(1):85

PubMed: 31142371 ( click the link to review the publication )

Acta Pharm Sin B, 2019, 9(5):937-951

PubMed: 31649844 ( click the link to review the publication )

Cells, 2019, 8(12)

PubMed: 31795298 ( click the link to review the publication )

Cancer Discov, 2019, 9(4):526-545

PubMed: 30709805 ( click the link to review the publication )

Front Immunol, 2019, 9:3162

PubMed: 30723480 ( click the link to review the publication )

Mol Cancer Ther, 2019, 18(5):900-908

PubMed: 30824609 ( click the link to review the publication )

Mol Oncol, 2019, 10.1002/1878-0261.12607

PubMed: 31782885 ( click the link to review the publication )

Epigenetics, 2019, 10.1080/15592294.2019.1656155

PubMed: 31423895 ( click the link to review the publication )

Epigenetics, 2019, 14(8):791-803

PubMed: 31088315 ( click the link to review the publication )

Epigenetics, 2019, 10.1080/15592294.2019.1656156

PubMed: 31423932 ( click the link to review the publication )

AIDS, 2019, 33(2):199-209

PubMed: 30562171 ( click the link to review the publication )

Hum Mol Genet, 2019, 10.1093/hmg/ddz254

PubMed: 31691806 ( click the link to review the publication )
Pharmacol Res, 2019, 139:524-534

PubMed: 30366100 ( click the link to review the publication )

Pharmacol Res, 2019, 146:104281

PubMed: 31125601 ( click the link to review the publication )

J Neurochem, 2019, 10.1111/jnc.14935

PubMed: 31811660 ( click the link to review the publication )

Mol Pharm, 2019, 16(9):3904-3915

PubMed: 31318566 ( click the link to review the publication )

Bone, 2019, 125:112-121

PubMed: 31100533 ( click the link to review the publication )

Front Cell Neurosci, 2019, 13:468

PubMed: 31708743 ( click the link to review the publication )

Int J Mol Sci, 2019, 20(13)

PubMed: 31269745 ( click the link to review the publication )

Apoptosis, 2019, 24(5-6):404-413

PubMed: 30997620 ( click the link to review the publication )

J Biol Chem, 2019, 294(12):4437-4449

PubMed: 30670592 ( click the link to review the publication )

Acta Pharmacol Sin, 2019, 40(5):677-688

PubMed: 30224636 ( click the link to review the publication )

NMR Biomed, 2019, 32(2):e4044

PubMed: 30561869 ( click the link to review the publication )

Stem Cells Dev, 2019, 28(7):438-453

PubMed: 30667343 ( click the link to review the publication )

Chem Biol Interact, 2019, 306:54-61

PubMed: 30958996 ( click the link to review the publication )

Gene Ther, 2019, 26(3-4):75-85

PubMed: 30538307 ( click the link to review the publication )

Cancer Med, 2019, 8(14):6383-6392

PubMed: 31456359 ( click the link to review the publication )

Tuberculosis (Edinb), 2019, 118:101861

PubMed: 31526947 ( click the link to review the publication )

PLoS One, 2019, 14(6):e0218382

PubMed: 31206526 ( click the link to review the publication )

Exp Hematol, 2019, 72:60-71

PubMed: 30769020 ( click the link to review the publication )

Nucl Med Biol, 2019, 74-75:1-11

PubMed: 31421440 ( click the link to review the publication )

Alcohol, 2019, 78:79-87

PubMed: 30851364 ( click the link to review the publication )

Anticancer Res, 2019, 39(7):3579-3584

PubMed: 31262882 ( click the link to review the publication )

Res Vet Sci, 2019, 126:207-212

PubMed: 31610471 ( click the link to review the publication )

Exp Ther Med, 2019, 17(6):4547-4553

PubMed: 31186678 ( click the link to review the publication )

Medicina (Kaunas), 2019, 55(2)

PubMed: 30700046 ( click the link to review the publication )
Cell Host Microbe, 2018, 24(5):689-702

PubMed: 30344003 ( click the link to review the publication )

Nat Commun, 2018, 13;9(1):2720

PubMed: 30006524 ( click the link to review the publication )

Clin Cancer Res, 2018, 24(16):3941-3954

PubMed: 29764852 ( click the link to review the publication )

Cancer Res, 2018, 78(10):2705-2720

PubMed: 29490948 ( click the link to review the publication )

J Control Release, 2018, 275:117-128

PubMed: 29474960 ( click the link to review the publication )

Haematologica, 2018, 103(4):679-687

PubMed: 29305415 ( click the link to review the publication )

J Hematol Oncol, 2018, 11(1):32

PubMed: 29486795 ( click the link to review the publication )

Cancer Lett, 2018, 432:121-131

PubMed: 29890207 ( click the link to review the publication )

Acta Biomater, 2018, 71:261-270

PubMed: 29526828 ( click the link to review the publication )

Sci Signal, 2018, 11(557)

PubMed: 30459282 ( click the link to review the publication )

J Exp Clin Cancer Res, 2018, 37(1):153

PubMed: 30012171 ( click the link to review the publication )

Mol Cancer Ther, 2018, 17(12):2767-2779

PubMed: 30232145 ( click the link to review the publication )

J Virol, 2018, 92(10)

PubMed: 29343578 ( click the link to review the publication )

J Virol, 2018, 92(6)

PubMed: 29298886 ( click the link to review the publication )

J Cell Mol Med, 2018, 22(5):2600-2611

PubMed: 29461008 ( click the link to review the publication )

Sci Rep, 2018, 8(1):3521

PubMed: 29476067 ( click the link to review the publication )

Front Microbiol, 2018, 9:2022

PubMed: 30283406 ( click the link to review the publication )

J Cell Biochem, 2018, 119(5):4193-4204

PubMed: 29274289 ( click the link to review the publication )

Retrovirology, 2018, 15(1):36

PubMed: 29751762 ( click the link to review the publication )

Exp Cell Res, 2018, 371(1):231-237

PubMed: 30107147 ( click the link to review the publication )

BMC Cancer, 2018, 18(1):466

PubMed: 29695239 ( click the link to review the publication )

Oncol Rep, 2018, 39(1):264-270

PubMed: 29115632 ( click the link to review the publication )

Ann Hematol, 2018, 97(5):839-849

PubMed: 29359239 ( click the link to review the publication )

Biochem Biophys Res Commun, 2018, 498(3):481-486

PubMed: 29505792 ( click the link to review the publication )
AAPS PharmSciTech, 2018, 19(2):634-647

PubMed: 28948528 ( click the link to review the publication )

Cell Biochem Funct, 2018, 36(8):398-407

PubMed: 30484863 ( click the link to review the publication )

Alcohol Clin Exp Res, 2018, 42(11):2160-2171

PubMed: 30103280 ( click the link to review the publication )

Sci Adv, 2018, 4(9):eaar4666

PubMed: 30263952 ( click the link to review the publication )

Nat Struct Mol Biol, 2017, 24(1):47-54

PubMed: 27870832 ( click the link to review the publication )

Clin Cancer Res, 2017, 23(12):3139-3149

PubMed: 27986747 ( click the link to review the publication )

Haematologica, 2017, 102(4):736-745

PubMed: 27979926 ( click the link to review the publication )

Clin Cancer Res, 2017, 23(12):3084-3096

PubMed: 27993968 ( click the link to review the publication )

Oncogene, 2017, 36(34):4859-4874

PubMed: 28414307 ( click the link to review the publication )

Oncogene, 2017, 36(12):1707-1720

PubMed: 27694895 ( click the link to review the publication )

Br J Pharmacol, 2017, 174(20):3608-3622

PubMed: 28749535 ( click the link to review the publication )

Eur J Med Chem, 2017, 127:531-553

PubMed: 28109947 ( click the link to review the publication )

Eur J Med Chem, 2017, 141:596-602

PubMed: 29102179 ( click the link to review the publication )

Cancer Sci, 2017, 108(7):1485-1492

PubMed: 28498513 ( click the link to review the publication )

Int J Mol Sci, 2017, 18(5)

PubMed: 28481295 ( click the link to review the publication )

J Biol Chem, 2017, 292(12):5043-5054

PubMed: 28167529 ( click the link to review the publication )

J Pharmacol Exp Ther, 2017, 363(2):211-220

PubMed: 28860353 ( click the link to review the publication )

Pharm Res, 2017, 34(3):668-679

PubMed: 28101809 ( click the link to review the publication )

Cancer Med, 2017, 6(11):2673-2685

PubMed: 29024573 ( click the link to review the publication )

Int J Cell Biol, 2017, 2017:6169310

PubMed: 28321257 ( click the link to review the publication )

Connect Tissue Res, 2017, 58(1):64-75

PubMed: 27404795 ( click the link to review the publication )

Pulm Pharmacol Ther, 2017, 44:88-95

PubMed: 28323055 ( click the link to review the publication )

Am J Surg, 2017, 213(4):645-651

PubMed: 28007318 ( click the link to review the publication )

Oncotarget, 2017, 8(28):45687-45697

PubMed: 28537899 ( click the link to review the publication )
Oncotarget, 2017, 9(1):512-523

PubMed: 29416632 ( click the link to review the publication )

Oncotarget, 2017, 8(31):51429-51446

PubMed: 28881658 ( click the link to review the publication )

CPT Pharmacometrics Syst Pharmacol, 2017, 6(11):756-764

PubMed: 29045072 ( click the link to review the publication )

Sci Rep, 2017, 7(1):2290

PubMed: 28536458 ( click the link to review the publication )

Oncotarget, 2017, 8(45):78480-78495

PubMed: 29108243 ( click the link to review the publication )

JCI Insight, 2017, 2(1):e85811

PubMed: 28097226 ( click the link to review the publication )

JCI Insight, 2017, 2(6):e90196

PubMed: 28352655 ( click the link to review the publication )

Oncotarget, 2017, 10.18632/oncotarget.15017

PubMed: 28157715 ( click the link to review the publication )

Oncotarget, 2017, 8(44):77254-77267

PubMed: 29100385 ( click the link to review the publication )

Cell Host Microbe, 2017, 21(5):569-579

PubMed: 28494238 ( click the link to review the publication )

Ann Oncol, 2016, 27(3):508-13

PubMed: 26658891 ( click the link to review the publication )

Nat Commun, 2016, 7:11363

PubMed: 27193833 ( click the link to review the publication )

Cancer Res, 2016, 76(23):7001-7011

PubMed: 27671680 ( click the link to review the publication )

Cancer Res, 2016, 76(8):2376-83

PubMed: 26941288 ( click the link to review the publication )

Int J Cancer, 2016, 139(1):194-204

PubMed: 26914605 ( click the link to review the publication )

Drug Discov Today, 2016, 21(9):1553-1560

PubMed: 27371506 ( click the link to review the publication )

mBio, 2016, 7(6)

PubMed: 27803184 ( click the link to review the publication )

J Med Chem, 2016, 59(4):1613-33

PubMed: 26681404 ( click the link to review the publication )

Mol Cancer Ther, 2016, 15(6):1364-75

PubMed: 27196750 ( click the link to review the publication )

Mol Cell Proteomics, 2016, 15(6):2076-92

PubMed: 27067055 ( click the link to review the publication )

Neuropharmacology, 2016, 107:111-121

PubMed: 26970016 ( click the link to review the publication )

Biochem Pharmacol, 2016, 102:130-140

PubMed: 26718586 ( click the link to review the publication )

Sci Rep, 2016, 6:38219

PubMed: 27910887 ( click the link to review the publication )

Am J Pathol, 2016, 186(10):2701-8

PubMed: 27555113 ( click the link to review the publication )
J Biol Chem, 2016, 291(19):10131-47

PubMed: 27022024 ( click the link to review the publication )

Neurochem Int, 2016, 96:24-31

PubMed: 27103167 ( click the link to review the publication )

Int J Oncol, 2016, 49(6):2453-2463

PubMed: 27748897 ( click the link to review the publication )

Am J Physiol Heart Circ Physiol, 2016, 311(5):H1139-H1149

PubMed: 27638876 ( click the link to review the publication )

Cancer Biol Ther, 2016, 17(1):27-35

PubMed: 26575826 ( click the link to review the publication )

Anal Bioanal Chem, 2016, 408(13):3547-53

PubMed: 26968571 ( click the link to review the publication )

BMC Cancer, 2016, 16:667

PubMed: 27549189 ( click the link to review the publication )

J Hum Genet, 2016, 10.1038/jhg.2016.61

PubMed: 27251006 ( click the link to review the publication )

Med Oncol, 2016, 33(2):11

PubMed: 26732474 ( click the link to review the publication )

Inflammation, 2016, 39(1):39-46

PubMed: 26228975 ( click the link to review the publication )

PLoS One, 2016, 11(8):e0160826

PubMed: 27536989 ( click the link to review the publication )

PLoS One, 2016, 11(1):e0145985

PubMed: 26726879 ( click the link to review the publication )

Onco Targets Ther, 2016, 9:6843-6855

PubMed: 27877053 ( click the link to review the publication )

Leuk Lymphoma, 2016, 57(3):692-9

PubMed: 26084206 ( click the link to review the publication )

Asian Pac J Trop Med, 2016, 9(6):572-6

PubMed: 27262069 ( click the link to review the publication )

Genet Mol Res, 2016, 15(4)

PubMed: 27819724 ( click the link to review the publication )

Oncotarget, 2016, 8(62):104733-104744

PubMed: 29285209 ( click the link to review the publication )

Oncotarget, 2016, 7(36):58142-58147

PubMed: 27494885 ( click the link to review the publication )

Sci Rep, 2016, 6:21678

PubMed: 26902929 ( click the link to review the publication )

Oncotarget, 2016, 7(6):6727-47

PubMed: 26734995 ( click the link to review the publication )

Nat Commun, 2015, 6:7888

PubMed: 26223951 ( click the link to review the publication )

Nat Commun, 2015, 3;6:10091

PubMed: 26631872 ( click the link to review the publication )

EMBO Mol Med, 2015, 10.15252/emmm.201404396

PubMed: 25872941 ( click the link to review the publication )

EMBO Mol Med, 2015, 10.15252/emmm.201404580

PubMed: 25759362 ( click the link to review the publication )
Clin Cancer Res, 2015, 10.1158/1078-0432.CCR-14-2701

PubMed: 25813020 ( click the link to review the publication )

Clin Cancer Res, 2015, 21(7):1628-38

PubMed: 25623213 ( click the link to review the publication )

Blood Cancer J, 2015, 5:e312

PubMed: 25978432 ( click the link to review the publication )

Int J Cancer, 2015, 136(11):2717-29

PubMed: ( click the link to review the publication )

EBioMedicine, 2015, 3:108-121

PubMed: 26870822 ( click the link to review the publication )

Cancer Lett, 2015, 356(2 Pt B):828-36

PubMed: 25449774 ( click the link to review the publication )

Cancer Lett, 2015, 366(1):32-43

PubMed: 26028172 ( click the link to review the publication )

Breast Cancer Res, 2015, 17:33

PubMed: 25888415 ( click the link to review the publication )

Cell Death Dis, 2015, 6:e1657

PubMed: 25695609 ( click the link to review the publication )

Acta Neuropathol Commun, 2015, 3(1):22

PubMed: 25853389 ( click the link to review the publication )

Endocr Relat Cancer, 2015, 22(5):777-92

PubMed: 26206775 ( click the link to review the publication )

Br J Haematol, 2015, 168(3):371-83

PubMed: ( click the link to review the publication )

Epigenetics, 2015, 10.1080/15592294.2015.1039216

PubMed: 25923331 ( click the link to review the publication )

Am J Cancer Res, 2015, 5(4):1337-52

PubMed: 26101701 ( click the link to review the publication )

Neuropharmacology, 2015, 99:67-78

PubMed: 26188143 ( click the link to review the publication )

Biochemical Pharmacology, 2015, 94(2):79-90

PubMed: ( click the link to review the publication )

Biochem Pharmacol, 2015, 94(2):79-90

PubMed: 25600908 ( click the link to review the publication )

Biochemical Pharmacology, 2015, 94(2):79-90

PubMed: ( click the link to review the publication )

Apoptosis, 2015, 20(7):975-85

PubMed: 25835755 ( click the link to review the publication )

J Biol Chem, 2015, 290(8):5028-40

PubMed: 25540204 ( click the link to review the publication )

J Biol Chem, 2015, 290(39):23725-37

PubMed: 26269591 ( click the link to review the publication )

J Biol Chem, 2015, 290(3):1829-36

PubMed: 25492871 ( click the link to review the publication )

J Biol Chem, 2015, 290(8):5028-40

PubMed: ( click the link to review the publication )

BMC Cancer, 2015, 15(1):273

PubMed: 25880212 ( click the link to review the publication )
FEBS Lett, 2015, 589(10):1080-8

PubMed: 25816750 ( click the link to review the publication )

J Biotechnol, 2015, 10.1016/j.jbiotec.2015.02.029

PubMed: 25746901 ( click the link to review the publication )

Mol Vis, 2015, 21:502-14

PubMed: 25999677 ( click the link to review the publication )

Mol Med Rep, 2015, 12(3):4291-4297

PubMed: 26095064 ( click the link to review the publication )

Oncotarget, 2015, 6(18):15814-27

PubMed: 26158412 ( click the link to review the publication )

Circ Heart Fail, 2015, 8(6):1094-104

PubMed: 26371176 ( click the link to review the publication )

Sci Transl Med, 2014, 6(256):256ra135

PubMed: 25273096 ( click the link to review the publication )

Acta Neuropathol, 2014, 128(2):291-303

PubMed: 24839957 ( click the link to review the publication )

Nat Commun, 2014, 5:3361

PubMed: 24553445 ( click the link to review the publication )

Clin Cancer Res, 2014, 10.1158/1078-0432.CCR-14-0384

PubMed: 25355930 ( click the link to review the publication )

Int J Cancer, 2014, 135(7):1721-32

PubMed: 24615207 ( click the link to review the publication )

Diabetes, 2014, 63(9):2924-34

PubMed: 24722245 ( click the link to review the publication )

Oncogene, 2014, 33(25):3307-15

PubMed: 23995789 ( click the link to review the publication )

Cancer Lett, 2014, 10.1016/j.canlet.2014.10.034

PubMed: ( click the link to review the publication )

Cancer Lett, 2014, 351(1):50-8

PubMed: 24814395 ( click the link to review the publication )

PLoS Pathog, 2014, 10(4):e1004071

PubMed: 24722454 ( click the link to review the publication )

Cell Death Dis, 2014, 5:e1134

PubMed: 24651437 ( click the link to review the publication )

Cell Death Dis, 2014, 5:e1177

PubMed: 24743732 ( click the link to review the publication )

Mol Cancer Ther, 2014, 13(12):2784-92

PubMed: 25319394 ( click the link to review the publication )

J Mol Biol, 2014, 426(20):3442-53

PubMed: 24657767 ( click the link to review the publication )

Hum Gene Ther, 2014, 25(7):599-608

PubMed: 24568341 ( click the link to review the publication )

J Biol Chem, 2014, 289(14):9918-25

PubMed: 24515107 ( click the link to review the publication )

Cancer Cell Int, 2014, 10.1186/s12935-014-0112-x

PubMed: ( click the link to review the publication )

Cancer Cell Int, 2014, 14(1):112

PubMed: 25546354 ( click the link to review the publication )
Mol Cell Biol, 2014, 34(7):1280-9

PubMed: 24469401 ( click the link to review the publication )

Proteomics Clin Appl, 2014, 8(11-12):924-31

PubMed: 25091122 ( click the link to review the publication )

J Alzheimers Dis, 2014, 41(4):1193-205

PubMed: 24844691 ( click the link to review the publication )

Virology, 2014, 462-463:328-39

PubMed: 25014309 ( click the link to review the publication )

Cancer Biol Ther, 2014, 15(5):578-85

PubMed: 24556916 ( click the link to review the publication )

BMC Cancer, 2014, 14(1):373

PubMed: 24886166 ( click the link to review the publication )

FEBS Lett, 2014, 588(9):1571-9

PubMed: 24607544 ( click the link to review the publication )

Mol Med Rep, 2014, 10(5):2729-35

PubMed: 25199623 ( click the link to review the publication )

Oncol Lett, 2014, 7(5):1673-1678

PubMed: 24765199 ( click the link to review the publication )

Pharmacol Res Perspect, 2014, 2(3):e00043

PubMed: 25505589 ( click the link to review the publication )

Head Neck, 2014, 10.1002/hed.23822.

PubMed: 24986420 ( click the link to review the publication )

Cytometry A, 2014, 85(1):78-87

PubMed: 24038859 ( click the link to review the publication )

Curr Pharm Desigh, 2014, 20(11):1874-80

PubMed: 23888956 ( click the link to review the publication )

Pharmacology Research Perspectives, 2014, 10.1002/prp2.43

PubMed: ( click the link to review the publication )

Oncotarget, 2014, 5(15):5965-77

PubMed: 25115389 ( click the link to review the publication )

Blood, 2013, 14;121(11):2038-50

PubMed: 23327920 ( click the link to review the publication )

Blood, 2013, 123(5):706-16

PubMed: 24319254 ( click the link to review the publication )

Nat Struct Mol Biol, 2013, 20(3):317-25

PubMed: 23377543 ( click the link to review the publication )

Proc Natl Acad Sci USA, 2013, 111(3):E364-73

PubMed: 24395801 ( click the link to review the publication )

PLoS Biol, 2013, 12(1):e1001758

PubMed: 24409098 ( click the link to review the publication )

Cancer Res, 2013, 73(8):2428-34

PubMed: 23382048 ( click the link to review the publication )

Cell Rep, 2013, 5(6):1679-89

PubMed: 24360956 ( click the link to review the publication )

Int J Cancer, 2013, 132(9):2200-8

PubMed: 23024001 ( click the link to review the publication )

Neuropsychopharmacology, 2013, 38(9):1674-84

PubMed: 23474591 ( click the link to review the publication )
Oncogene, 2013, 33(33):4265-72

PubMed: 24292675 ( click the link to review the publication )

Oncogene, 2013, 32(10):1316-29

PubMed: 22543582 ( click the link to review the publication )

Cell Death Dis, 2013, 4:e733

PubMed: 23868066 ( click the link to review the publication )

Cell Death Dis, 2013, 4:e951

PubMed: 24309938 ( click the link to review the publication )

Br J Haematol, 2013, 160(2):188-98

PubMed: 23167276 ( click the link to review the publication )

AIDS, 2013, 27(18):2853-62

PubMed: 24189584 ( click the link to review the publication )

J Biol Chem, 2013, 288(35):25593-602

PubMed: 23878197 ( click the link to review the publication )

J Biol Chem, 2013, 288(20):14400-7

PubMed: 23539624 ( click the link to review the publication )

PLoS Comput Biol, 2013, 9(2):e1002887

PubMed: 23408876 ( click the link to review the publication )

Mol Carcinog, 2013, 52(3):218-28

PubMed: 22121107 ( click the link to review the publication )

Front Pharmacol, 2013, 4:44

PubMed: 23596417 ( click the link to review the publication )

Genes Brain Behav, 2013, 13(1):69-86

PubMed: 24286462 ( click the link to review the publication )

Cell Cycle, 2013, 12(13):2073-83

PubMed: 23759592 ( click the link to review the publication )

PLoS One, 2013, 8(6):e66130

PubMed: 23762475 ( click the link to review the publication )

PLoS One, 2013, 8(1):e53766

PubMed: 23320102 ( click the link to review the publication )

J Thromb Thrombolysis, 2013, 35(2):185-92

PubMed: 23229086 ( click the link to review the publication )

Cell Death Dis, 2013, 4:e655

PubMed: 23744355 ( click the link to review the publication )

Blood, 2012, 8;120(19):3958-67

PubMed: 22983447 ( click the link to review the publication )

J Exp Med, 2012, 209(1):35-50

PubMed: 22231305 ( click the link to review the publication )

Clin Cancer Res, 2012, 18(14):3822-33

PubMed: 22623731 ( click the link to review the publication )

Clin Cancer Res, 2012, 18(2):408-16

PubMed: 22038994 ( click the link to review the publication )

Cancer Res, 2012, 72(9):2251-61

PubMed: 22422937 ( click the link to review the publication )

Cell Death Differ, 2012, 19(12):2029-39

PubMed: 22858545 ( click the link to review the publication )

Cell Death Differ, 2012, 19(8):1317-27

PubMed: 22322857 ( click the link to review the publication )
Eur J Cancer, 2012, 48(7):1096-107

PubMed: 22154545 ( click the link to review the publication )

Diabetologia, 2012, 55(9):2421-31

PubMed: 22772764 ( click the link to review the publication )

FASEB J, 2012, 26(7):3032-41

PubMed: 22459148 ( click the link to review the publication )

J Neurochem, 2012, 123 Suppl 2:108-15

PubMed: 23050648 ( click the link to review the publication )

J Leukoc Biol, 2012, 91(5):701-9

PubMed: 22028329 ( click the link to review the publication )

J Biol Chem, 2012, 287(43):36609

PubMed: 22952229 ( click the link to review the publication )

Mol Carcinog, 2012, 52(6):459-74

PubMed: 22308110 ( click the link to review the publication )

Invest New Drugs, 2012, 30(2):541-7

PubMed: 21107885 ( click the link to review the publication )

Pharm Res, 2012, 29(7):1960-76

PubMed: 22415140 ( click the link to review the publication )

Oncol Rep, 2012, 28(1):105-10

PubMed: 22484732 ( click the link to review the publication )

PLoS One, 2012, 7(9):e44265

PubMed: 22957056 ( click the link to review the publication )

PLoS One, 2012, 7(12):e52335

PubMed: 23272238 ( click the link to review the publication )

PLoS One, 2012, 7(12):e52753

PubMed: 23300762 ( click the link to review the publication )

Chronobiol Int, 2012, 29(8):982-93

PubMed: 22891617 ( click the link to review the publication )

Biochem Biophys Res Co, 2012, 420(2):325-30

PubMed: 22425986 ( click the link to review the publication )

Pediatr Surg Int, 2012, 28(6):579-89

PubMed: 22526548 ( click the link to review the publication )

Protein Expr Purif, 2012, 86(1):45-52

PubMed: 21992606 ( click the link to review the publication )

Brain, 2011, 134(Pt 8):2408-21

PubMed: 21772061 ( click the link to review the publication )

Clin Cancer Res, 2011, 17(9):2819-29

PubMed: 21357681 ( click the link to review the publication )

Clin Cancer Res, 2011, 17(16):5311-21

PubMed: 21724551 ( click the link to review the publication )

Genes Dev, 2011, 25(24):2610-8

PubMed: 22016339 ( click the link to review the publication )

J Neurosci, 2011, 31(11):3990-9

PubMed: 21411642 ( click the link to review the publication )

J Transl Med, 2011, 9:37

PubMed: 21477288 ( click the link to review the publication )

Retrovirology, 2011, 2(3):411-23

PubMed: 21966324 ( click the link to review the publication )
Mol Med, 2011, 17(5-6):466-72

PubMed: 21424110 ( click the link to review the publication )

PLoS One, 2011, 6(7):e22739

PubMed: 21818379 ( click the link to review the publication )

BMC Neurosci, 2011, 12:50

PubMed: 21615950 ( click the link to review the publication )

Sci Signal, 2010, 3(146):ra80

PubMed: 21045206 ( click the link to review the publication )

J Pharmacol Exp Ther, 2010, 86(16):8765-72

PubMed: 20739454 ( click the link to review the publication )

Exp Dermatol, 2010, 19(12):1096-102

PubMed: 20629733 ( click the link to review the publication )

Purity & Quality Control

Choose Selective HDAC Inhibitors

Biological Activity

Description

Vorinostat (suberoylanilide hydroxamic acid, SAHA, MK0683) is an HDAC inhibitor with IC50 of ~10 nM in a cell-free assay. Vorinostat abrogates productive HPV-18 DNA amplification.

Targets

HDAC ^[1]
(Cell-free assay)

~10 nM

In vitro

Vorinostat inhibits the activities of HDAC1 and HDAC3 with IC50 of 10 nM and 20 nM, respectively. Vorinostat also results in a marked hyperacetylation of histone H4. ^[1] Vorinostat inhibits the growth of three prostate cancer cell lines LNCaP, PC-3 and TSU-Pr1 at micromolar concentrations (2.5-7.5 μM), and induces dose-dependent cell death in LNCaP cells. ^[2] Vorinostat treatment in MCF-7 cells inhibits cell proliferation at an IC50 of 0.75 μM resulting in the accumulation of cells in the G1 and G2-M phase of the cell cycle. Vorinostat also induces differentiation in the estrogen receptor-negative cell line SKBr-3 and the retinoblastoma-negative cell line MDA-468. ^[3] Vorinostat treatment at 1 μM for 8 hours or more is sufficient to irreversibly induce apoptosis of human multiple myeloma (MM) cells. The gene expression profiles of Vorinostat treated MM cells are not hallmarked by global transcriptional activation, but by coordinated transcriptional changes of specific functional groups of genes such as cytokine-induced proliferative/survival signaling cascades, oncogenes-tumor suppressor genes, regulators of apoptosis, DNA synthesis-repair and cell cycle, and proteasome-ubiquitin function. ^[4]

Cell Data

Cell Lines	Assay Type	Concentration	Incubation Time	Formulation	Activity Description	PMID
A20	MkXDT4lv[XOnIFHzd4F6		MXOxJIg>	NV:1W\|ZKTE2VTx?=	NYPDTWtw[W62aT3ISGFEOSCjY4Tpeol1gSC5aYToJGlEPTBib3[gNE4yOTJizszN	M4j0XlEyQTZyNEi5
Friend leukemic cell	NIT5UFBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NX:yR2NbPTBizszN	MV:3NkBp	M{XaemROW09?	M33GTmlEPTB;MD65PUDPxE1?	MUixNlExQTlzMx?=
K562	NIPFeppMcW6jc3WgRZN{[Xl?		NWXSbJg6PiCq	MXzEUXNQ	NI\X[FFKdmirYnn0bY9vKG:oIHj1cYFvKGirc4TvcoUh\GWjY3X0fYxie2ViKH3pfJR2emVib3[gTGRCSzFiYX7kJGhFSUN{KTD3bZRpKEmFNUCgc4YhOC5yMTFOwG0>	NYTTZXZzOTJ2MUmzPFA>
HT1080	NVnZSmkyT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=		MnHhO\|IhcA>?	NF:5WIRFVVOR	NWOz[4l{UUN3ME2yMlQh\|ryP	MmLZNVIzPzBzN{W=
H1299	MVrLbY5ie2ViQYPzZZk>		MV:yNEBucW5?	MYrEUXNQ	M4fO[2lvcGmkaYTvdpkh[WO2aY\peJkh[WejaX7zeEBJTEGFIHXufplu\SC5aYToJGlEPTBib3[gNE4yQTRizszN	NIruUokyPDV{MUSyNi=>
H1299	NYm5VFdXT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=		M1LWPVczKGh?	NFzWV2FFVVOR	MVzJR\|UxRTdwMkSg{txO	MmLzNVQ2OjF2MkK=
HeLa	MX3LbY5ie2ViQYPzZZk>		M2W4cFMxKG2rbh?=		NVHvNmV[UW6qaXLpeI9zgSClb37j[Y51emG2aX;uJIFo[Wmwc4SgbIl{fG:wZTDk[YFk\XS7bHHz[UB4cXSqIFnDOVAhd2ZiMD6yPEDPxE1?	NFTDRpQyPTZyM{m0PS=>
LOX-IMVI	MV3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?		MofEOFghcA>?		M{\lUGlEPTB;MT6zJO69VQ>?	NHnTTZoyPTdzNUS3NC=>
NCI-H226	NHS4OGJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=		M{nWTVQ5KGh?		NXS0TZNSUUN3ME2yMlYh\|ryP	NFTpVHkyPTdzNUS3NC=>
RXF-631L	NV6xNJFOT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=		NEH0SXk1QCCq		NEDFbm1KSzVyPUKg{txO	MUOxOVcyPTR5MB?=
SNB-78	M{HoZ2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7		MnzJOFghcA>?		NHH3fldKSzVyPUG2JO69VQ>?	NY\mbZpEOTV5MUW0O\|A>
St-4	MYfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?		NETGR4k1QCCq		NInLfoZKSzVyPUWuNkDPxE1?	NHL3dVIyPTdzNUS3NC=>
ARP1	MnP5SpVv[3Srb36gRZN{[Xl?	M1v2W\|Ih\|ryP	MVi2JIg>		NYG3UnpEUW6mdXP0bY9vKG:oIGCyNXdCTjFiZ3Xu[UBmgHC{ZYPzbY9v	NHTGcHkyPDd\|NEiwOi=>
CEM	NYPpZnFlU2mwYYPlJGF{e2G7		M{jqW\|EhcA>?	NEm0[\|JFVVOR	MWLJcohq[mm2aX;uJI9nKEiGQVOge4l1cCCLQ{WwJI9nKDBwM{Og{txO	M{LEd\|E3PDJyME[0
HCT15	M1TBWWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7		NXHyUphLPDhiaB?=		Mn\RS2k2OD1yLkiyJO69VQ>?	MXixOlczOzJ{Nx?=
NCI-H23	Mme4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?		MkXhOFghcA>?		M3rMe2dKPTB;MD65NkDPxE1?	MnexNVY4OjN{Mke=
GM15850	NXHHRndtU2mwYYPlJGF{e2G7	MnflNk42KM7:TR?=	Mn\SPVYhcA>?	MWfEUXNQ	NXmwZnBwUW6qaXLpeIlwdiCxZjDISGFEKGG\|c3Xzd4VlKGG\|IHnuZ5Jm[XOnIHnuJIhqe3SxbnWgTFMhdHm\|aX7lJFE1KGGlZYT5cIF1cW:wIH;mJGZZViCpZX7l	M3:yd\|E3QTJzM{[3
GM15850	MXTLbY5ie2ViQYPzZZk>	NX3TOmZJOi53IN88US=>	NHPtc3o6PiCq	NILvXplFVVOR	MnPMTY5pcWKrdHnvckBw\iCKRFHDJIF{e2W\|c3XkJIF{KGmwY4LlZZNmKGmwIHjpd5RwdmViSESgcJl{cW6nIEWgZYNmfHmuYYTpc44hd2ZiRmjOJIdmdmV?	MX[xOlkzOTN4Nx?=
GM15850	MX3LbY5ie2ViQYPzZZk>	MlrmNk42KM7:TR?=	NYfYNWZPQTZiaB?=	M1zrVmROW09?	MlLBTY5pcWKrdHnvckBw\iCKRFHDJIF{e2W\|c3XkJIF{KGmwY4LlZZNmKGmwIHjpd5RwdmViSESgcJl{cW6nIEGyJIFk\XS7bHH0bY9vKG:oIF\YUkBo\W6n	NIHsWlYyPjl{MUO2Oy=>
GM15850	Mn21T4lv[XOnIFHzd4F6	MUGyMlUh\|ryP	MXK5OkBp	MnPDSG1UVw>?	MnqzTY5pcWKrdHnvckBw\iCKRFHDJIF{e2W\|c3XkJIF{KGmwY4LlZZNmKGmwIHjpd5RwdmViSEOgcJl{cW6nIEmgZYNmfHmuYYTpc44hd2ZiRmjOJIdmdmV?	NEfITXgyPjl{MUO2Oy=>
GM15850	MXTLbY5ie2ViQYPzZZk>	NFjYcG0zNjVizszN	NYjIWZhHQTZiaB?=	NH7ZZXZFVVOR	MX\Jcohq[mm2aX;uJI9nKEiGQVOgZZN{\XO\|ZXSgZZMhcW6lcnXhd4UhcW5iaHnzeI9v\SCKNDDsfZNqdmViODDhZ4V1gWyjdHnvckBw\iCIWF6g[4Vv\Q>?	M131dFE3QTJzM{[3
GM15850	NF\XTGlMcW6jc3WgRZN{[Xl?	NEjBWI4zNjVizszN	NVK5UolSQTZiaB?=	M1WxVmROW09?	NUDacIV5UW6qaXLpeIlwdiCxZjDISGFEKGG\|c3Xzd4VlKGG\|IHnuZ5Jm[XOnIHnuJIhqe3SxbnWgTFQhdHm\|aX7lJFE3KGGlZYT5cIF1cW:wIH;mJGZZViCpZX7l	NVrSUnVTOTZ7MkGzOlc>
U937	Mn\6SpVv[3Srb36gRZN{[Xl?	NHHzcoU2KM7:TR?=	NH;BRWYzPCCq	MlztSG1UVw>?	NEH3dnZE\WyuIHP5Z4xmKGG{cnXzeEBjgSCjY3P1cZVt[XSrb36gZZQhWy:JMj;NJJBp[XOn	M2riPFE4ODB2N{G4
H661	MmHUS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?		NI\BS281QCCq		NVXtW2c{UUN3ME2xJO69VQ>?	NVz5XGRCOTdzNUewNFk>
U937	M2W3W2Z2dmO2aX;uJGF{e2G7	NVP0Zmt2PSEQvF2=	Mnv2NlQhcA>?	MlGySG1UVw>?	MVXJcoNz\WG\|ZTDpckBpcXO2b37lJGg{KGGlZYT5cIF1cW:w	M1[ybFE4PDR5N{Ww
U937	NFH6[pZHfW6ldHnvckBCe3OjeR?=	MUWxJO69VQ>?	MkPvNlQhcA>?	MX7EUXNQ	NX;CTWd{TW[oZXP0JI9vKGGucHjhJJR2[nWuaX6gZYNmfHmuYYTpc44>	M3rPSlE4PDR5N{Ww
RAW264.7	NUTiWlBkTnWwY4Tpc44hSXO\|YYm=	NF3rOlEyOCEQvF2=	M1XsOlI1cA>?	M{i5TpdifGW{	MnjnTY5pcWKrdHnvckBw\iCOUGOtd5RqdXWuYYTl[EBVVk[jbIDoZUBxem:mdXP0bY9vKHerdHigTWM2OCCxZjCwMlc3KM7:TR?=	Ml7RNVc1Pzd3MUi=
RAW264.7	NHHLO3dHfW6ldHnvckBCe3OjeR?=	NXvMVnM6OTBizszN	NGfHXpkzPGh?	NF62cXJ4[XSnch?=	M3\oOmlvcGmkaYTpc44hd2ZiTGDTMZN1cW23bHH0[YQhVk9icILv[JVkfGmxbjD3bZRpKEmFNUCgc4YhOS56ODFOwG0>	M4PaOlE4PDd5NUG4
SC9	M4LLPWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7		NIGyOFg1QCCq		MnznTWM2OD1yLk[wOkDPxE1?	NFS3OJAyPzVyN{KxPS=>
ST14A	NYC1cVZ5TnWwY4Tpc44hSXO\|YYm=	Ml[3OUBvVQ>?	NWrSSXlUPzJiaB?=		M3K1bWlv[3KnYYPlJIlvKFKHU2SvUnJUTiCvUl7BJIV5eHKnc4Ppc44>	MlTONVc2PjV7OUO=
ST14A	MVnGeY5kfGmxbjDBd5NigQ>?	MmXKOUBvVQ>?	MmL6O\|IhcA>?		MnTETY5kemWjc3WgbY4hTTKIMTDtVm5CKGW6cILld5Nqd25?	NUfJbmhnOTd3NkW5PVM>
PANC1	NEnvT4hIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NHH3TYYyKM7:TR?=			MkWyTWM2OD1yLkS1JO69VQ>?	NFvMRlIyPzV6OEe0OC=>
PANC1	M4\aZWZ2dmO2aX;uJGF{e2G7	M3\Sb\|Eh\|ryP	Mkj3NlQhcA>?		MXPJcoNz\WG\|ZTDpckBxOjGZQV[xM2NKWDFiZ3Xu[UBmgHC{ZYPzbY9v	M{ToW\|E4PTh6N{S0
PANC1	M363fWZ2dmO2aX;uJGF{e2G7	M4TmdFEh\|ryP	MVqyOEBp		NEX6O2ZKdmO{ZXHz[UBqdiCyMkfrbZAyKGenbnWg[ZhxemW\|c3nvci=>	MXixO\|U5QDd2NB?=
PT45	NWi3NJk{T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MnPJTWM2OD12IN88US=>	NV\QTWZbOTd3OEi3OFQ>
ACHN	M{TjOWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7		M3nCfFIyKGh?		M1PsNmdKPTB;MD62OUDPxE1?	MnX3NVc3PjJ4ME[=
PC3	Ml7US5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?		MXKyNUBp		MlTiS2k2OD1yLkexJO69VQ>?	Ml\VNVc3PjJ4ME[=
A431	M1H4fmN6fG:2b4jpZ{BCe3OjeR?=		MofoO\|IhcA>?		MUTJR\|UxRTRwMjFOwG0>	Mo[zNVc3QTF5NkO=
Cal27	Mlf5R5l1d3SxeHnjJGF{e2G7		M1\NXFczKGh?		MkXZTWM2OD1\|LkKg{txO	NFu1NosyPzZ7MUe2Ny=>
CCRF-CEM	M4XNc2N6fG:2b4jpZ{BCe3OjeR?=		NV7FOmtWPzJiaB?=		NU\HWYlsUUN3ME2wMlgh\|ryP	MnzlNVc3QTF5NkO=
EOL1	NGL2UVVEgXSxdH;4bYMhSXO\|YYm=		NGK0WGo4OiCq		M{XNU2lEPTB;MTFOwG0>	MXixO\|Y6OTd4Mx?=
Hec-1-A	MU\DfZRwfG:6aXOgRZN{[Xl?		M3fP[FczKGh?		MlO1TWM2OD1zIN88US=>	MYmxO\|Y6OTd4Mx?=
HeLa	M32xSGtqdmG\|ZTDBd5NigQ>?	NYPydo1kOTBizszN	NVT2dXhLOzBibXnu	Mn3NSG1UVw>?	MX7Jcohq[mm2aX;uJI9nKHKnY3;tZolv[W62IFjERWMyKHerdHigTWM2OCCxZjCwMlAzKM7:TR?=	M4PQbFE4PjlzN{[z
RKOp21	Ml71R5l1d3SxeHnjJGF{e2G7		MWO3NkBp		NGPa[m9KSzVyPUGuO\|Yh\|ryP	NH3mc4kyPzZ7MUe2Ny=>
Saos2	NFj3ZVNEgXSxdH;4bYMhSXO\|YYm=		MYW3NkBp		M1f0NGlEPTB;Mj6zJO69VQ>?	MVyxO\|Y6OTd4Mx?=
SK-OV-3	MYrDfZRwfG:6aXOgRZN{[Xl?		NVTnSZk6PzJiaB?=		M33id2lEPTB;Mj6yJO69VQ>?	MYixO\|Y6OTd4Mx?=
U87MG	M4HNOWN6fG:2b4jpZ{BCe3OjeR?=		NWXOXHU5PzJiaB?=		NX[zR2gyUUN3ME2xNUDPxE1?	NWfmNJFuOTd4OUG3OlM>
NUGC3	MVTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NUPtbppoPSEQvF2=	M1jYXFI1KGh?		NYDKd\|hMT0l3ME2yMlc6KM7:TR?=	NIWxWlAyPzlyNEi0Ny=>
CCD1059SK	M1vLOmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MkjITWM2OD12Mz61JO69VQ>?	MYixPFI1PzV3NB?=
HepG2	MXrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MlOwTWM2OD1yLkCwNFYh\|ryP	NVjOcWF[OTh{NEe1OVQ>
HT1080	M3jHWWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MmfKTWM2OD1yLkCwNlQh\|ryP	NXy3SZc3OTh{NEe1OVQ>
SKBR3	MlfZS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MmfQTWM2OD1yLkig{txO	NFzOSFYyQDJ2N{W1OC=>
SNB78	MYnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NWPlU2h1TUN3ME2xOkDPxE1?	NIPNN5EyQDJ2N{W1OC=>
SQ20B	MWXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MoTJTWM2OD1\|IN88US=>	MlP3NVgzPDd3NUS=
St4	NUP3elNuT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NUXhNWVHTUN3ME21MlIh\|ryP	MVyxPFI1PzV3NB?=
MCF7	NV7KUnF6TnWwY4Tpc44hSXO\|YYm=	MmnFNVAh\|ryP	NXO3fmpMQCCq	MnLkSG1UVw>?	NFXJTXhKdmS3Y4Tpc44hd2ZidIXieYxqdiCqeYDldoFk\XS7bHH0bY9v	MU[xPFI3QTJ{Nh?=
HEK293	MUnLbY5ie2ViQYPzZZk>		NFTp[XgyKGh?	MkLGSG1UVw>?	M2jlcGlvcGmkaYTpc44hd2ZiSFTBR\|Ehf2m2aDDJR\|UxKG:oIECuNFMh\|ryP	NXTab3c{OTh\|MEi1OlM>
HEK293	M4rIdGtqdmG\|ZTDBd5NigQ>?		MoLTNUBp	Mle4SG1UVw>?	NHrjWY5KdmirYnn0bY9vKG:oIFjERWM{KHerdHigTWM2OCCxZjCwMlA2PyEQvF2=	NIHicXoyQDNyOEW2Ny=>
G401	Mlv5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?		NXnETIZCPzJiaB?=	NEnUSYJFVVOR	M{DweGlEPTB;MTFOwG0>	MknaNVg{PzB\|N{O=
HeLa	NFzzOpVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=		NI[1[FU4OiCq	NI\GPHdFVVOR	NFvsOnhKSzVyPUCuOFYh\|ryP	NFrrWnAyQDN5MEO3Ny=>
Human renal epithelial cell	MXTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?		NGG2W2g4OiCq	NHThTVhFVVOR	MoPVTWM2OD1zNDFOwG0>	NVjJd3FJOTh\|N{CzO\|M>
U937	M4\WdGZ2dmO2aX;uJGF{e2G7	NFO4[FQ2KM7:TR?=	M4jVdFI1KGh?		M2nWVWlv\HWldHnvckBw\iCqaYP0c45mKEh2IHj5dIVz[WOndInsZZRqd25?	MUCxPFM5OTJ\|OB?=
U937	MmHZSpVv[3Srb36gRZN{[Xl?	NUi0XYZlPSEQvF2=	NWTLS5B2OjRiaB?=		MXjJcoR2[3Srb36gc4Yh[WyyaHGgeJVjfWyrbjDofZBmemGlZYT5cIF1cW:w	Ml;6NVg{QDF{M{i=
U937	MVjGeY5kfGmxbjDBd5NigQ>?	NYnFOWd5PSEQvF2=	MV:yOEBp		M1nWPWlv\HWldHnvckBw\iCyMkGg[ZhxemW\|c3nvci=>	M4nX[VE5OzhzMkO4
U937	NWL4UWtYTnWwY4Tpc44hSXO\|YYm=	MUi1JO69VQ>?	MXiyOEBp		MYLJcoR2[3Srb36gc4Yh[XCxcITvd4l{	NFzFb4IyQDN6MUKzPC=>
U937	MmfUSpVv[3Srb36gRZN{[Xl?	M3[yW\|Uh\|ryP	MoP0NlQhcA>?		M2K5Wmlv\HWldHnvckBw\iCpcnHueYxw[3m2aXOg[Iln\mW{ZX70bYF1cW:w	Mle1NVg{QDF{M{i=
U937	MV;LbY5ie2ViQYPzZZk>	NXSwWnU4PSEQvF2=	NHPUOYozPCCq		NVztZXhFUW6qaXLpeIlwdiCxZjDoeY1idiCKRFHDNS=>	NVXZWoRlOTh\|OEGyN\|g>
U937	M4O1b2tqdmG\|ZTDBd5NigQ>?	Ml3zOUDPxE1?	NVGxSJljOjRiaB?=		NWm5eG4zUW6qaXLpeIlwdiCxZjDoeY1idiCKRFHDOC=>	NIHYOpgyQDN6MUKzPC=>
HEK-TE	NX7lNmZ4TnWwY4Tpc44hSXO\|YYm=	Mny4OUDPxE1?	MVK2bC=>	MmL1SG1UVw>?	NWjXe4o4UW6lcnXhd4UhcW5iaHnzeI9v\SCKMzDhZ4V1gWyjdHnvci=>	MVixPFQ{PDF2NB?=
HPDE6c7	NUHIbVZmS3m2b4TvfIlkKEG\|c3H5	M4jEUVUxKM7:TR?=	M1LTWFczKGh?	NY\mSWVNTE2VTx?=	MXrJR\|UxRTFwMzFOwG0>	NYHzTo1vOTh2OUS0OlM>
Human microvascular epithelial cell	M3PLbmN6fG:2b4jpZ{BCe3OjeR?=	NX:1dG9MPTBizszN	MljQO\|IhcA>?	M1;pTGROW09?	NYHrXFBWUUN3ME2xMlMh\|ryP	MV2xPFQ6PDR4Mx?=
Hup T3	MYfDfZRwfG:6aXOgRZN{[Xl?	NYe1eJk6PTBizszN	NYqzUHR6PzKq	NILzZodFVVOR	NHjCU5VKSzVyPUCuPEDPxE1?	NF7uT20yQDR7NES2Ny=>
Mia Paca2	NV\ROHdyS3m2b4TvfIlkKEG\|c3H5	MonkOVAh\|ryP	NFXTbHg4Omh?	MmHKSG1UVw>?	MVjJR\|UxRTFwMTFOwG0>	NYrDRZhoOTh2OUS0OlM>
Panc 04.03	NHK1Zm9EgXSxdH;4bYMhSXO\|YYm=	MmnJOVAh\|ryP	MX23Nog>	NVTYZpJOTE2VTx?=	NYflTWdlUUN3ME2xMlIh\|ryP	MXmxPFQ6PDR4Mx?=
SU 86.86	NF\QPYZEgXSxdH;4bYMhSXO\|YYm=	M1HOS\|UxKM7:TR?=	MnLQO\|Jp	M2i4OmROW09?	NELmXpdKSzVyPUGuN{DPxE1?	Mnf1NVg1QTR2NkO=
HEK293	Ml3rT4lv[XOnIFHzd4F6		MXKzJIg>		MnX6TY5pcWKrdHnvckBw\iC{ZXPvcYJqdmGwdDDISGFEPiCneIDy[ZN{cW:wIIfpeIghUUN3MDDv[kAxNjBzOTFOwG0>	NGTXc5gyQDV3OE[2PS=>
HeLa	MV3LbY5ie2ViQYPzZZk>		MWiyJIg>		NEW2cIRKdmirYnn0bY9vKG:oIH71Z4xm[XJiSFTBR{B4cXSqIFnDOVAhd2ZiMD6wPFMh\|ryP	NELwT2kyQDV3OE[2PS=>
RAW264.7	NV3OSJp5TnWwY4Tpc44hSXO\|YYm=	NGjOT3YzKM7:TR?=	MorRN{42KGh?	MX3EUXNQ	M3\WS2FvfGmvYXzhdolidCCjY4Tpeol1gSCjZ3HpcpN1KFCuYYPtc4RqfW1iZnHsZ4lx[XK3bTDpcoZm[3SnZDD3bZRpKEmFNUCgc4YhOC5zMTFOwG0>	NFPCRWQyQDZ2NEm2PS=>
NB4			NGTsWJQ1QGh?	MYTEUXNQ	NVvlRWFXUUN3ME2wMlYh\|ryP	NHrod3IyQDd{M{O0PS=>
HEK293	MlX2SpVv[3Srb36gRZN{[Xl?	MlLnNVAh\|ryP	NFPWT3UzPCCq	NETTRXhFVVOR	MnfDRYN1cX[jdHnvckBw\iCvb4Xz[UBYdnR\|YTDzbYdv[Wyrbneg[ZhxemW\|c3Xk	NILaOVIyQTB{Mk[3OS=>
HCT116	MXPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?		NGTwUmg4Omh?	NU\MZlBZTE2VTx?=	NVW3OGJFUUN3ME2wMlMyKM7:TR?=	NYjtRnpNOTlyOESyPVQ>
HeLa	Mo\BT4lv[XOnIFHzd4F6	NHr1bFczKM7:TR?=	MX:zNEBucW5?	NUnyPHBETE2VTx?=	Ml7uTY5pcWKrdHnvckBw\iCKRFHDNkBqdiCqdX3hckBJ\UyjIHPlcIx{KHerdHigTWM2OCCxZjCwMlEh\|ryP	NUi5eYdWOTlyOESyPVQ>
IGROV1	M1L2[Wdzd3e2aDDJcohq[mm2aX;uJGF{e2G7		NE[zZZk4OiCq	MVjEUXNQ	MlqyTWM2OD1{LkKg{txO	M3vzeVE6ODh2Mkm0
IGROV1	M2\VWWtqdmG\|ZTDBd5NigQ>?	NX;Od4dTPSEQvF2=	MnrzNlQhcA>?	NIe0fpZFVVOR	NGfJR3FKdmirYnn0bY9vKG:oIFjERWMh[XO\|ZYPz[YQh[XNicEWzJIFk\XS7bHH0bY9v	NYHoVplXOTlyOESyPVQ>
IGROV1	MXXLbY5ie2ViQYPzZZk>	NF3lPIUyOCEQvF2=	NGfpXVc1KGh?	NVrDdIVUTE2VTx?=	NWDEXohGUW6qaXLpeIlwdiCxZjDISGFEKGG\|c3Xzd4VlKGG\|IHjpd5RwdmVvSESgZYNmfHmuYYTpc44>	MVKxPVA5PDJ7NB?=
IGROV1	NWDjOYtHU2mwYYPlJGF{e2G7	MmTmNVAh\|ryP	NFnINY41KGh?	Mn75SG1UVw>?	NYj0RnVrUW6qaXLpeIlwdiCxZjDISGFEPiCjc4Pld5Nm\CCjczDhcJBp[S22dXL1cIlvKGGlZYT5cIF1cW:w	MorUNVkxQDR{OUS=
T24	NIjxU4lMcW6jc3WgRZN{[Xl?		NXyzfnVUOyCq		Ml\oTY5lfWO2aX;uJI9nKGirc4TvcoUhUDNiYXPleJlt[XSrb36ge4l1cCCHQ{WwJI9nKDBwMUKg{txO	M{O5elE6ODh2M{m1
T24	MX7LbY5ie2ViQYPzZZk>		NGTTNVI{KGh?		MkfaTY5lfWO2aX;uJI9nKGGucHjhJJR2[nWuaX6gZYNmfHmuYYTpc44hf2m2aDDFR\|UxKG:oIECuNlUh\|ryP	MYmxPVA5PDN7NR?=
HeLa	M{nzWGtqdmG\|ZTDBd5NigQ>?		NYfJSpE6OTVibXnu	M4Oyc2ROW09?	NWDNcll7UW6qaXLpeIlwdiCxZjDISGFEPiCocn;tJI52[2ynYYKg[Zh1emGldDD3bZRpKEmFNUCgc4YhOC5yOEW1JO69VQ>?	MWOxPVA6Ozh6NB?=
HeLa	NWHzfY1FU2mwYYPlJGF{e2G7		M2[xOFE2KG2rbh?=	NUOzOoViTE2VTx?=	MlvoTY5pcWKrdHnvckBw\iCKRFHDPEBnem:vIH71Z4xm[XJiZYj0doFkfCC5aYToJGlEPTBib3[gNU45PiEQvF2=	M2OwTFE6ODl\|OEi0
NCI-H69	MlS3R5l1d3SxeHnjJGF{e2G7		M2HqTVczKGh?	MlfCSG1UVw>?	NFrpNVhKSzVyPUKuNFYh\|ryP	M3TBdlE6ODl\|OEi0
SKMES1	NGPHXZNEgXSxdH;4bYMhSXO\|YYm=		MmS3O\|IhcA>?	MXLEUXNQ	NFvHOlhKSzVyPUKuOFIh\|ryP	MnLZNVkxQTN6OES=
S2	NUfCWYFRU2mwYYPlJGF{e2G7	NXPCd2xtOC5zLUGwJO69VQ>?	M37rblEhcA>?		MXzJcohq[mm2aX;uJI9nKFCuYYPtc4RqfW1iZnHsZ4lx[XK3bTDISGFEOSCneIDy[ZN{\WRid3n0bEBKSzVyIH;mJFAvODV7IN88US=>	Mn\FNVk{OTd2NUC=
SHSY5Y	M3\kTGtqdmG\|ZTDBd5NigQ>?	NGO5fJAyOCEQvF2=	MX20PEBp	M3LuXGROW09?	MoHkTY5pcWKrdHnvckBw\iCKRFHDJJdqfGhiSVO1NEBw\iByLkWg{txO	MmG3NVk{PDRzN{W=
SHSY5Y	MX;DfZRwfG:6aXOgRZN{[Xl?	M4S1RVExKM7:TR?=	M4H4NVQ5KGh?	NYOw[mExTE2VTx?=	M{fG[GlEPTB;MjFOwG0>	MknWNVk{PDRzN{W=
DMS114	MY\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?		MmHYOFghcA>?		NWf3R3pxT0l3ME2yMlkh\|ryP	MWGxPVQyQTJyNR?=
HBC5	MYjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?		NYP3TmJnPDhiaB?=		NYPaW4liT0l3ME2xO{DPxE1?	MnTpNVk1OTl{MEW=
SNB78	NWLJOXBZT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=		MkDjOFghcA>?		MV3HTVUxRTF4IN88US=>	M4HzPFE6PDF7MkC1
HeLa	NU[5e4pqT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=		NEH2fZI4OiCq	NHnpbHRFVVOR	MV3JR\|UxRTBwNE[g{txO	M3r4VlE6PDRzOES2
BHK	NUX0UW52U2mwYYPlJGF{e2G7	NXjaU4FrPSEQvF2=	NELRWpIzPCCq	NVnscpMyTE2VTx?=	MojmTY5pcWKrdHnvckBw\iCKRFHDO{BmgHC{ZYPz[YQh[XO\|ZYPz[YQh[XNiaX7jdoVie2ViaX6gdIxie22jIH3lcYJz[W6nIF\k[Yx1[TVyODDDSnRTKHC{b4TlbY4>	NEDjdIkyQTl4Nke4PS=>
CFBE41o-	MXrLbY5ie2ViQYPzZZk>	MXy1JO69VQ>?	MXu4JIg>	MkfLSG1UVw>?	MU\Jcohq[mm2aX;uJI9nKEiGQVOgZZN{\XO\|ZXSgZZMhcHmyZYLhZ4V1gWyjdHnvckBw\iCqaYP0c45mKEh\|	M3j3cFE6QTZ4N{i5
CFBE41o-	NWjMeY51U2mwYYPlJGF{e2G7	MUW1JO69VQ>?	MmnKOEBp	MkTQSG1UVw>?	MW\Jcohq[mm2aX;uJI9nKEiGQVOgZZN{\XO\|ZXSgZZMhcW6lcnXhd4UhcW5ibYX0ZY51KE[mZXz0ZVUxQCCFRmTSJJBzd3SnaX6gcIV3\Wx?	NIrKOmUyQTl4Nke4PS=>
CFBE41o-	M1nGOmtqdmG\|ZTDBd5NigQ>?	NHf6[4EyKM7:TR?=	NUHLW4JoOSCq	MYrEUXNQ	NGrRfIxKdmirYnn0bY9vKG:oIFjERWMh[XO\|ZYPz[YQh[XNiaX7jdoVie2ViaX6gR2ZVWiCycn;0[YlvKGyndnXs	NEDvW2kyQTl4Nke4PS=>
Primary bronchial epithelial cell	NEn1cJBMcW6jc3WgRZN{[Xl?	M3yzT\|Eh\|ryP	Ml\ZNlQhcA>?	MkSzSG1UVw>?	M1vOfWlvcGmkaYTpc44hd2ZiSFTBR\|ch[XO\|ZYPz[YQh[XNiaX7keYN1cW:wIH;mJI12fGGwdDDG[IVtfGF3MEigR2ZVWiCycn;0[YlvKGGyaXPhcEB{fXKoYXPlJIxw[2GuaYrheIlwdg>?	MoK3NVk6PjZ5OEm=
CFBE41o-	NWTjToxxU2mwYYPlJGF{e2G7	M{LpXlEh\|ryP	NY\I[mNkPSCmYYnz	NXLTdZA3TE2VTx?=	M1nLOmlvcGmkaYTpc44hd2ZiSFTBR\|ch[XO\|ZYPz[YQh[XNiaX7jdoVie2ViaX6gd5Ri[mmuaYrheIlwdiCxZjDG[IVtfGF3MEigR2ZVWiCycn;0[Ylv	MlrsNVk6PjZ5OEm=
CFBE41o-	MWTLbY5ie2ViQYPzZZk>	M1zUOFEh\|ryP	NHi1TmkzPCCq	M33D[mROW09?	NFzLeVlKdmirYnn0bY9vKG:oIFjERWM4KGG\|c3Xzd4VlKGG\|IHnuZ5Jm[XOnIHnuJGZl\Wy2YUWwPEBETlSUIIDyc5RmcW5idILh[oZq[2urbne=	NH3rRogyQTl4Nke4PS=>
CFBE41o-	NEjpb3dMcW6jc3WgRZN{[Xl?	MnPDOUDPxE1?	MmXVNlQhcA>?	MWHEUXNQ	NELlS\|RKdmirYnn0bY9vKG:oIFjERWM4KGG\|c3Xzd4VlKGG\|IHnuZ5Jm[XOnIHnuJJJifGVib3[gcYF1fXKjdHnvckBw\iCFRmTSJJBzd3SnaX6geI8hcXS\|IHfsfYNw\m:{bR?=	MlHkNVk6PjZ5OEm=
CFBE41o-	NVTGUWhkU2mwYYPlJGF{e2G7	M2nRW\|Uh\|ryP	MYGyOEBp	M37J[GROW09?	MoS0TY5pcWKrdHnvckBw\iCKRFHDO{Bie3Onc4Pl[EBieyCrbnPy[YF{\SCrbjDzeIFjcWyrdImgc4YhTmSnbIThOVA5KEOIVGKgdJJwfGWrbh?=	MV:xPVk3Pjd6OR?=
CFBE41o-	M{jITGtqdmG\|ZTDBd5NigQ>?	MkW4OUDPxE1?	Mn7FNlQhcA>?	NGDR[WJFVVOR	MVnJcohq[mm2aX;uJI9nKEiGQVO3JIF{e2W\|c3XkJIF{KGOxcoLlZ5Rqd25ib3[gcZV1[W62IF\k[Yx1[TVyODDDSnRTKHS{YX\mbYNscW6pIITvJINmdGxic4Xy[oFk\SCjczDncJlkd2[xcn2=	M4LFRlE6QTZ4N{i5
Primary bronchial epithelial cell	MlzxT4lv[XOnIFHzd4F6	NX[4c3ZlPSEQvF2=	NIXVelYzPCCq	MYXEUXNQ	NWPwcnVKUW6qaXLpeIlwdiCxZjDISGFEKGG\|c3Xzd4VlKGG\|IHnu[JVkfGmxbjDv[kBufXSjboSgSoRmdHSjNUC4JGNHXFJicILveIVqdiCjcHnjZYwhe3W{ZnHj[UBtd2OjbHn6ZZRqd25?	M{XiVVE6QTZ4N{i5
Primary bronchial epithelial cell	NVnDZlRZU2mwYYPlJGF{e2G7	M4fpd\|Eh\|ryP	MkXuPVYhcA>?	NGPpZWtFVVOR	M3rvVGlvcGmkaYTpc44hd2ZiSFTBR\|ch[XO\|ZYPz[YQh[XNiaX7jdoVie2ViaX6gd4hwenRiY3nyZ5VqfCCldYLy[Y51ew>?	M2O2XVE6QTZ4N{i5
BxPC3	NIHjc4pIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=		NEHyXFk4OiCq		M2XFXmlEPTB;Mj63JO69VQ>?	NWnrbIgxOjBzNEO3O\|g>
CAL27	NXy0[3J4T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=		MlLYO\|IhcA>?		MWrJR\|UxRTNwN{Kg{txO	MXSyNFE1Ozd5OB?=
Capan1	M4DRVmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7		MUS3NkBp		M{X2fGlEPTB;Nz6zJO69VQ>?	NVfTVm1EOjBzNEO3O\|g>
HCC827	MnXES5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?		MYW3NkBp		NVHCU4pRUUN3ME2xMlgh\|ryP	MkPvNlAyPDN5N{i=
LNCAP	MYnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?		NF6yfJE4OiCq		M4DlTWlEPTB;MD61PEDPxE1?	NHnjbIczODF2M{e3PC=>
NCI-H2122	NHLl[21Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=		NGLHNYw4OiCq		MX7JR\|UxRTdwNTFOwG0>	NXL2V5kzOjBzNEO3O\|g>
NCI-H358	MlnpS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?		M4HMWFczKGh?		M4TTOWlEPTB;Mj61JO69VQ>?	NEPFUpEzODF2M{e3PC=>
SCC15	M37zXmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7		NUfiRoRQPzJiaB?=		MnPDTWM2OD1{LkS5JO69VQ>?	MWGyNFE1Ozd5OB?=
SCC25	NWrNWFBMT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=		MYO3NkBp		MkjqTWM2OD1zLkmzJO69VQ>?	MV2yNFE1Ozd5OB?=
SKHEP1	NEHFNm1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=		NFn1T2E4OiCq		M{L2VWlEPTB;Mz60OkDPxE1?	NEfZPIQzODF2M{e3PC=>
BJ	M3nQ[Wdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NFHoUGwyODBizszN	M1TT[VQ5KGh?	MmTUSG1UVw>?	NHHW[VdIem:5dHigbY5pcWKrdHnvckBifCByLkC1JJRwKDFyMDD1US=>	MkXKNlAyPDN6NEC=
MUF	M3OxdWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MWKxNFAh\|ryP	MWS0PEBp	MWfEUXNQ	NYrlb4NnT3Kxd4ToJIlvcGmkaYTpc44h[XRiMD6wOUB1dyBzMECgeW0>	NF7rd40zODF2M{i0NC=>
Caco-2	M1y4TGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MlzMNVAxKM7:TR?=	M1jucVQ5cA>?	MkXySG1UVw>?	NFjTXlBKSzVyPUiuNUDPxE1?	MWOyNFE1Ozh2MB?=
Caco-2	Mlm0T4lv[XOnIFHzd4F6	M4r6NFUh\|ryP	NEnxS5E1KGh?	NYDNcmV6TE2VTx?=	MUnJcoR2[3Srb36gc4YhUESDQz3t[YRq[XSnZDDobZN1d26nIHHj[ZR6dGG2aX;uJGlEPTBib3[gNE4xOzdizszN	NYHjbnZNOjBzNEO4OFA>
Caco-2	NFWwfFJMcW6jc3WgRZN{[Xl?	M4[xelAvOzF4IH7NJJRwKDNzLk[g{txO	NHezflQ1KGh?	NWnUcYtlTE2VTx?=	NGXTUJVGgCC4aY\vJIlvcGmkaYTpc44hd2ZiaIXtZY4hUESDQ{Gge4l1cCCLQ{WwJI9nKDBwMUG5JO69VQ>?	M3;ub\|IxOTR\|OESw
Caco-2	M1j1fWtqdmG\|ZTDBd5NigQ>?	NYP0UJpuOC5\|MU[gcm0hfG9iM{GuOkDPxE1?	MUm0JIg>	M4f5TGROW09?	NFzsWYdGgCC4aY\vJIlvcGmkaYTpc44hd2ZiaIXtZY4hUESDQ{Oge4l1cCCLQ{WwJI9nKDBwMUS3JO69VQ>?	NGLlU40zODF2M{i0NC=>
Caco-2	NYHHeY1lU2mwYYPlJGF{e2G7	M3[x[lYvOzJibl2geI8hPjN{IN88US=>	NHrIRoE1KGh?	M2LpXWROW09?	Mk\zSZghfmm4bzDpcohq[mm2aX;uJI9nKGi3bXHuJGhFSUN3IIfpeIghUUN3MDDv[kAyOi54IN88US=>	M4qye\|IxOTR\|OESw
Caco-2	M3vJV2tqdmG\|ZTDBd5NigQ>?	M3SxT\|YvOzJibl2geI8hPjN{IN88US=>	MWK0JIg>	NETieVZFVVOR	Mn7CSZghfmm4bzDpcohq[mm2aX;uJI9nKGi3bXHuJGhFSUN5IIfpeIghUUN3MDDv[kA1OSEQvF2=	MmSxNlAyPDN6NEC=
Caco-2	MoPkT4lv[XOnIFHzd4F6	NHfGcnAxNjNzNjDuUUB1dyB\|MT62JO69VQ>?	NGTaTVU1KGh?	MmXTSG1UVw>?	MmPFSZghfmm4bzDpcohq[mm2aX;uJI9nKGi3bXHuJGhFSUN4	MkDtNlAyPDN6NEC=
HepG2	M{POSGtqdmG\|ZTDBd5NigQ>?	M4T3NFUh\|ryP	MXO2bC=>	Mn\KSG1UVw>?	MVTJcoR2[3Srb36gc4YhUESDQz3t[YRq[XSnZDDobZN1d26nIHHj[ZR6dGG2aX;u	M3TvXVIxOTR\|OESw
HepG2	M1nQXWtqdmG\|ZTDBd5NigQ>?	Mo\kOUDPxE1?	Mon2Oog>	MkTPSG1UVw>?	Ml\ITY5lfWO2aX;uJI9nKEiGQVOtcYVlcWG2ZXSgbIl{fG:wZTDofZBmemGlZYT5cIF1cW:w	NWPJR2N4OjBzNEO4OFA>
HepG2	NHrwcYRMcW6jc3WgRZN{[Xl?	NWXNWGt[PSEQvF2=	MljkOog>	MmHTSG1UVw>?	M3\hbGlv\HWldHnvckBw\iCKRFHDMY1m\GmjdHXkJIFteGijLYT1ZpVtcW5iYXPleJlt[XSrb36=	NFu3[VAzODF2M{i0NC=>
HepG2	M2\qXGtqdmG\|ZTDBd5NigQ>?	Mn3DOUDPxE1?	NEHocZY3cA>?	M3HTc2ROW09?	MVPJcoR2[3Srb36gc4YhUESDQz3t[YRq[XSnZDDIN{9JPCCqaYP0c45mKGGlZYT5cIF1cW:w	NFvhXJYzODF2M{i0NC=>
COLO205	NEDWRVVMcW6jc3WgRZN{[Xl?	NGXIUHIyOCEQvF2=	MVWyOEBp	NVX0OVFVTE2VTx?=	NVLzb5JvUW6qaXLpeIlwdiCxZjDISGFEOSCjc4Pld5Nm\CCjczDpcoR2[3Srb36gc4YhcGm\|dH;u[UBJOyCjY3X0fYxifGmxbjD3bZRpKEmFNUCgc4YhOi5{IN88US=>	NEXRbHYzODR3MUO3PC=>
SCC4	NUDhNoJSU2mwYYPlJGF{e2G7	MX6xJO69VQ>?	NY[0UVd7OjSq		NXzxb4VSUW6qaXLpeIlwdiCxZjDISGFEKGG\|c3Xzd4VlKGG\|IHnuZ5Jm[XOnIHnuJJR2[nWuaX6gZYNmfHmuYYTpc44>	MnzsNlA1PTJ{MkW=
SCC4	Mom2T4lv[XOnIFHzd4F6	NGfUfXUyKM7:TR?=	M2L5eFI1cA>?		MkHhTY5pcWKrdHnvckBw\iCKRFHDJIF{e2W\|c3XkJIF{KGmwY4LlZZNmKGmwIHjpd5RwdmViYXPleJlt[XSrb36=	NVnqUYtWOjB2NUKyNlU>
SCC4	M4rrU2Z2dmO2aX;uJGF{e2G7	NVfMVGlpOSEQvF2=	M{jRXVUhdWmw		Mo\YRYdwdmm\|dDDhZ5Rqfmm2eTDheEBXTFJiYYPz[ZN{\WRiYYOgbY5lfWO2aX;uJI9nKEO\UEK0JIdmdmViZYjwdoV{e2mxbh?=	MUGyNFQ2OjJ{NR?=
NB4	Mn;VSpVv[3Srb36gRZN{[Xl?	NIfaNWI2KM7:TR?=	MknONlQhcA>?	NHraNHZFVVOR	MWLD[YxtKGO7Y3zlJIFzemW\|dDDhd5Nme3OnZDDhd{BqdmO{ZXHz[UBqdiCjY3P1cZVt[XSrb36gZZQheHKnLVexJJBp[XOn	NWXLbJpOOjB2OUG0OFA>
NB4	MkjlT4lv[XOnIFHzd4F6	Ml7aOUDPxE1?	MXmyOEBp	MXjEUXNQ	M{jiSmlvcGmkaYTpc44hd2ZiSFTBR{Bie3Onc4Pl[EBieyCrbnPy[YF{\SCrbjDhZ4V1gWyjdHWgeJVjfWyrbjDs[ZZmdA>?	MV2yNFQ6OTR2MB?=
NB4	NYLmdXM4TnWwY4Tpc44hSXO\|YYm=	NF[4NZE2KM7:TR?=	NFPvZmYzPCCq	MYnEUXNQ	MXPJcoR2[3Srb36gc4YheDJzV1HGNU9EUVBzIHX4dJJme3Orb36=	NVHKTGx7OjB2OUG0OFA>
NB4	M1vVU2tqdmG\|ZTDBd5NigQ>?	M1Kwc\|Uh\|ryP	Mn7qNlQhcA>?	NG\jXlJFVVOR	Mn[0TY5pcWKrdHnvckBw\iCKRFHDJIF{e2W\|c3XkJIF{KGmwY4LlZZNmKGmwIHjpd5RwdmViSEOgZYNmfHmuYYTpc44>	NE\id5EzODR7MUS0NC=>
NUGC3	NEHp[4lIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M3fSR2dKPTB;Mj65OEDPxE1?	MXGyNFg2ODl5MR?=
A549	MUXGeY5kfGmxbjDBd5NigQ>?	M4TmZVUh\|ryP	MV:zJIg>	NV64Ro9yTE2VTx?=	NFT6e\|RKdmS3Y4Tpc44hd2ZiYYX0c5Bp[We7IHnuJIh2dWGwIFG1OFkh[2WubIOgZZN{\XO\|ZXSgZZMhcW6lcnXhd4UhcW5iTFOzTWk>	NXKwdGtVOjB6NUWyNFg>
HUT78	NFTuSIVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=		NUD2boxFPzJiaB?=	M3;OfGROW09?	M4HvXWdKPTB;MD6zJO69VQ>?	MWqyNFg5PDJyOB?=
U937	NV;RR3NtT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=		NWn4Rm8{PzJiaB?=	NGfFS2xFVVOR	NGflbo5IUTVyPUCuN\|kh\|ryP	MWCyNFg5PDJyOB?=
A431	M4XrcmN6fG:2b4jpZ{BCe3OjeR?=		M4LTTlczKGh?		M3HnUWN6fG:2b4jpZ4l1gSCjZ3HpcpN1KGi3bXHuJGE1OzFiY3XscJMhd3[ncnX4dJJme3OrbnegSWdHWiC5aYToJGlEPTBib3[gOE4zKM7:TR?=	MnLtNlExQDB4Mkm=
A549	NXHPZ\|lJS3m2b4TvfIlkKEG\|c3H5		M{noclczKGh?		MWfDfZRwfG:6aXPpeJkh[WejaX7zeEBpfW2jbjDBOVQ6KGOnbHzzJI93\XKneIDy[ZN{cW6pIFjERWMhf2m2aDDJR\|UxKG:oIEGuPEDPxE1?	M2e2bFIyODhyNkK5
CAL27	NEXLb5pEgXSxdH;4bYMhSXO\|YYm=		NFfpXYU4OiCq		NV\iSGhQS3m2b4TvfIlkcXS7IHHnZYlve3RiaIXtZY4hS0GOMkegZ4VtdHNib4\ldoV5eHKnc4PpcochTUeIUjD3bZRpKEmFNUCgc4YhOy5{IN88US=>	MWqyNVA5ODZ{OR?=
HeLa	MmezR5l1d3SxeHnjJGF{e2G7		M3zlRlczKGh?		MoLTR5l1d3SxeHnjbZR6KGGpYXnud5QhcHWvYX6gTIVN[SClZXzsd{BwfmW{ZYjwdoV{e2mwZzDISGFEKHerdHigTWM2OCCxZjCxMlUh\|ryP	NUfHTHl3OjFyOEC2Nlk>
Sf21	NXn4ZpF3U2mwYYPlJGF{e2G7		M2nYUVMhcA>?		NF3J[YFKdmirYnn0bY9vKG:oIF\sZYchfGGpZ3XkJIh2dWGwIILlZ49u[mmwYX70JGhFSUN6IHX4dJJme3OnZDD3bZRpKEmFNUCgc4YhOS5{IN88US=>	MojRNlExQDB4Mkm=
SKBR3	NITlUG1EgXSxdH;4bYMhSXO\|YYm=		MWO3NkBp		MofXR5l1d3SxeHnjbZR6KGGpYXnud5QhcHWvYX6gV2tDWjNiY3XscJMhd3[ncnX4dJJme3OrbnegTGVTOiC5aYToJGlEPTBib3[gNk43KM7:TR?=	NYPFS4lIOjFyOEC2Nlk>
SKOV3	MknqR5l1d3SxeHnjJGF{e2G7		NWLqOXhHPzJiaB?=		MW\DfZRwfG:6aXPpeJkh[WejaX7zeEBpfW2jbjDTT29XOyClZXzsd{BwfmW{ZYjwdoV{e2mwZzDISXIzKHerdHigTWM2OCCxZjCyMlIh\|ryP	NU\SW4R[OjFyOEC2Nlk>
COR-L23	MonzS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MWmxNEDPxE1?	NEnOfGw4OiCq	NFr1coZFVVOR	M4K2[mdKPTB;MT6xJO69VQ>?	NUnyZ5JzOjFyOEC2OFc>
DU145	MX3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MoPwNVAh\|ryP	NEC4TmI4OiCq	NFHHV4ZFVVOR	NF\5d3FIUTVyPUGuNFUh\|ryP	NVPRXWZ2OjFyOEC2OFc>
LoVo	NGHEUYNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NGC3WpoyOCEQvF2=	MnKwO\|IhcA>?	MkLHSG1UVw>?	NV3NbnY1T0l3ME2xMlch\|ryP	MVmyNVA5ODZ2Nx?=
MCR5-SV2	NHHpe4dIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MkjaNVAh\|ryP	MYe3NkBp	Mnj4SG1UVw>?	NWjyOXRET0l3ME2yMlEh\|ryP	NFTVU2EzOTB6ME[0Oy=>
HCT116	MknMT4lv[XOnIFHzd4F6	M4fHPFMxKM7:TR?=	NVzYXFhIOzBiaB?=	MoXUSG1UVw>?	NVHwTXBoUW6qaXLpeIlwdiCxZjDISGFEPiCjc4Pld5Nm\CCjczDpcoR2[3Srb36gc4Yh[WyyaHGteJVjfWyrbjDhZ4V1gWyjdHnvci=>	MYKyNVA5ODZ2Nx?=
HCT116	MUjLbY5ie2ViQYPzZZk>	NEDwT4w{OCEQvF2=	MkKzN\|AhcA>?	Mn\GSG1UVw>?	NEfsPI9KdmirYnn0bY9vKG:oIFjERWMyKGG\|c3Xzd4VlKGG\|IHnu[JVkfGmxbjDv[kBpcXO2b37lJGg{UzliYXPleJlt[XSrb36=	NXfnNIwxOjFyOEC2OFc>
U937	NW\LTG1EU2mwYYPlJGF{e2G7	M1nX[\|Uh\|ryP	MnnBNlQhcA>?	MlP1SG1UVw>?	MnrCTY5pcWKrdHnvckBw\iCqaYP0c45mKGGlZYT5cJRz[W6\|ZnXyZZNmKGG\|c3Xzd4VlKGG\|IHnuZ5Jm[XOnIH;mJIFk\XS7bHH0bY9vKG:oIHjpd5RwdmViSEOgZZQhUzl?	M13xe\|IyOjl{NEmy
U937	NXzncnVvU2mwYYPlJGF{e2G7	MXO1JO69VQ>?	M1vFU\|I1KGh?	NYTzWmRsTE2VTx?=	MmfYTY5pcWKrdHnvckBw\iCqaYP0c45mKGGlZYT5cJRz[W6\|ZnXyZZNmKGG\|c3Xzd4VlKGG\|IHnuZ5Jm[XOnIH;mJIFk\XS7bHH0bY9vKG:oIHjpd5RwdmViSEOgZZQhUzF6	NYjNU4ZbOjF{OUK0PVI>
U937	NI\JNnlMcW6jc3WgRZN{[Xl?	NH\VXoQ2KM7:TR?=	NUG3do16OjRiaB?=	MoP4SG1UVw>?	M3PXdWlvcGmkaYTpc44hd2ZiaHnzeI9v\SCjY3X0fYx1emGwc3\ldoF{\SCjc4Pld5Nm\CCjczDpcoNz\WG\|ZTDv[kBx[W5vYXPleJlt[XSnZDDobZN1d26nIFi0JIxmfmWu	M3fFTlIyOjl{NEmy
U937	Mo[3T4lv[XOnIFHzd4F6	NVXKVI93PSEQvF2=	MWixOUBucW5?	MmrHSG1UVw>?	MVPJcohq[mm2aX;uJI9nKGirc4TvcoUh[WOndInseJJidnOoZYLhd4Uh[XO\|ZYPz[YQh[XNiaX7jdoVie2Vib3[gbIl{fG:wZTDIN{Bi[2W2eXzheIlwdiCuZY\lcC=>	Ml22NlEzQTJ2OUK=
A2780	NYC4XFZoT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=		NWHINHhSQTZiaB?=	MVPEUXNQ	MWPJR\|UxRTFwNkKg{txO	M1ixNlIyPjN2NEOw
COLO205	M{LW[mdzd3e2aDDJcohq[mm2aX;uJGF{e2G7		MUi5OkBp	MlXwSG1UVw>?	M4LhWWlEPTB;Mj6xNkDPxE1?	MoLuNlE3OzR2M{C=
Hep3B	MW\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?		NVnLWog5PDhiaB?=	NHjlWYdFVVOR	M1LBc2dKPTB;MT6yNUDPxE1?	MV2yNVcyOjF2Nh?=
GM11272	NFO4ToJHfW6ldHnvckBCe3OjeR?=	M3uzeVExOCCwTR?=	MUW3NkBp	NGToPVVFVVOR	NV;ZT3ozWmWjY4TpeoF1cW:wIH;mJG1mS3B{IH31eIFvfCCneIDy[ZN{cW:wIHH0JFExKHSxIEGwNEBvVQ>?	NWLz[IM5OjF6NEC3NVY>
CFBE41o	M{nyUGtqdmG\|ZTDBd5NigQ>?	NF[3WpE2KM7:TR?=		MoHmSG1UVw>?	M2\6RWRwf25icnXneYxifGmxbjDv[kBJTEGFNzDheEAxNjJidH:gOUB2VQ>?	MVSyNVk5PDl3OB?=
CFBE41o	Mnv1SpVv[3Srb36gRZN{[Xl?	MnK4NUDPxE1?	NVHDcFN{OjRiaB?=	NYTnVWw6TE2VTx?=	NGLXXYFT\XO2b4LheIlwdiCxZjDDSnRTKGSnbIThSlUxQCCvdYThcpQhfHKjZn\pZ4tqdmdidH:gZ4VtdCC\|dYLmZYNmKGG\|IHfsfYNw\m:{bYO=	MXyyNVk5PDl3OB?=
DU145	MXnLbY5ie2ViQYPzZZk>	MlzINk42KM7:TR?=	MonMNlQhcA>?	M1PpZ2ROW09?	NVPYe3dpUW6qaXLpeIlwdiCxZjDISGFEKGG\|c3Xzd4VlKGG\|IIXwdoVofWyjdHnvckBw\iCyMkH3ZYYyKHC{b4TlbY4h\XiycnXzd4lwdg>?	NV3X[4NROjJ{NkCxOlY>
DU145	NHHPSI1McW6jc3WgRZN{[Xl?	NUj0O4Y{PSEQvF2=	Mlu1NlQhcA>?	M3jCTGROW09?	MYHJcohq[mm2aX;uJI9nKEiGQVOgZZN{\XO\|ZXSgZZMhcGm\|dH;u[UBJPCCjY3X0fYxifGmxbh?=	MkWyNlIzPjBzNk[=
DU145	MX7LbY5ie2ViQYPzZZk>	M1TIOlUh\|ryP	Mnu1NlQhcA>?	NGS4fXRFVVOR	MkG4TY5pcWKrdHnvckBw\iCKRFHDJIF{e2W\|c3XkJIF{KGirc4TvcoUhUDNiaInw[ZJi[2W2eXzheIlwdg>?	MlH4NlIzPjBzNk[=
786-0	MWHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MmTHOk4zKM7:TR?=	NUfVVmQ4PzJiaB?=	NE\PfYZFVVOR	M4DBT2dKPTB;Mz6yJO69VQ>?	NHXVUYszOjR\|NU[2PS=>
A498	MUfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NVTRTIlGPi5{IN88US=>	NEmxWIE4OiCq	NHj3U2RFVVOR	M2fmTWdKPTB;MT62JO69VQ>?	NGf6bmQzOjR\|NU[2PS=>
A549/ATCC	M4DE[Gdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MlfBOk4zKM7:TR?=	MoCzO\|IhcA>?	MlL4SG1UVw>?	NVnhfmpYT0l3ME2xMlYh\|ryP	MWiyNlQ{PTZ4OR?=
ACHN	M{XHcmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MoXXOk4zKM7:TR?=	MYm3NkBp	M3ezXWROW09?	NWK0dohST0l3ME2xMlMh\|ryP	M2rBbFIzPDN3Nk[5
BT549	NYThc3NbT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MX62MlIh\|ryP	Mkn6O\|IhcA>?	Mmn6SG1UVw>?	MYHHTVUxRTFwMzFOwG0>	M33He\|IzPDN3Nk[5
EKVX	MkThS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NIXOS3o3NjJizszN	MnTGO\|IhcA>?	NI\RR2pFVVOR	M4HUO2dKPTB;MT6zJO69VQ>?	NEfG[JIzOjR\|NU[2PS=>
HCT15	MkHHS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MmfLOk4zKM7:TR?=	NFTy[ZY4OiCq	NUjOVopWTE2VTx?=	NYXPbHVDT0l3ME2yMlUh\|ryP	MYOyNlQ{PTZ4OR?=
HOP92	MUXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MXy2MlIh\|ryP	NYnBXmJHPzJiaB?=	NXzpTVhTTE2VTx?=	Mlv4S2k2OD12IN88US=>	NWr2VYtHOjJ2M{W2Olk>
IGROV1	MmHKS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MYW2MlIh\|ryP	M2P4RlczKGh?	NXjmfWd[TE2VTx?=	NVmwUmNUT0l3ME2xMlMh\|ryP	NIDoVWIzOjR\|NU[2PS=>
LOXIMVI	MnHmS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M3rIT\|YvOiEQvF2=	NY[wXI5qPzJiaB?=	NGKzboJFVVOR	NF;RZ41IUTVyPUGg{txO	NFy2VFczOjR\|NU[2PS=>
M14	NHrLZXBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MmraOk4zKM7:TR?=	NYfhSolTPzJiaB?=	M{TSSWROW09?	NVvUeJRJT0l3ME2xMlMh\|ryP	Mn\WNlI1OzV4Nkm=
MALME-3M	NHrrdnFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M{HXS\|YvOiEQvF2=	MX[3NkBp	MYfEUXNQ	MlToS2k2OD1yLkOyJO69VQ>?	M4\GZ\|IzPDN3Nk[5
MCF10A	NU\yPYw{T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	Mo\XOk4zKM7:TR?=	M{nMWFQ5KGh?	M4K0RmROW09?	MoTOS2k2OD17Lk[g{txO	NES3fpIzOjR\|NU[2PS=>
MDA-MB-435	Mnf5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MVm2MlIh\|ryP	M3PFUVczKGh?	Mlj5SG1UVw>?	MVnHTVUxRTBwNTFOwG0>	MknRNlI1OzV4Nkm=
MDA-MB-468	MkPwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M1PEcFYvOiEQvF2=	NV:5VGFNPzJiaB?=	NV;sOnhtTE2VTx?=	Mnj4S2k2OD1yLk[zJO69VQ>?	NY\pOnVKOjJ2M{W2Olk>
MOLT4	MX;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MnLmOk4zKM7:TR?=	NUDxcGk1PzJiaB?=	NETpPWxFVVOR	M4[0OWdKPTB;MD60JO69VQ>?	NWHpUmdpOjJ2M{W2Olk>
NCI-ADR-RES	MnPPS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MnqzOk4zKM7:TR?=	NGm3VmI4OiCq	NUDLSW92TE2VTx?=	NX\BPYtiT0l3ME2wMlE3KM7:TR?=	MniwNlI1OzV4Nkm=
NCI-H23	NXPyXmR4T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NIXoO4o3NjJizszN	NVvncmZ1PzJiaB?=	NUj5T\|dGTE2VTx?=	NYX6V255T0l3ME2xJO69VQ>?	MX:yNlQ{PTZ4OR?=
NCI-H322M	NFLSdGRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MojFOk4zKM7:TR?=	NXrI[lk6PzJiaB?=	NIrZSWlFVVOR	MlPJS2k2OD1yLke5JO69VQ>?	M37tdlIzPDN3Nk[5
NCI-H460	NX;vXoR[T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NVPnPZN4Pi5{IN88US=>	M{jKT\|czKGh?	M1e3TGROW09?	M1ztfmdKPTB;MD63PUDPxE1?	M1;I[VIzPDN3Nk[5
NCI-H522	NV7SNGYxT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MYW2MlIh\|ryP	M3nv[VczKGh?	MkH1SG1UVw>?	MYjHTVUxRTBwNTFOwG0>	M4HSS\|IzPDN3Nk[5
OVCAR3	MYLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NYCzNXpqPi5{IN88US=>	NGDnPWk4OiCq	M1;2fWROW09?	MVnHTVUxRTFwMzFOwG0>	MnvqNlI1OzV4Nkm=
OVCAR4	NXfoN5A5T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MY[2MlIh\|ryP	M2rPcFczKGh?	M4XjTWROW09?	NI[5XotIUTVyPUSg{txO	M1\Lc\|IzPDN3Nk[5
OVCAR5	MkHmS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MVe2MlIh\|ryP	Mnj4O\|IhcA>?	MX;EUXNQ	M1XveWdKPTB;MD63PUDPxE1?	MVmyNlQ{PTZ4OR?=
OVCAR8	MVHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NX3OUldXPi5{IN88US=>	NH34fYw4OiCq	MkPuSG1UVw>?	M{TCcmdKPTB;MD61JO69VQ>?	M1HBNlIzPDN3Nk[5
RXF393	M2HZOWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MkHjOk4zKM7:TR?=	MlTOO\|IhcA>?	NHjiN4xFVVOR	MVXHTVUxRTFwMzFOwG0>	MWKyNlQ{PTZ4OR?=
SF268	M3TtNWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NYfD[Zc6Pi5{IN88US=>	MUO3NkBp	NWXyRpdzTE2VTx?=	M4LmfWdKPTB;MT62JO69VQ>?	NX;qfHBvOjJ2M{W2Olk>
SF295	M1rufWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NFnKOoM3NjJizszN	MVO3NkBp	NVrsVpZJTE2VTx?=	MlmxS2k2OD1zLk[g{txO	NG\EPWEzOjR\|NU[2PS=>
SF539	MnP4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M{D0NVYvOiEQvF2=	MoriO\|IhcA>?	MmK1SG1UVw>?	MnTCS2k2OD1{IN88US=>	MV6yNlQ{PTZ4OR?=
SK-MEL-2	M2jhOGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NHuzcZM3NjJizszN	NUP4S20{PzJiaB?=	MknLSG1UVw>?	M2DLfWdKPTB;MT6zJO69VQ>?	NUPHc3BWOjJ2M{W2Olk>
SK-MEL-28	NFHUTI1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NUHjW3h4Pi5{IN88US=>	MVy3NkBp	Ml7xSG1UVw>?	NIm4blhIUTVyPUGg{txO	NWf2SIpmOjJ2M{W2Olk>
SK-MEL-5	Mn\RS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	Moi4Ok4zKM7:TR?=	M3L4NlczKGh?	NF;3O25FVVOR	NV;IcGVpT0l3ME2wMlY{KM7:TR?=	NV[4UVRxOjJ2M{W2Olk>
SKOV3	M{P1Zmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NGnzOlY3NjJizszN	NY\OeXA2PzJiaB?=	MX\EUXNQ	MYrHTVUxRTFizszN	MkHmNlI1OzV4Nkm=
SN12C	M4\Cb2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MVi2MlIh\|ryP	MnTUO\|IhcA>?	MnjkSG1UVw>?	NXPsWFNXT0l3ME2yJO69VQ>?	NYL0coczOjJ2M{W2Olk>
SNB19	MWLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NYjue4h3Pi5{IN88US=>	NV;tU\|g{PzJiaB?=	MoLSSG1UVw>?	NWPKNVV7T0l3ME2wMlY{KM7:TR?=	M1LV[FIzPDN3Nk[5
SNB75	MnyxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NXLzeGtrPi5{IN88US=>	NVztW4M2PzJiaB?=	MoDGSG1UVw>?	NFO0cFJIUTVyPUCuO\|kh\|ryP	NHvQe4IzOjR\|NU[2PS=>
SR	MVLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M3zQNVYvOiEQvF2=	NUXBWIg{PzJiaB?=	Mnj5SG1UVw>?	MXjHTVUxRTBwNDFOwG0>	NYXrSIVQOjJ2M{W2Olk>
T47D	NWCwZ2ZjT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NYnvfFlNPi5{IN88US=>	M4jzZVczKGh?	MmPCSG1UVw>?	MYrHTVUxRTBwNTFOwG0>	Ml\ENlI1OzV4Nkm=
TK10	NYPNWWpRT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M2jJWlYvOiEQvF2=	MkS3O\|IhcA>?	NFjYWIlFVVOR	MmXBS2k2OD1yLk[zJO69VQ>?	NWq2fnZYOjJ2M{W2Olk>
UACC257	NFr4[HhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	Mn7pOk4zKM7:TR?=	MoDDO\|IhcA>?	M4C2V2ROW09?	MknES2k2OD1yLkWg{txO	MnTKNlI1OzV4Nkm=
UACC62	MX\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	Mo\tOk4zKM7:TR?=	Mmr0O\|IhcA>?	NVfDe5g5TE2VTx?=	MU\HTVUxRTBwNDFOwG0>	M2HaNFIzPDN3Nk[5
UO31	NGHJVJRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M3\UPFYvOiEQvF2=	NH:2UWs4OiCq	MlzpSG1UVw>?	MkLNS2k2OD1yLkWg{txO	MV6yNlQ{PTZ4OR?=
Hep3B	M4PpNmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7		NHvnWos1QCCq	NIjuXotFVVOR	M4HEW2dKPTB;MD62PUDPxE1?	MmnwNlI1Ozl6NkO=
BE(2)-C	MYrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?		M1r0O\|czKGh?	MnOzSG1UVw>?	MXTJR\|cxRTJizszN	MUWyNlk{OjNzNh?=
Bel7402	M3q2bGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7		M3raTVczKGh?	NYrGTowxTE2VTx?=	M4Lx[GdKQTB;MUeg{txO	NWrMfVlZOjNyNkGzO\|Y>
Bel7404	MV7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?		M{LWfVczKGh?	MWfEUXNQ	M{nOWGdKQTB;MUig{txO	NYrUeoQ4OjNyNkGzO\|Y>
BGC823	Mn7pS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?		M1;0O\|czKGh?	NFzMV5VFVVOR	MX\HTVkxRTdwNTFOwG0>	MXWyN\|A3OTN5Nh?=
MGC803	Mn7MS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?		MmfyO\|IhcA>?	NFzod3ZFVVOR	NIjZR3FIUTlyPUGwMlgh\|ryP	NH;RfXIzOzB4MUO3Oi=>
SGC7901	NI[xfnhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=		NGHvZno4OiCq	MYLEUXNQ	NUPKd5NOT0l7ME25MlQh\|ryP	MkL5NlMxPjF\|N{[=
SKHEP1	MlTqS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?		NFX4W2c4OiCq	NF\vWXNFVVOR	MVvHTVkxRTF5IN88US=>	NVLmSHFWOjNyNkGzO\|Y>
SMMC7721	M3P6TGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7		NWrGbmY1PzJiaB?=	NGLXbmlFVVOR	NWLUW\|lbT0l7ME2yNEDPxE1?	Mof1NlMxPjF\|N{[=
NUGC3	Mn\MS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NHXoe2UyOCEQvF2=			M4HDbmdKRTJwOUSg{txO	MoWyNlMyPjN\|M{K=
A2780 CisR	NXO4XGpoU2mwYYPlJGF{e2G7		MX6xPEBp		NF;2OG1KdmirYnn0bY9vKG:oIFjERWMhf2m2aDDJR\|UxKG:oIECuOFQh\|ryP	MnfUNlMzPTJ4MEO=
CAL27 sens	NYPoTItnU2mwYYPlJGF{e2G7		MkPwNVghcA>?		MWDJcohq[mm2aX;uJI9nKEiGQVOge4l1cCCLQ{WwJI9nKDBwM{[g{txO	NHTaSZQzOzJ3Mk[wNy=>
CAL27 CisR	M3PMdWtqdmG\|ZTDBd5NigQ>?		NH31XJAyQCCq		M1vWVWlvcGmkaYTpc44hd2ZiSFTBR{B4cXSqIFnDOVAhd2ZiMD62NUDPxE1?	NHnUfIEzOzJ3Mk[wNy=>
KYSE-510 CisR	NHHBPIZMcW6jc3WgRZN{[Xl?		NHP6SHcyQCCq		MWjJcohq[mm2aX;uJI9nKEiGQVOge4l1cCCLQ{WwJI9nKDBwNUmg{txO	MnrMNlMzPTJ4MEO=
KYSE-510 sens	MUfLbY5ie2ViQYPzZZk>		M4T3b\|E5KGh?		NGTiem5KdmirYnn0bY9vKG:oIFjERWMhf2m2aDDJR\|UxKG:oIECuO{DPxE1?	MnPmNlMzPTJ4MEO=
MDA-MB-231 sens	MWTLbY5ie2ViQYPzZZk>		MWOxPEBp		MULJcohq[mm2aX;uJI9nKEiGQVOge4l1cCCLQ{WwJI9nKDBwNkGg{txO	NUTVNGZNOjN{NUK2NFM>
MDA-MB-231 CisR	MULLbY5ie2ViQYPzZZk>		MmO1NVghcA>?		MlzpTY5pcWKrdHnvckBw\iCKRFHDJJdqfGhiSVO1NEBw\iByLk[xJO69VQ>?	M2[1dlI{OjV{NkCz
ES2	MlztS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?		MlHJOFghcA>?	M4nh[WROW09?	NGPUTXZKSzVyPUGyMlch\|ryP	MUiyN\|Q6OzR2OR?=
MDA-MB-231	M4fiRmtqdmG\|ZTDBd5NigQ>?	Ml:1NVAh\|ryP	NGi0cmI{OCCvaX6=	NFnnU\|ZFVVOR	MVjJcohq[mm2aX;uJI9nKEiGQVOyZS=>	MX:yN\|Q6OzR2OR?=
MDA-MB-231	MYrLbY5ie2ViQYPzZZk>	NFXI[FYyKM7:TR?=	MVyyOEBp	NWPCPJk2TE2VTx?=	MXvJcohq[mm2aX;uJI9nKEiGQVO2JIF{e2W\|c3XkJIF{KGGlZYT5cIF1cW:wIHzleoVteyCxZjD0eYJ2dGmw	M2PQVFI{PDl\|NES5
HS68	MXzDfZRwfG:6aXOgRZN{[Xl?	Mn73NVAh\|ryP	MnPKO\|IhcA>?	NWXQbpZOTE2VTx?=	NHz1No5KSzVyPUSuOkDPxE1?	NVTjfFE3OjN3N{C1OFI>
MEF	NF\IcW1EgXSxdH;4bYMhSXO\|YYm=	Ml7ENVAh\|ryP	Ml7WO\|IhcA>?	NUW3XpAyTE2VTx?=	NGnOWItKSzVyPUSuOEDPxE1?	M4HRPFI{PTdyNUSy
BGC823	NWXZVZlZT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=			NHvOWVdFVVOR	NVTUcmJRT0l3ME2zMlA6KM7:TR?=	MknyNlM3ODF5ME[=
High5	NVH0WnA{U2mwYYPlJGF{e2G7		M4XReFI1KGh?		NFfpXZpKdmirYnn0bY9vKG:oIHj1cYFvKHKnY3;tZolv[W62IFjERWM3KHerdHigTWM2OCCxZjCwMlA6KM7:TR?=	MluyNlM3ODJ3MkO=
High5	MoHQT4lv[XOnIFHzd4F6		M2fhbVI1KGh?		NH\rSoVKdmirYnn0bY9vKG:oIHj1cYFvKHKnY3;tZolv[W62IFjERWMyKHerdHigTWM2OCCxZjCwMlEzKM7:TR?=	MWSyN\|YxOjV{Mx?=
High5	NULpcoJIU2mwYYPlJGF{e2G7		M3[xWlI1KGh?		NWL5[mYxUW6qaXLpeIlwdiCxZjDoeY1idiC{ZXPvcYJqdmGwdDDISGFEOyC5aYToJGlEPTBib3[gNE4yPyEQvF2=	Mlm0NlM3ODJ3MkO=
A549	NUWwXYJKT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=			NVna[XhmTE2VTx?=	NULkd\|BiUUN3ME2xMlA4QSEQvF2=	MlTuNlM3PDR{MUC=
HCT116	Ml\5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?			MknnSG1UVw>?	NW\mcWtIUUN3ME2wMlc2PyEQvF2=	MoLlNlM3PDR{MUC=
K562	NUmzTYw{T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=			MYPEUXNQ	NGruTVhKSzVyPUCuOlQ2KM7:TR?=	NF;n[oszOzZ2NEKxNC=>
GBC-SD	NFXIZZVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M3fnS\|Uh\|ryP	NXyxe\|hGPzJiaB?=	M4nEcGROW09?	NHnJdYhKSzVyPUG0Mlgh\|ryP	MV[yN\|cxPzJ4MB?=
HGC27	NH\IPW9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M4Px[\|Uh\|ryP	MXy3NkBp	NVGxWVJoTE2VTx?=	MVjJR\|UxRTVwNDFOwG0>	NX:5VFRGOjN5MEeyOlA>
HL60	NHnuSmtMcW6jc3WgRZN{[Xl?	MonHOUDPxE1?	MYCyOEBp	MWDEUXNQ	MYDJcohq[mm2aX;uJI9nKEiGQVO=	NUHC[GJ[OjN5MEeyOlA>
Vero	NHHS[WtIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=		NH3sb4k4OiCq	MlLISG1UVw>?	MnjWTWM2OD1yLkmg{txO	M3jYfVI{Pzh4NEWy
NCI60	MWfDfZRwfG:6aXOgRZN{[Xl?		NHeyb4o1QCCq	NGDs[GhFVVOR	M3v5XGdKRTBwNUOg{txO	NFnsdmYzPDBzNUOyOy=>
SW620	M2S5VmN6fG:2b4jpZ{BCe3OjeR?=		Mk\QOFghcA>?	NGDvco5FVVOR	MXvHTV0xNjV2IN88US=>	NX[4e3l3OjRyMUWzNlc>
U251	MWrDfZRwfG:6aXOgRZN{[Xl?		M4fKe\|Q5KGh?	NFvwe4RFVVOR	NI\ZTFNIUT1zLkWzJO69VQ>?	M1nOelI1ODF3M{K3
KM12	M{XsZmN6fG:2b4jpZ{BCe3OjeR?=		NWLNcJdzPDhiaB?=	M1rsbWROW09?	NIfWdpNIUT1zLki4JO69VQ>?	MWCyOFAyPTN{Nx?=
Hs578T	MWfDfZRwfG:6aXOgRZN{[Xl?		MVK0PEBp	M1vXRmROW09?	M2ewd2dKRTRwOEOg{txO	NYLkemZ7OjRyMUWzNlc>
MDA-MB-231	NXTKU5UzT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=		NUHG[WVxPDhiaB?=		NWf5eFh6UUN3ME2wMlE3KM7:TR?=	NVnUeWVCOjRyOUWwNVY>
MCF7	NXn1UYVZT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=		M4rNN\|Q5KGh?		MnPjS2k:OC52NTFOwG0>	NWLnO5VnOjRzMUm1OVU>
MDA-MB-435	NHnEZVRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=		NXPTd4dOPDhiaB?=		M1;TbGdKRTBwOEig{txO	NF7WcVQzPDFzOUW1OS=>
AsPC1	M4nH[mdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MX6zNEDPxE1?	MkHaOFghcA>?	NITle2RFVVOR	MUTJR\|UxRTNwNk[g{txO	NH;3W3IzPDF6NUO3PC=>
Jurkat E6.1	MYTLbY5ie2ViQYPzZZk>		M1rpZVIhcA>?	NX62fHVRTE2VTx?=	NHL5W5NKdmirYnn0bY9vKG:oIFjERWM1KHerdHigTWM2OCCxZjCwMlA1KM7:TR?=	MmntNlQzPjF6NkK=
KG1	MoTZS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?		MYq0PEBp		M1WxcmlEPTB;MT6xOUDPxE1?	MV2yOFUzPTByMx?=
HEL	MlfyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?		M2nPNlQ5KGh?	M3HFVmROW09?	M1;5[GlEPTB;MD60PUDPxE1?	MUeyOFY6PDB3NR?=
HSC3	NHHTRopEgXSxdH;4bYMhSXO\|YYm=		M37seFEzKGh?	MWjEUXNQ	MVvJR\|UxRTBwN{Gg{txO	MoP5NlQ4PjZ3NkC=
HT-29	NHrtWnpEgXSxdH;4bYMhSXO\|YYm=		MmH0NVIhcA>?	NXzLXINnTE2VTx?=	M17OVWlEPTB;MD63NkDPxE1?	M1jiTVI1PzZ4NU[w
KB	NH\lb49EgXSxdH;4bYMhSXO\|YYm=		NEDEUoMyOiCq	M4DjRWROW09?	NVfEdWtzUUN3ME2wMlc2KM7:TR?=	NH[xUGozPDd4NkW2NC=>
H460	M37aWWN6fG:2b4jpZ{BCe3OjeR?=		MnzGNVIhcA>?	MojTSG1UVw>?	NX35clVmUUN3ME2wMlgzKM7:TR?=	M{TL[\|I1PzZ4NU[w
MONE1	MkHQR5l1d3SxeHnjJGF{e2G7		NUH3TXllOTJiaB?=	NXXscZpFTE2VTx?=	MV7JR\|UxRTFwMUig{txO	NYjFeIo5OjR5Nk[1OlA>
MKN45	NVnMVYVlS3m2b4TvfIlkKEG\|c3H5		MkPUNVIhcA>?	MoHuSG1UVw>?	MXnJR\|UxRTFwMkWg{txO	NVrzR5Z[OjR5Nk[1OlA>
TSGH	MmHQR5l1d3SxeHnjJGF{e2G7		NXK5Vlg3OTJiaB?=	NYjxWoU1TE2VTx?=	NU[zXHVTUUN3ME2yMlA6KM7:TR?=	MWOyOFc3PjV4MB?=
HL60	MUnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?		MVW3NkBp	NF\wXYxFVVOR	M3LlNmdKPTB;MD65N{DPxE1?	MV[yOFkxODVyMB?=
HEK293	M2rTemdzd3e2aDDJcohq[mm2aX;uJGF{e2G7		NIOzb\|A4OiCq	NFfOcJlFVVOR	M2r2O2dKPTB;MUOg{txO	MUOyOFkxODVyMB?=
Jurkat	NEn4cVFEgXSxdH;4bYMhSXO\|YYm=	M1ntflExOCEQvF2=	MXW3NkBp		M1H6XWdKPTB;MD65JO69VQ>?	MYSyOFkxODd2Mx?=
GM15850	NYHaSYpXU2mwYYPlJGF{e2G7	NFzRNYYzNjVizszN	NWDlXHJ2QTZiaB?=	Mo\PSG1UVw>?	Ml7Q[I9meyCwb4SgbY5pcWKrdDDISGFEKGG\|c3Xzd4VlKGG\|IHnuZ5Jm[XOnIHnuJIhqe3SxbnWgTFMhdHm\|aX7lJFE1KGGlZYT5cIF1cW:wIH;mJGZZViCpZX7l	MXmxOlkzOTN4Nx?=
GM15850	NInDfnlMcW6jc3WgRZN{[Xl?	M{XQfVIvPSEQvF2=	MojpPVYhcA>?	MnLSSG1UVw>?	NGnRVG9ld2W\|IH7veEBqdmirYnn0JGhFSUNiYYPz[ZN{\WRiYYOgbY5kemWjc3WgbY4hcGm\|dH;u[UBJPCCueYPpcoUhPSCjY3X0fYxifGmxbjDv[kBHYE5iZ3Xu[S=>	NYL3VYxnOTZ7MkGzOlc>
GM15850	M1XabmtqdmG\|ZTDBd5NigQ>?	NFvyO3IzNjVizszN	MlPKPVYhcA>?	NHzSUWpFVVOR	Monn[I9meyCwb4SgbY5pcWKrdDDISGFEKGG\|c3Xzd4VlKGG\|IHnuZ5Jm[XOnIHnuJIhqe3SxbnWgTFQhdHm\|aX7lJFEzKGGlZYT5cIF1cW:wIH;mJGZZViCpZX7l	MUmxOlkzOTN4Nx?=
GM15850	MmjpT4lv[XOnIFHzd4F6	NXfOVGtDOi53IN88US=>	MmHHPVYhcA>?	NETabYhFVVOR	Mo\J[I9meyCwb4SgbY5pcWKrdDDISGFEKGG\|c3Xzd4VlKGG\|IHnuZ5Jm[XOnIHnuJIhqe3SxbnWgTFMhdHm\|aX7lJFkh[WOndInsZZRqd25ib3[gSnhPKGenbnW=	MWqxOlkzOTN4Nx?=
GM15850	MXfLbY5ie2ViQYPzZZk>	MoW4Nk42KM7:TR?=	MmrBPVYhcA>?	Mk\BSG1UVw>?	NHfhXlZld2W\|IH7veEBqdmirYnn0JGhFSUNiYYPz[ZN{\WRiYYOgbY5kemWjc3WgbY4hcGm\|dH;u[UBJPCCueYPpcoUhQCCjY3X0fYxifGmxbjDv[kBHYE5iZ3Xu[S=>	M3rzUFE3QTJzM{[3
GM15850	M2\kTmtqdmG\|ZTDBd5NigQ>?	NGnRV3EzNjVizszN	NFnheZI6PiCq	NYPRXW1DTE2VTx?=	M{XC[4Rw\XNibn;0JIlvcGmkaYSgTGRCSyCjc4Pld5Nm\CCjczDpcoNz\WG\|ZTDpckBpcXO2b37lJGg1KGy7c3nu[UAyPiCjY3X0fYxifGmxbjDv[kBHYE5iZ3Xu[S=>	M3TURlE3QTJzM{[3
GM15850	NWnRSnJETnWwY4Tpc44hSXO\|YYm=	MVm1JO69VQ>?	MojiNVIhcA>?	M1PaeWROW09?	M2P4OYhieyCwbzDl[oZm[3Rib36gSnhPKG2UTlGg[ZhxemW\|c3nvci=>	MVWxOlkzOTN4Nx?=
U937	NEPISmNMcW6jc3WgRZN{[Xl?	Mn\QOUDPxE1?	NGr1NYszPCCq	NY[xV2lNTE2VTx?=	MV7oZZMhdm9iZX\m[YN1KG:wIHHsdIhiKHS3YoXsbY4h[WOndInsZZRqd25?	M2KxTVE4PDR5N{Ww
U937	M4Pme2tqdmG\|ZTDBd5NigQ>?	NXXUd5NIOSEQvF2=	NHm5TJozPCCq	NWrOPIRiTE2VTx?=	NEPWeWtp[XNibn:g[YZn\WO2IH;uJIFteGijIIT1ZpVtcW5iYXPleJlt[XSrb36=	MoXkNVc1PDd5NUC=
PANC1	MmjJSpVv[3Srb36gRZN{[Xl?	NGnJSoEyKM7:TR?=	MYKyOEBp		MYHkc4V{KG6xdDDpcoNz\WG\|ZTDpckBxOjetaYCxJIdmdmViZYjwdoV{e2mxbh?=	NVvpUXhWOTd3OEi3OFQ>
PANC1	MmrRSpVv[3Srb36gRZN{[Xl?	MmPhNUDPxE1?	M4jVNlQ5KCCq		MYTkc4V{KG6xdDDpcoNz\WG\|ZTDpckBxOjetaYCxJIdmdmViZYjwdoV{e2mxbh?=	M3T3dFE4PTh6N{S0
Caco-2	M2i3O2Z2dmO2aX;uJGF{e2G7	MVy1JO69VQ>?	M{TXPVI1KGh?	NHXndJdFVVOR	NFn6dW5ld2W\|IH7veEBqdmS3Y3WgVFIyX0GIMTDn[Y5mKGW6cILld5Nqd25?	NEXkVIszODF2M{i0NC=>
SCC4	MUjGeY5kfGmxbjDBd5NigQ>?	MnHVNUDPxE1?	NFPwPJEyOCCvaX6=	MVXEUXNQ	NUPlSIFLcGG\|IH7vJIFod26rc4SgZYN1cX[rdImgZZQhXkSUIHHzd4V{e2WmIHHzJIlv\HWldHnvckBw\iCFWWCyOEBo\W6nIHX4dJJme3Orb36=	NV\zU5V2OjB2NUKyNlU>
A549	MlzqSpVv[3Srb36gRZN{[Xl?	MkPEOUDPxE1?	MmGxN{Bp	NWLOSYVPTE2VTx?=	NY\teGNx\G:nczDuc5QhcW6mdXPlJIF2fG:yaHHnfUBie3Onc4Pl[EBieyCrbnPy[YF{\SCrbjDMR\|NKUQ>?	MWeyNFg2PTJyOB?=
HCT116	NILoWIhMcW6jc3WgRZN{[Xl?	NYn2e5E5OC5\|IN88US=>	NXKzbZZFOzBiaB?=	MmP6SG1UVw>?	Ml23[I9meyCwb4SgbY5pcWKrdDDISGFEOSCjc4Pld5Nm\CCjczDpcoR2[3Srb36gc4YhcGm\|dH;u[UBJO0t7IHHj[ZR6dGG2aX;u	M1n0XlIyODhyNkS3
HepG2	MV3GeY5kfGmxbjDBd5NigQ>?	M4PlPVExKM7:TR?=	M1qwclI1KGh?	M2nlO2ROW09?	NIPRPJlld2W\|IH7veEBqdmS3Y3WgZZBweHSxc3nzJIF{e2W\|c3XkJIF{KGi7cHXyZYNmfHmuYYTpc44hd2ZicEWz	Mnv3NlE2PDh3OEK=
GM11272	MnzWSpVv[3Srb36gRZN{[Xl?	MV:wMlEh\|ryP	NYTFbYx[PzJiaB?=	NUfFT2U6TE2VTx?=	MYfkc4V{KG6xdDDy[YFkfGm4YYTlJG1mS3B{IH31eIFvfCCneIDy[ZN{cW:w	NF[5N4szOTh2MEexOi=>
MDA-MB-231	NWLZVph1U2mwYYPlJGF{e2G7	MoDxNVAh\|ryP	MUK1JI1qdg>?	M4Xkc2ROW09?	NGf3UINld2W\|IH7veEBqdmirYnn0JGhFSUN{YR?=	Mn33NlM1QTN2NEm=
MDA-MB-231	M1fCUmtqdmG\|ZTDBd5NigQ>?	NFfmToMyKM7:TR?=	NXS1VHhYOjRiaB?=	Ml;qSG1UVw>?	M{K2bYRw\XNibn;0JIlvcGmkaYSgTGRCSzZiYYPz[ZN{\WRiYYOgZYNmfHmuYYTpc44hdGW4ZXzzJI9nKHS3YoXsbY4>	MWOyN\|Q6OzR2OR?=
K562	M3LHOmtqdmG\|ZTDBd5NigQ>?				MYDkc4V{KG6xdDDpcohq[mm2IFjERWM>	Ml7aNlM2QTFzMUG=
Jurkat	Mn\6R5l1d3SxeHnjJGF{e2G7	NUfr[I5OOjBizszN	NWiwe5plPzJiaB?=	MkThSG1UVw>?	M2TOe45wKGO7dH;0c5hq[2m2eTDhd5Nme3OnZDDhd{Boem:5dHigbY5pcWKrdHnvci=>	Mm[4NlQ{ODR\|NEi=
HCT116	NGi3d4VCeG:ydH;zbZMhSXO\|YYm=	NHe1cIc{KM7:TR?=	NVW3eFdvOjRiaB?=	NUPWWnIzTE2VTx?=	MmjZ[I9meyCwb4SgbY5lfWOnIHHwc5B1d3OrczDhd5Nme3OnZDDhd{BqdmO{ZXHz[UBqdiCyNUOgdJJwfGWrbjDs[ZZmdA>?	NUHGS\|dbOjR5Nk[1OlA>
KASUMI-1	MYTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NIfseYlKSzVyPUm5MlE4KG6P	NF;qfIVUSU6JRWK=
KARPAS-45	NXm4PIMyT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MV;JR\|UxRTF5Mz64PUBvVQ>?	MYjTRW5ITVJ?
BHT-101	M37jV2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M1jue2lEPTB;MkS0MlE5KG6P	MkLvV2FPT0WU
H9	MlmzS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NIX2UpVKSzVyPUK1OU4xPCCwTR?=	MYjTRW5ITVJ?
PA-1	MVjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MWnJR\|UxRTJ6Nj6yOkBvVQ>?	M1PBNXNCVkeHUh?=
NEC8	MkS4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MmLmTWM2OD1{OEmuN\|ghdk1?	MX;TRW5ITVJ?
MHH-PREB-1	NYLaNnM2T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NILsbZVKSzVyPUK5OE42OyCwTR?=	M37oZ3NCVkeHUh?=
NB7	MXTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MljKTWM2OD1\|NEWuO\|Qhdk1?	NVPUUWtIW0GQR1XS
A3-KAW	NYPifW1ZT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MmDRTWM2OD12MECuOVkhdk1?	MWDTRW5ITVJ?
NB69	NEjoTGtIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MXTJR\|UxRTRzMT63NUBvVQ>?	MlfRV2FPT0WU
EoL-1-cell	M2eyb2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				Ml\NTWM2OD12NUSyOUBvVQ>?	MUDTRW5ITVJ?
CHP-212	MWXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NELKTnRKSzVyPUS1O{42OyCwTR?=	NIrmb25USU6JRWK=
C2BBe1	NF\oe3JIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MoXVTWM2OD12N{KuNVkhdk1?	NXrWeo1NW0GQR1XS
697	M3G4d2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M37uZWlEPTB;NEezMlQyKG6P	M4PGTXNCVkeHUh?=
BCPAP	NEPFNnlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NFG2d21KSzVyPUWwNU41OiCwTR?=	MkLCV2FPT0WU
L-363	MWfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M{jRTWlEPTB;NUCzMlEhdk1?	MmjEV2FPT0WU
ES8	MVjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NV[xbnM{UUN3ME21NlMvPTNibl2=	M{DrSnNCVkeHUh?=
BE-13	NFzRcZBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NUXzVFZIUUN3ME21NlYvQTZibl2=	M1HSTnNCVkeHUh?=
CTB-1	MVfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MV\JR\|UxRTV\|Nz65NkBvVQ>?	MX;TRW5ITVJ?
HD-MY-Z	NGPEWIxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MVvJR\|UxRTV\|OD6xN{BvVQ>?	M4jaOXNCVkeHUh?=
NKM-1	Mn[3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MUfJR\|UxRTV2ND6yO{BvVQ>?	M4Ta[3NCVkeHUh?=
NCI-H720	NUX1UphMT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M4P2SGlEPTB;NU[wMlE5KG6P	M1r3eXNCVkeHUh?=
KY821	NVTwUZBuT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MU\JR\|UxRTV4Mz6yOUBvVQ>?	MnG5V2FPT0WU
OVCAR-5	MlHBS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NH:wOWxKSzVyPUW3Ok4yOSCwTR?=	M3L1T3NCVkeHUh?=
CTV-1	MYTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MWLJR\|UxRTV6MT61OkBvVQ>?	M3[0eXNCVkeHUh?=
P12-ICHIKAWA	M4PvN2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MkjITWM2OD13OU[uOVEhdk1?	NFXyc5ZUSU6JRWK=
DB	M{HnSmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MkS2TWM2OD13OUiuOVchdk1?	MnLNV2FPT0WU
CHL-1	NF7OeFJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MWnJR\|UxRTZ2Mj6wPEBvVQ>?	MVvTRW5ITVJ?
A4-Fuk	M2TJ[Wdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NFm1V4pKSzVyPU[0OE46OSCwTR?=	NY\HSWtVW0GQR1XS
MV-4-11	MWDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M2DXZ2lEPTB;NkW5MlEhdk1?	M3G2[nNCVkeHUh?=
RPMI-8226	MnnsS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MmDWTWM2OD14N{iuNVghdk1?	NW\PXmJXW0GQR1XS
NB14	MX;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MlryTWM2OD14OU[uPVUhdk1?	NIqxPHVUSU6JRWK=
DOHH-2	NH\hd\|BIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MX\JR\|UxRTdyNj62PEBvVQ>?	NXuzTmhmW0GQR1XS
D-423MG	MYfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M2jldGlEPTB;N{C2Mlg6KG6P	NGrJPHpUSU6JRWK=
D-283MED	NF;SOnFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MYfJR\|UxRTdzND6xOEBvVQ>?	MkHiV2FPT0WU
ES1	NFO3XFNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MoPGTWM2OD15MkSuOEBvVQ>?	M3\nT3NCVkeHUh?=
GOTO	NHzxToVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M1XkXWlEPTB;N{K5MlEzKG6P	M2HM[XNCVkeHUh?=
NCI-H209	NUjwU5JuT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NYToe3FXUUN3ME23NlkvQSCwTR?=	NWj4VJJOW0GQR1XS
MOLT-13	MoXrS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NW[wSFZUUUN3ME23N\|gvQThibl2=	M1PBU3NCVkeHUh?=
ATN-1	NIi3Vm5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MkjDTWM2OD15NECuNlghdk1?	M4PxO3NCVkeHUh?=
DU-4475	M3WxfGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NVO2N2NOUUN3ME23OVEvQTFibl2=	Mn;RV2FPT0WU
NB10	M{\hNWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M4r1RmlEPTB;N{WxMlkzKG6P	Mo\RV2FPT0WU
KG-1	M2iwTWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NEj6UFFKSzVyPUe3OU41PSCwTR?=	NVvGNXRbW0GQR1XS
MOLT-4	MX7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MmmyTWM2OD15OEeuOFYhdk1?	M16xdXNCVkeHUh?=
TE-1	MnLSS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NVfKOYhvUUN3ME23PVEvOSCwTR?=	M2jJXnNCVkeHUh?=
SBC-1	NV7oUJhwT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MlviTWM2OD15OUOuPFQhdk1?	M4PGSnNCVkeHUh?=
HEL	NHHmb3RIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NVXRU5kzUUN3ME24NFYvODhibl2=	NYTyPGFqW0GQR1XS
SK-MEL-2	M1TJbmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MWfJR\|UxRThyOT60OEBvVQ>?	NEf5[JVUSU6JRWK=
KU812	M1\wfWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				Ml;jTWM2OD16MUOuNUBvVQ>?	NFzDdVdUSU6JRWK=
RPMI-8866	M2\vWWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				Mme3TWM2OD16MUOuOlchdk1?	MlroV2FPT0WU
ALL-PO	NX65U4RuT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NIn1cJdKSzVyPUixOE43PiCwTR?=	NFTJNVRUSU6JRWK=
LU-139	MUfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M1TsZ2lEPTB;OEKyMlg3KG6P	NFjLNnpUSU6JRWK=
RS4-11	MkTDS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MnjMTWM2OD16M{KuOFUhdk1?	M1;Ic3NCVkeHUh?=
EW-18	NYi3XGZ[T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MWnJR\|UxRTh\|Mj65OkBvVQ>?	NFzi[VJUSU6JRWK=
P30-OHK	MnW0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M13oSWlEPTB;OEO1Mlchdk1?	Mlm5V2FPT0WU
D-566MG	NXnNWZVuT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NGTveoNKSzVyPUizPE43OiCwTR?=	MYjTRW5ITVJ?
HSC-4	MVTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NETHPIpKSzVyPUi0Ok42OSCwTR?=	MUjTRW5ITVJ?
QIMR-WIL	MnH5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M2L0d2lEPTB;OE[yMlA{KG6P	MYfTRW5ITVJ?
SW954	Mn\BS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NW\zR5c2UUN3ME24OlMvOTZibl2=	MUnTRW5ITVJ?
HGC-27	M1vGc2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MnnTTWM2OD16N{KuN\|Qhdk1?	MnK5V2FPT0WU
HH	NULwcHRST3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M1;Bb2lEPTB;OEm0MlEzKG6P	MV;TRW5ITVJ?
KE-37	M1;ndWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M4HrSWlEPTB;OEm0MlYzKG6P	MXzTRW5ITVJ?
SK-N-DZ	MYHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MnLlTWM2OD17MECuOFMhdk1?	MorpV2FPT0WU
J-RT3-T3-5	MlmxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MWXJR\|UxRTlzMD60PUBvVQ>?	NXT1N4pPW0GQR1XS
A427	NILDVmtIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MYnJR\|UxRTl{MD64OEBvVQ>?	NWXXSGgxW0GQR1XS
ECC10	NIL2VXdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NHjuZ\|dKSzVyPUm0OU45PyCwTR?=	MYLTRW5ITVJ?
EW-1	NFrEZ49Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M1XoUGlEPTB;OUS3MlI3KG6P	NVLiU5pVW0GQR1XS
MIA-PaCa-2	NW\nbFJyT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NH\GOmZKSzVyPUm0PU4yOiCwTR?=	MWjTRW5ITVJ?
HCC2218	Mnu2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NXnNTFl7UUN3ME25OVgvPDhibl2=	NGDVT5RUSU6JRWK=
HAL-01	MWLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NV\GVnRyUUN3ME25OlgvODRibl2=	M2TTTnNCVkeHUh?=
RD	NEfXTGxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M3vpUWlEPTB;OUe0MlQ2KG6P	MX7TRW5ITVJ?
SK-N-AS	M2\oOWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NGDVdWJKSzVyPUm4PE4yKG6P	M4fCOHNCVkeHUh?=
ML-2	NVLhR3BUT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M1XiN2lEPTB;MT6wNFQxPyEQvF2=	MlX1V2FPT0WU
MEL-HO	MkHrS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M{HDUmlEPTB;MT6wNFU5OiEQvF2=	NVjlPWZMW0GQR1XS
MS-1	MWTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M33QNWlEPTB;MT6wNFYyPyEQvF2=	MXjTRW5ITVJ?
NCI-SNU-1	Mnm1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M4fWUmlEPTB;MT6wNlM{OSEQvF2=	M1;JVHNCVkeHUh?=
8505C	M33sV2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MXTJR\|UxRTFwMEKzN\|Eh\|ryP	MYTTRW5ITVJ?
MN-60	M3jqRmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NGi2SolKSzVyPUGuNFI3QCEQvF2=	NH30fWhUSU6JRWK=
SAS	NXrXUXJUT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NETQbpZKSzVyPUGuNFQxQDFizszN	M1KyUnNCVkeHUh?=
EFM-19	M1ywUWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M4XOVGlEPTB;MT6wOFg4QSEQvF2=	NVzqNWtmW0GQR1XS
Ca9-22	MoDIS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M1LFe2lEPTB;MT6wOVExPyEQvF2=	NHntempUSU6JRWK=
NBsusSR	MX;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M3fwUGlEPTB;MT6wOVE3PiEQvF2=	MXHTRW5ITVJ?
NB13	MnTjS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NYGzdlVZUUN3ME2xMlA2PTBzIN88US=>	MXjTRW5ITVJ?
SF295	MUXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MUDJR\|UxRTFwME[2NlQh\|ryP	M4LqXHNCVkeHUh?=
U-2-OS	MWPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NVjsVGlHUUN3ME2xMlA4QTFzIN88US=>	M2DSdnNCVkeHUh?=
NCI-H526	MV;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MV;JR\|UxRTFwMEiyPVEh\|ryP	M3PUdnNCVkeHUh?=
KMOE-2	NIf0cG9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MXrJR\|UxRTFwMEm0NlIh\|ryP	NXXEc3JNW0GQR1XS
RCM-1	MkjVS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NWfER5M5UUN3ME2xMlEzOTB{IN88US=>	NILZNolUSU6JRWK=
MC116	MWLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NH7WN2NKSzVyPUGuNVM3OjFizszN	NIfsR2RUSU6JRWK=
NCI-H1092	M3y2Wmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NH65O5ZKSzVyPUGuNVU1ODZizszN	M4nJ[XNCVkeHUh?=
EW-3	M{PC[2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MYPJR\|UxRTFwMUeyNVIh\|ryP	MlHWV2FPT0WU
HCT-116	MVTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NEPxcZRKSzVyPUGuNVc4PSEQvF2=	NYe5fnFKW0GQR1XS
MC-IXC	M2rodmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MUPJR\|UxRTFwMUe4PFEh\|ryP	MYPTRW5ITVJ?
LB1047-RCC	M4fncmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NUjncHZ5UUN3ME2xMlE5OzF{IN88US=>	Mn3XV2FPT0WU
VM-CUB-1	M4W3TGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NFn3SVBKSzVyPUGuNVkyODhizszN	MnHBV2FPT0WU
NB5	MXXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MnXETWM2OD1zLkG5PFU3KM7:TR?=	NX7pSZdVW0GQR1XS
SKG-IIIa	M{Drdmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				Mnq1TWM2OD1zLkKzOFY1KM7:TR?=	MWLTRW5ITVJ?
HO-1-N-1	MV3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NVKwRY9mUUN3ME2xMlI{QDN3IN88US=>	M2H0N3NCVkeHUh?=
EFO-27	MUXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NYXld3dWUUN3ME2xMlI2ODR\|IN88US=>	NWfoXWY4W0GQR1XS
MHH-NB-11	M4C3e2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M{Dnc2lEPTB;MT6yPFMzQSEQvF2=	NEDOXo5USU6JRWK=
SW620	M17w[Wdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NHfMSpFKSzVyPUGuNlkxOThizszN	Mn7kV2FPT0WU
MOLT-16	NHPzTIJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MWPJR\|UxRTFwMkm3PVch\|ryP	M1TmUHNCVkeHUh?=
NTERA-S-cl-D1	NWDxZWJrT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MVjJR\|UxRTFwM{G3OlEh\|ryP	MmrCV2FPT0WU
VA-ES-BJ	M33lUWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NGXuS3RKSzVyPUGuN\|I1PzdizszN	NYj6TpJFW0GQR1XS
HCC1419	Mn\wS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NWPSSFhyUUN3ME2xMlM1ODJ5IN88US=>	NE\weFdUSU6JRWK=
NCI-H69	NGDLXZhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MYXJR\|UxRTFwM{SxNVIh\|ryP	NWXFUlFpW0GQR1XS
DEL	M1Tyd2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MoPsTWM2OD1zLkO1NVYzKM7:TR?=	NVXNem5DW0GQR1XS
LXF-289	NUW5cVBvT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NGHjXolKSzVyPUGuN\|UzPCEQvF2=	M4LkcHNCVkeHUh?=
EW-11	NHrNZWpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NUCyb\|JWUUN3ME2xMlM3ODJ4IN88US=>	MWfTRW5ITVJ?
KP-4	NFqwOYlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NIPTZWxKSzVyPUGuN\|cxQDVizszN	M13HS3NCVkeHUh?=
NOS-1	NFW1WG1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NH7sfYtKSzVyPUGuOFEyQTRizszN	NWj1N3RHW0GQR1XS
SK-NEP-1	NVnkNnczT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MVXJR\|UxRTFwNEG2PVMh\|ryP	NEHOT\|lUSU6JRWK=
LAMA-84	M1;2Z2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				Ml76TWM2OD1zLkSzPVQ2KM7:TR?=	MXjTRW5ITVJ?
ES5	NILPcJdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M1qxe2lEPTB;MT60OFMh\|ryP	MYXTRW5ITVJ?
HuO9	MYHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MX3JR\|UxRTFwNEWzOlIh\|ryP	NFfoUXdUSU6JRWK=
COLO-684	NYPvOGpET3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NYLSfZM6UUN3ME2xMlQ3OTF6IN88US=>	M3\a[XNCVkeHUh?=
EW-24	NWTSfXVvT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NYWycIRXUUN3ME2xMlQ3PTNzIN88US=>	NFnuN4hUSU6JRWK=
BV-173	NXi0cItLT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NFi0SZdKSzVyPUGuOFczQTFizszN	Ml7jV2FPT0WU
NCI-H1770	NGm4SYRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M4PhNmlEPTB;MT60PFU{PiEQvF2=	NIT2SJNUSU6JRWK=
HuP-T4	M{\ieGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NXW2emg4UUN3ME2xMlQ6OyEQvF2=	MlXxV2FPT0WU
TYK-nu	NET5Wo9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MmfuTWM2OD1zLkS5PFUyKM7:TR?=	MYXTRW5ITVJ?
YH-13	MkjqS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NVf4cFFyUUN3ME2xMlQ6QDl2IN88US=>	MYjTRW5ITVJ?
H4	MYjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NXz6ZmFnUUN3ME2xMlUxQTF{IN88US=>	NVrGUWZlW0GQR1XS
OVCAR-8	Ml;3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M2rmb2lEPTB;MT61OFQ4PyEQvF2=	NFy0dlZUSU6JRWK=
NCI-H23	MXLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				Ml\0TWM2OD1zLkW0OlQ2KM7:TR?=	NHnTNVFUSU6JRWK=
ES7	NYSzdIpxT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NHnJ[4ZKSzVyPUGuOVQ4PzNizszN	MXzTRW5ITVJ?
COR-L88	NUe4R5NiT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				Ml30TWM2OD1zLkW2OFI1KM7:TR?=	MYrTRW5ITVJ?
TI-73	M3r1NWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MWLJR\|UxRTFwNUmwOkDPxE1?	M3eyT3NCVkeHUh?=
RT-112	MlnvS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M2C4XGlEPTB;MT61PVI5PCEQvF2=	MVHTRW5ITVJ?
HuO-3N1	NHraOI5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MUnJR\|UxRTFwNUmzPFUh\|ryP	MnryV2FPT0WU
HC-1	MnvlS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MUHJR\|UxRTFwNUm4OlYh\|ryP	NH[0UYxUSU6JRWK=
HT55	MWfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				Mkf0TWM2OD1zLk[1NVMyKM7:TR?=	MlLkV2FPT0WU
IA-LM	MkD0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NH3iUJdKSzVyPUGuOlkzPzhizszN	NILUWJVUSU6JRWK=
EM-2	NEXZSIVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MnvDTWM2OD1zLkewNFE1KM7:TR?=	M3;KSHNCVkeHUh?=
MHH-ES-1	Ml\tS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M{\oV2lEPTB;MT63NFQ{PSEQvF2=	NF7qXFdUSU6JRWK=
CAL-27	M{HXWmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NUTDXHF4UUN3ME2xMlcxPjJzIN88US=>	NGHqSmtUSU6JRWK=
COLO-800	NVfQT2NtT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M1XNTWlEPTB;MT63NVE4QSEQvF2=	MX\TRW5ITVJ?
HCE-T	Ml60S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NW\sd\|hTUUN3ME2xMlcyPSEQvF2=	Ml3jV2FPT0WU
CAMA-1	NXzLXItZT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MYfJR\|UxRTFwN{G5O\|Eh\|ryP	MljGV2FPT0WU
LOXIMVI	MkDNS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MVrJR\|UxRTFwN{KxNUDPxE1?	MmW5V2FPT0WU
NH-12	NIDLUJBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M3PqSGlEPTB;MT63NlY6OSEQvF2=	MV3TRW5ITVJ?
TCCSUP	NVTi[FdbT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M2\GWWlEPTB;MT63NlgzQSEQvF2=	NW[0SFlDW0GQR1XS
MDA-MB-361	MYnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NGjLfWJKSzVyPUGuO\|MyPTdizszN	NX3HRm9tW0GQR1XS
EW-16	NHXZSZFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MWnJR\|UxRTFwN{SxNFch\|ryP	NE\xTIdUSU6JRWK=
SNU-423	NWH6Z\|lWT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MUTJR\|UxRTFwN{W4Nlch\|ryP	NGLXZnVUSU6JRWK=
Daoy	NYrUSItyT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MYLJR\|UxRTFwN{[zNVkh\|ryP	NIXOfY1USU6JRWK=
ES4	MV3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MnzMTWM2OD1zLke4O\|QyKM7:TR?=	NEGwO4NUSU6JRWK=
PFSK-1	Mlz3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M4jDNGlEPTB;MT64NFM4KM7:TR?=	MVTTRW5ITVJ?
ES3	NFTO[mRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NHzSSpBKSzVyPUGuPFI3QDFizszN	MVvTRW5ITVJ?
ONS-76	NUnlSnM6T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M1zxeGlEPTB;MT64Nlg6PyEQvF2=	MV3TRW5ITVJ?
JVM-3	MlLES5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MlHQTWM2OD1zLki1OFUyKM7:TR?=	M{S3TnNCVkeHUh?=
OS-RC-2	NFvQboRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MkPwTWM2OD1zLki3NVUyKM7:TR?=	MVHTRW5ITVJ?
COLO-320-HSR	NWLHZ\|hPT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MWHJR\|UxRTFwOEixPVch\|ryP	NHfVUWxUSU6JRWK=
HN	M1u4dWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NGDmU2tKSzVyPUGuPFg4OjVizszN	Moe3V2FPT0WU
HT	M2TlPWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NEX3O4FKSzVyPUGuPFg6PDdizszN	NGfiSVdUSU6JRWK=
LoVo	MYTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M4[5NGlEPTB;MT64PVgyKM7:TR?=	M4j3NnNCVkeHUh?=
CGTH-W-1	NWnJPZUyT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MnfCTWM2OD1zLki5PVQ3KM7:TR?=	MlT3V2FPT0WU
NB6	M3WycWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				Ml3vTWM2OD1zLkmxNlk5KM7:TR?=	M3;QfnNCVkeHUh?=
EW-22	MnvBS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NE\rbmhKSzVyPUGuPVI5QDdizszN	MmTVV2FPT0WU
ES6	NFzQOGVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MkTOTWM2OD1zLkmzOlMyKM7:TR?=	MmTiV2FPT0WU
SCC-15	NEDU[ZVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M3vQbGlEPTB;MT65N\|gyQSEQvF2=	MmjGV2FPT0WU
HL-60	MlPVS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NVTkcWt3UUN3ME2xMlk{QTB{IN88US=>	M2DtWHNCVkeHUh?=
human HOP-92	MVTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NFfOeWNKSzVyPUGuPVQxPjVizszN	MoLLV2FPT0WU
SW626	M4fqU2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MWDJR\|UxRTFwOUS4PVkh\|ryP	NGPxNolUSU6JRWK=
HEC-1	NYHCZlh2T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MofWTWM2OD1zLkm1N\|Yh\|ryP	NIP3e4lUSU6JRWK=
LB2241-RCC	NIfRXZpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NIj0W3lKSzVyPUGuPVgzOzFizszN	NIrHTVBUSU6JRWK=
Ramos-2G6-4C10	NX\Le3EzT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M1L3ZmlEPTB;MT65PVQ6OyEQvF2=	MVnTRW5ITVJ?
A101D	MoLUS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MUTJR\|UxRTJwMkCzNFMh\|ryP	Mle2V2FPT0WU
NCI-H446	Ml3hS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				Ml\tTWM2OD1{LkC0OVk6KM7:TR?=	NWLGNHVKW0GQR1XS
SBC-5	MojsS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MWLJR\|UxRTJwME[xOFch\|ryP	NF;ZVVFUSU6JRWK=
HOS	MVrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MkPtTWM2OD1{LkC3OlU{KM7:TR?=	NUf5R2NwW0GQR1XS
K5	MVzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NFHp[5NKSzVyPUKuNFc5OTFizszN	M3jN[nNCVkeHUh?=
HLE	M3XpdWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MorQTWM2OD1{LkC4OVI6KM7:TR?=	MXrTRW5ITVJ?
HSC-2	MWTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MmfnTWM2OD1{LkGyPFk5KM7:TR?=	NV\NZZhoW0GQR1XS
LCLC-97TM1	NFXaTmhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NV;UZW5DUUN3ME2yMlE1PTh\|IN88US=>	M4HiN3NCVkeHUh?=
DMS-273	MlvMS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NE\NUlVKSzVyPUKuNVQ5OzdizszN	NGDRcYhUSU6JRWK=
TE-8	MkHHS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NFfmdWlKSzVyPUKuNVU4PjVizszN	M1PuTnNCVkeHUh?=
DSH1	M3HCdGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NVXvfWt{UUN3ME2yMlE3Ozl6IN88US=>	NGrSeIhUSU6JRWK=
CAL-51	MWTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NXeySI42UUN3ME2yMlE3Pjl7IN88US=>	MlS1V2FPT0WU
IST-SL1	NXXMe2xOT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MmXwTWM2OD1{LkG2PFQ1KM7:TR?=	NYfUdpFRW0GQR1XS
GCT	M1;TZ2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MnL3TWM2OD1{LkG3O\|ch\|ryP	M1\YbXNCVkeHUh?=
SW948	MUjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M1\wVWlEPTB;Mj6xPFQ2PiEQvF2=	NGDKU\|FUSU6JRWK=
NOMO-1	NUDQNGMyT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MnHCTWM2OD1{LkG5N\|E4KM7:TR?=	MkSwV2FPT0WU
C8166	NUjPRmp5T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MXrJR\|UxRTJwMkGzN\|Qh\|ryP	NGj2RVJUSU6JRWK=
OC-314	M2\vdWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MYLJR\|UxRTJwMkOyOVkh\|ryP	MWjTRW5ITVJ?
CAL-39	M1e2Rmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MWXJR\|UxRTJwMkO2NlYh\|ryP	MofJV2FPT0WU
MDA-MB-453	MXLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NEfCd4ZKSzVyPUKuNlQzPzVizszN	MmC5V2FPT0WU
A673	MnLSS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MX3JR\|UxRTJwMkW4OlIh\|ryP	NHnJco9USU6JRWK=
HTC-C3	M3nqbGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NF\RNIVKSzVyPUKuNlY5PSEQvF2=	NE\IcZNUSU6JRWK=
NCI-H1666	Ml;lS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M{Xtd2lEPTB;Mj6yPFEyOSEQvF2=	NH3XPFJUSU6JRWK=
PSN1	NVmyNFBDT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M3XIfmlEPTB;Mj6yPFkyOyEQvF2=	NGrHeFBUSU6JRWK=
GI-1	Mk\CS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MnfYTWM2OD1{LkOwOVQ{KM7:TR?=	NFPsT29USU6JRWK=
HuH-7	MV\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MXPJR\|UxRTJwM{C2N\|ch\|ryP	NE\PTFlUSU6JRWK=
JAR	NWTlUldHT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MnG0TWM2OD1{LkOxPVg4KM7:TR?=	NX\TVoh{W0GQR1XS
5637	NF\SNW1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				Mn;JTWM2OD1{LkOyNVI6KM7:TR?=	MlLhV2FPT0WU
GB-1	NH7hVZZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M2OyfGlEPTB;Mj6zNlM{PSEQvF2=	M{C2[HNCVkeHUh?=
KP-N-YS	MXPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MnfKTWM2OD1{LkOyOlE2KM7:TR?=	NIfCSXdUSU6JRWK=
OAW-42	NFPy[mFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NF3SO25KSzVyPUKuN\|M1OTZizszN	M1HJfnNCVkeHUh?=
8-MG-BA	M4q0c2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M3LIbGlEPTB;Mj6zN\|kxPiEQvF2=	M{WyRnNCVkeHUh?=
RH-18	M2SwTmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				Mk\LTWM2OD1{LkO1NFIzKM7:TR?=	M2LX[nNCVkeHUh?=
NCI-H1155	Mm\oS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M1W2W2lEPTB;Mj6zOlczPSEQvF2=	Mn;KV2FPT0WU
NB17	M1TReWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NHLueGhKSzVyPUKuN\|gzPDNizszN	M2f4WXNCVkeHUh?=
NCI-H1437	NWnveXBYT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MnziTWM2OD1{LkSxPFc{KM7:TR?=	NGfKVnhUSU6JRWK=
SN12C	MUXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MlLDTWM2OD1{LkSzNlE1KM7:TR?=	MoXSV2FPT0WU
HSC-3	NYXGSXh4T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				Mk\GTWM2OD1{LkS0OVA6KM7:TR?=	MXPTRW5ITVJ?
GAMG	NYnmO\|lQT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NI[5SFRKSzVyPUKuOFQ2PjFizszN	NXrEW3dnW0GQR1XS
HT-1080	MmPFS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MVrJR\|UxRTJwNES4OlQh\|ryP	NY\pUWhxW0GQR1XS
A549	NIPN[ItIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M3XHZmlEPTB;Mj60OFg6OyEQvF2=	NVzPV21CW0GQR1XS
KNS-62	NWK2d2d1T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NIPZSGJKSzVyPUKuOFUxPjFizszN	NUHrSY1UW0GQR1XS
YKG-1	MoPvS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MnqxTWM2OD1{LkS1OFM4KM7:TR?=	MlPxV2FPT0WU
LU-134-A	MmHRS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NH;LVXhKSzVyPUKuOFcxODhizszN	NIjuVldUSU6JRWK=
FADU	MkTYS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NWLSSIFVUUN3ME2yMlQ4OTZ{IN88US=>	NInFZWFUSU6JRWK=
TGBC11TKB	Mly0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MojzTWM2OD1{LkS3NVc4KM7:TR?=	NXHRe2djW0GQR1XS
HT-3	NVH1XIk1T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M2PYVmlEPTB;Mj60PVU{PSEQvF2=	M1vpfXNCVkeHUh?=
NCI-H2170	MWnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MXvJR\|UxRTJwNUC1OFkh\|ryP	NIDlWJpUSU6JRWK=
Mo-T	MWDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MUPJR\|UxRTJwNUC5Nlch\|ryP	MnSxV2FPT0WU
CCRF-CEM	Mn\lS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NVvlT2VsUUN3ME2yMlU{ODR\|IN88US=>	MorzV2FPT0WU
KU-19-19	NGHWdmRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MWDJR\|UxRTJwNUO1NVMh\|ryP	MkC0V2FPT0WU
NCI-H1048	MmP1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NF\KS3JKSzVyPUKuOVUxOjVizszN	MUPTRW5ITVJ?
KOSC-2	Ml7wS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NIPJZVFKSzVyPUKuOVYxPzZizszN	MnPDV2FPT0WU
A431	MlLmS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NHLN[5RKSzVyPUKuOVY{OzVizszN	NUO1cHBHW0GQR1XS
COR-L23	NIjkSYVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MWjJR\|UxRTJwNUi1OlYh\|ryP	NEC0NIVUSU6JRWK=
MKN28	MVLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MUDJR\|UxRTJwNUmwN\|ch\|ryP	M4LJeHNCVkeHUh?=
22RV1	NFLuVpBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NUjFdIxvUUN3ME2yMlU6Ojd2IN88US=>	NX;OW2JMW0GQR1XS
ABC-1	NVzzeW9bT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NXfwd\|R6UUN3ME2yMlYxPDZizszN	NFfQRVJUSU6JRWK=
NCI-H2126	MmnzS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M3\aU2lEPTB;Mj62NFk5PCEQvF2=	MVvTRW5ITVJ?
DoTc2-4510	M2LxUWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NGPjeHdKSzVyPUKuOlIyQDVizszN	M4Lj[HNCVkeHUh?=
SCC-4	MUnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NWDPRlkzUUN3ME2yMlY{ODF{IN88US=>	MmLjV2FPT0WU
NCI-H661	MXzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MYjJR\|UxRTJwNkSwPFUh\|ryP	MXXTRW5ITVJ?
RPMI-2650	NYO0O3lLT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M1zGcWlEPTB;Mj62OFE1OyEQvF2=	NYrsRVlJW0GQR1XS
NCI-H510A	NY\YVYVsT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NGjtSVFKSzVyPUKuOlQ1OjZizszN	NF23R\|FUSU6JRWK=
BPH-1	M1mzXWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NWfydJV4UUN3ME2yMlY2QDVizszN	MlfOV2FPT0WU
M14	NFPNUZRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NUPhTnNXUUN3ME2yMlY3QTl\|IN88US=>	M1ztT3NCVkeHUh?=
G-402	MV7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NV;1eI1[UUN3ME2yMlcxPDVzIN88US=>	M{HYU3NCVkeHUh?=
AsPC-1	NVu2SpJIT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NGrKTVFKSzVyPUKuO\|EyPyEQvF2=	NWT1bFNMW0GQR1XS
NB12	MYLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				Mli2TWM2OD1{LkexO\|Eh\|ryP	M1KySnNCVkeHUh?=
SK-HEP-1	MmrRS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M2HT[WlEPTB;Mj63OFM6OSEQvF2=	MoTYV2FPT0WU
U-266	MnjwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NXntdmNzUUN3ME2yMlc4OTJzIN88US=>	M2DDcXNCVkeHUh?=
AM-38	MVHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				Mo[wTWM2OD1{Lke3N\|U2KM7:TR?=	M2rmcnNCVkeHUh?=
PC-14	MkPIS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NV;yW4FIUUN3ME2yMlgxPTFizszN	NYC2PYtZW0GQR1XS
EGI-1	NXjaTVBuT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NFjjZoNKSzVyPUKuPFE4PDNizszN	NXr0[mJZW0GQR1XS
LS-411N	MmL4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M4\ifGlEPTB;Mj64NlM{KM7:TR?=	NF;R[VJUSU6JRWK=
BFTC-905	NW\4dWZxT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NVHtO\|BUUUN3ME2yMlg2PTJ\|IN88US=>	NVnsT3BqW0GQR1XS
CaR-1	NXHGbpBvT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MnTRTWM2OD1{Lki2JO69VQ>?	NXnUbolPW0GQR1XS
NCI-H292	MV\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				Ml3vTWM2OD1{Lki2OVk3KM7:TR?=	NGju[2JUSU6JRWK=
8305C	NWLsV3VUT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NYDobY1PUUN3ME2yMlg3PjR3IN88US=>	NI[0PZVUSU6JRWK=
SNU-449	NUD4R4RtT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M4rwdGlEPTB;Mj64PVE5OiEQvF2=	NYW5eZA4W0GQR1XS
LCLC-103H	MmTOS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M2LuU2lEPTB;Mj65NFQ{QCEQvF2=	MnHwV2FPT0WU
SW1573	Mk[2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MYDJR\|UxRTJwOU[wPFIh\|ryP	MmWwV2FPT0WU
MLMA	Ml3XS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MnPOTWM2OD1{Lkm2O\|E4KM7:TR?=	M2X0N3NCVkeHUh?=
NCI-H1355	NHfSfIdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MYXJR\|UxRTNwMEC3PVYh\|ryP	MYnTRW5ITVJ?
RMG-I	NW\EOnhLT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NGLwPWpKSzVyPUOuNFI2QTJizszN	MYHTRW5ITVJ?
BB65-RCC	NEnnWVdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M1S4cWlEPTB;Mz6wN\|MyPCEQvF2=	M{DtfXNCVkeHUh?=
PC-3	NH\UdolIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MXPJR\|UxRTNwMEO4O\|Qh\|ryP	M2fSdnNCVkeHUh?=
SF268	NX3kUmZ3T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NWXwTHl6UUN3ME2zMlA1PTJ\|IN88US=>	MW\TRW5ITVJ?
NCI-H810	M3fuTmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MnfKTWM2OD1\|LkC0PFI{KM7:TR?=	NVHTR\|FRW0GQR1XS
MEG-01	M3vETGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				Ml\HTWM2OD1\|LkC2NVY1KM7:TR?=	NVPrdHdsW0GQR1XS
SW13	M33sbGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NVHw[29zUUN3ME2zMlA4QDR5IN88US=>	Mo\qV2FPT0WU
RH-1	MVnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NXrncYNOUUN3ME2zMlExOjd6IN88US=>	MkTmV2FPT0WU
GT3TKB	MoP6S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M2LqdWlEPTB;Mz6xNVI5OyEQvF2=	NFm0XmRUSU6JRWK=
TK10	NUDPTo1sT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MX7JR\|UxRTNwMUO3NlQh\|ryP	MVXTRW5ITVJ?
T-24	MkHYS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NUSyWZpWUUN3ME2zMlE2ODdizszN	NGTjNpNUSU6JRWK=
A498	M3;kdGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NX\UbWxTUUN3ME2zMlIxQDdzIN88US=>	MlfhV2FPT0WU
GR-ST	MXfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NFGyfHpKSzVyPUOuNlIyOzlizszN	NV;xR25zW0GQR1XS
LB2518-MEL	M3LUemdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NFnKTm9KSzVyPUOuNlI{QThizszN	MYLTRW5ITVJ?
T47D	M1vxNWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NHHuN4xKSzVyPUOuNlM3OjdizszN	M3XWTXNCVkeHUh?=
NCI-H1651	MX7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NHjCb\|ZKSzVyPUOuNlQ3PDRizszN	NW\TSotlW0GQR1XS
EC-GI-10	MVzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MYnJR\|UxRTNwMk[xOVMh\|ryP	MlPuV2FPT0WU
HT-29	MmW2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MkT0TWM2OD1\|LkK2OlE1KM7:TR?=	MkC5V2FPT0WU
GI-ME-N	NFT2[3NIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NHyzeVJKSzVyPUOuNlk2OTFizszN	MkLkV2FPT0WU
SW756	NFuxcYRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NX3CSlBPUUN3ME2zMlI6PjJ7IN88US=>	NX3CXYF6W0GQR1XS
RKO	MkP6S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NETRWGtKSzVyPUOuN\|A4PTdizszN	Moq0V2FPT0WU
NCI-H1563	NVeyfpNUT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NVvzS2xsUUN3ME2zMlM{ODF6IN88US=>	MkDmV2FPT0WU
DJM-1	NWS5[oRjT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NVPQXWR2UUN3ME2zMlM4Pjd2IN88US=>	MnPpV2FPT0WU
L-428	MlHHS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MV7JR\|UxRTNwNECwOFUh\|ryP	MWHTRW5ITVJ?
NCI-H2122	NX\jZphOT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MofLTWM2OD1\|LkSxN\|EzKM7:TR?=	MYDTRW5ITVJ?
Ca-Ski	NHPuU\|RIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M2TD[2lEPTB;Mz60OVQ{KM7:TR?=	NX[4fHFxW0GQR1XS
639-V	NXLZR3ZtT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NV7OWllqUUN3ME2zMlQ3ODV5IN88US=>	NHuwfXNUSU6JRWK=
SW1116	MYfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MnL0TWM2OD1\|LkS2NlY6KM7:TR?=	NHfvPFJUSU6JRWK=
DMS-114	MkLYS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MWHJR\|UxRTNwNEewOlYh\|ryP	NGGxb5hUSU6JRWK=
MZ2-MEL	NIPPXG1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M{T5XWlEPTB;Mz60O\|Y5OSEQvF2=	M{PGR3NCVkeHUh?=
COLO-829	MV7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				Ml7KTWM2OD1\|LkWwNFc{KM7:TR?=	Mn3GV2FPT0WU
J82	NV;UZpBYT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MmHYTWM2OD1\|LkWwOVch\|ryP	MlzoV2FPT0WU
EW-13	MWrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NWHzN5ByUUN3ME2zMlUzPTFizszN	MnjmV2FPT0WU
RXF393	MVTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MnzYTWM2OD1\|LkWzNlk1KM7:TR?=	MXHTRW5ITVJ?
CAL-62	NWLyW\|E3T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MUXJR\|UxRTNwNUS1NVQh\|ryP	NHexcmJUSU6JRWK=
OCUB-M	NXnpfXVGT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NITNXIVKSzVyPUOuOVQ3PjVizszN	M1jVRnNCVkeHUh?=
BT-474	NXWxT\|J4T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M{WwcmlEPTB;Mz62N\|MyKM7:TR?=	NXjyV\|ZEW0GQR1XS
KYSE-180	MVvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NFfiUWFKSzVyPUOuOlM{PzJizszN	MWHTRW5ITVJ?
NCI-H650	MnzMS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				Mm\OTWM2OD1\|Lk[0Nlg4KM7:TR?=	MmK3V2FPT0WU
Detroit562	MXXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NIDlcIFKSzVyPUOuOlUxOjJizszN	NFzKUGVUSU6JRWK=
SW48	NFfrSm1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MY\JR\|UxRTNwNkW2OVch\|ryP	MYXTRW5ITVJ?
KYSE-450	MXvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				Mn3YTWM2OD1\|Lk[4OVgzKM7:TR?=	MmDTV2FPT0WU
KYSE-510	NI\2fFdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M2\wTGlEPTB;Mz63NlE5OSEQvF2=	MlrXV2FPT0WU
GP5d	NEXhe41Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MVzJR\|UxRTNwN{K5OUDPxE1?	M3S2[HNCVkeHUh?=
RPMI-7951	MVfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NGPsbWdKSzVyPUOuO\|Q4OjNizszN	Moq0V2FPT0WU
Becker	M2Hs[Wdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NVHQd\|YzUUN3ME2zMlc2ODF{IN88US=>	NGT0b4ZUSU6JRWK=
WM-115	MWDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MlruTWM2OD1\|Lke4NVk2KM7:TR?=	NF;tdFdUSU6JRWK=
G-401	MlrOS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				Mo\STWM2OD1\|Lke5NFg2KM7:TR?=	NUfpfmF2W0GQR1XS
PANC-08-13	NGn4eHFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NX\kcVVHUUN3ME2zMlc6PjB{IN88US=>	NYDkUXJQW0GQR1XS
SW982	MYjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M4PiVWlEPTB;Mz64NFU2OSEQvF2=	M13R[3NCVkeHUh?=
D-263MG	MoPwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NEXTbZBKSzVyPUOuPFIxPTFizszN	MnrKV2FPT0WU
KM-H2	M1nkO2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M1P4PGlEPTB;Mz64NlYzPCEQvF2=	NVH3OnBSW0GQR1XS
SK-MEL-3	NGr5T3dIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M{HFVmlEPTB;Mz64Nlg1OSEQvF2=	M1O2TnNCVkeHUh?=
NCI-H1581	M3jw[Wdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M2e4[WlEPTB;Mz64OFQ5QCEQvF2=	NWHBVHBKW0GQR1XS
LS-123	MoH4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M1LTXWlEPTB;Mz64O\|kxQSEQvF2=	MYPTRW5ITVJ?
CAKI-1	NVe1[\|NXT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MmjQTWM2OD1\|Lki5NFUzKM7:TR?=	NWHZOHhSW0GQR1XS
MEL-JUSO	MlP4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MnraTWM2OD1\|Lki5NVU{KM7:TR?=	NGLBW2pUSU6JRWK=
HCE-4	NH3WXGZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NVvLVW9YUUN3ME2zMlkyPjZ\|IN88US=>	MXfTRW5ITVJ?
TE-10	NFr3TJJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NITmSXNKSzVyPUOuPVIxOSEQvF2=	NFjaR2lUSU6JRWK=
OVCAR-4	NIXXbZhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NFnx[WxKSzVyPUOuPVI5QDlizszN	MlLiV2FPT0WU
ETK-1	MlfxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M4rBPWlEPTB;Mz65OFY{PSEQvF2=	M1TkSnNCVkeHUh?=
A2780	MkLxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NWXSV4d[UUN3ME20MlA2QTZ4IN88US=>	NUfQfm1KW0GQR1XS
LU-65	NEXs[FNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MV\JR\|UxRTRwMEe2N\|Mh\|ryP	NITadnRUSU6JRWK=
BHY	MXLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NITEPHJKSzVyPUSuNVI1QTVizszN	MX\TRW5ITVJ?
COR-L105	M{LDdmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MlXkTWM2OD12LkGzNFUyKM7:TR?=	NYm0fW5nW0GQR1XS
CAL-12T	MVjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NVTVd3pNUUN3ME20MlE{OTB\|IN88US=>	M3GzXnNCVkeHUh?=
SCH	M1rIeGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NFXjfmpKSzVyPUSuNVU4PDNizszN	M4SxVXNCVkeHUh?=
CW-2	M1qx[mdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M4DZeGlEPTB;ND6xPVAxOSEQvF2=	NY[1XoZnW0GQR1XS
HCC1806	M{jhZWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NH\DZnJKSzVyPUSuNlA{OTJizszN	MXTTRW5ITVJ?
KP-N-YN	NWTLUHJPT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NX7vXpdZUUN3ME20MlIxQTJ5IN88US=>	MV3TRW5ITVJ?
T98G	M1qydWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NXnMTIJTUUN3ME20MlIzOTV5IN88US=>	NYXrZmpKW0GQR1XS
CAL-54	MkWzS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NYLzR2w4UUN3ME20MlIzOzhzIN88US=>	M33aPXNCVkeHUh?=
CAL-33	M1TBSmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M2f3PGlEPTB;ND6yN\|A3PCEQvF2=	MmnhV2FPT0WU
SNU-C2B	MmnKS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NFntZlhKSzVyPUSuNlQ4PjlizszN	MWHTRW5ITVJ?
NUGC-3	NV:yW3RjT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				Mn24TWM2OD12LkK1OVA2KM7:TR?=	NIXYfIZUSU6JRWK=
DOK	M1XhWmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NXSzNm5EUUN3ME20MlI3PTl\|IN88US=>	M{\WXnNCVkeHUh?=
MMAC-SF	MmDwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NVr5SFNjUUN3ME20MlI3QDV7IN88US=>	NETSeXpUSU6JRWK=
KYSE-70	MnnSS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MmXGTWM2OD12LkK5N\|Qh\|ryP	NV:0[YFzW0GQR1XS
A204	MUTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MV3JR\|UxRTRwM{W4NFMh\|ryP	NUnrdJF1W0GQR1XS
SCC-25	NW\2bmtGT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MmPVTWM2OD12LkO1PFE6KM7:TR?=	MmLBV2FPT0WU
EPLC-272H	NFPFdVdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NV7pOpFGUUN3ME20MlM5QTVizszN	MXTTRW5ITVJ?
CAL-120	NX[4Um5MT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NVTDVnBMUUN3ME20MlM5QTl{IN88US=>	MkH5V2FPT0WU
LS-513	NVLjU5drT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NWLNVIpQUUN3ME20MlQzOTl6IN88US=>	NXm2R5RUW0GQR1XS
CAPAN-1	MojaS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MmXLTWM2OD12LkSyN\|gzKM7:TR?=	NGn0bmxUSU6JRWK=
ESS-1	MV\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NHvaOHJKSzVyPUSuOFI4OjRizszN	M4fqWnNCVkeHUh?=
GMS-10	MVfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				Mo\6TWM2OD12LkSyPFE6KM7:TR?=	NUizfGNJW0GQR1XS
NCI-N87	NVnJ[Zl6T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NGS0bXlKSzVyPUSuOVA5PjhizszN	NUi4T2tvW0GQR1XS
HMV-II	NEO1SJlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NVjjO4ZCUUN3ME20MlUyPzNizszN	NYKxXJRmW0GQR1XS
COLO-741	NGXmXnVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M2TxVGlEPTB;ND61OVk6PCEQvF2=	M4Dse3NCVkeHUh?=
MKN45	M{\xRmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MYLJR\|UxRTRwNUe3N\|Ih\|ryP	NEDhSoVUSU6JRWK=
OAW-28	NFTaR5dIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				Ml30TWM2OD12LkW4N\|k5KM7:TR?=	M4LDdXNCVkeHUh?=
OCI-AML2	MmPuS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MULJR\|UxRTRwNkWyN\|gh\|ryP	NWDaPG1[W0GQR1XS
MDA-MB-231	MkPQS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M3Xp[WlEPTB;ND63NFI1OyEQvF2=	MljNV2FPT0WU
NCI-H1648	NI\rN5ZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				Mn3WTWM2OD12LkeyNlc{KM7:TR?=	M2fwcnNCVkeHUh?=
NCI-H1792	MYDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NYjWN3prUUN3ME20Mlc3OTB5IN88US=>	NYXyNnNwW0GQR1XS
GCIY	MYHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M37JeGlEPTB;ND63O\|QzPCEQvF2=	MYPTRW5ITVJ?
Hs-578-T	NH2xNlNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NH7vcnpKSzVyPUSuO\|c3PTVizszN	MojKV2FPT0WU
SW962	NUjiRWJRT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NWDWNJJNUUN3ME20Mlc5ODFzIN88US=>	MX\TRW5ITVJ?
NCI-H630	NH7ONopIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MY\JR\|UxRTRwN{iwPFEh\|ryP	Ml\0V2FPT0WU
786-0	Mlu2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M2fWeGlEPTB;ND63PFc4OyEQvF2=	NUDVWYs1W0GQR1XS
FTC-133	Mny0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NY[2[5ZRUUN3ME20Mlc6OjZ\|IN88US=>	MX\TRW5ITVJ?
BT-20	MXrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MkLvTWM2OD12Lke5OFI6KM7:TR?=	NH;WT\|FUSU6JRWK=
Mewo	MkfPS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MUPJR\|UxRTRwOEG3OFch\|ryP	NETiS41USU6JRWK=
SW780	NEf3SVdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MYTJR\|UxRTRwOEW3OlYh\|ryP	M4\lWXNCVkeHUh?=
OE33	Mke1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MVfJR\|UxRTRwOEe3NVMh\|ryP	NGL0bnpUSU6JRWK=
HCC1569	NV7PZXp2T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M3;mXWlEPTB;ND64PFQ2QCEQvF2=	NFXIT4xUSU6JRWK=
TE-6	MY\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NFjRR4lKSzVyPUSuPVM6PzdizszN	MnT3V2FPT0WU
SK-N-FI	MljCS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MXXJR\|UxRTRwOUS0NlEh\|ryP	M4LFOXNCVkeHUh?=
PANC-03-27	MXfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				Ml7vTWM2OD12Lkm5PVYzKM7:TR?=	M{TufHNCVkeHUh?=
MCF7	MnP6S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MkHUTWM2OD13LkCwO\|M5KM7:TR?=	M165RnNCVkeHUh?=
UACC-257	M1[4bWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M{ToeGlEPTB;NT6wNlg1PSEQvF2=	NHT3SGpUSU6JRWK=
SW1088	M3jCemdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MX7JR\|UxRTVwMEK5OFQh\|ryP	NI\wVldUSU6JRWK=
A704	NWT2V2UzT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M4rS[2lEPTB;NT6wN\|A3KM7:TR?=	M2LTd3NCVkeHUh?=
A2058	M1fkXGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MUPJR\|UxRTVwMEW5NFgh\|ryP	MU\TRW5ITVJ?
Calu-3	M{Lw[Gdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MmLSTWM2OD13LkC2OFUzKM7:TR?=	NGXqNoRUSU6JRWK=
RERF-LC-MS	NV71[VFZT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M3WwdGlEPTB;NT6wOlkxOyEQvF2=	NIDjcXpUSU6JRWK=
AU565	NH3nPWRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MoL2TWM2OD13LkC5O\|AzKM7:TR?=	NWPRd41jW0GQR1XS
DMS-79	M3K2T2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MYDJR\|UxRTVwMUO4PFMh\|ryP	NUHtOHk2W0GQR1XS
DK-MG	MXLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NVToV4QzUUN3ME21MlE5PDN6IN88US=>	NFXtTZpUSU6JRWK=
HuCCT1	NYjRfZJbT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MV3JR\|UxRTVwMkO4OVYh\|ryP	M2TNbHNCVkeHUh?=
HT-144	MmPPS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NXr0O3pqUUN3ME21MlI1QTh5IN88US=>	NVHJR4N[W0GQR1XS
M059J	MknBS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M1y2[GlEPTB;NT6yOVc3KM7:TR?=	M3jhZXNCVkeHUh?=
COLO-792	NX;ZUYNTT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NUP3fW42UUN3ME21MlI3OzV4IN88US=>	M3TJW3NCVkeHUh?=
SF539	MVPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MYnJR\|UxRTVwMk[2N\|Ih\|ryP	MUTTRW5ITVJ?
SK-UT-1	NH\PXVVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MmjGTWM2OD13LkK3O\|UyKM7:TR?=	MWPTRW5ITVJ?
NCI-H1703	NIqx[oxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MVPJR\|UxRTVwM{W4NlYh\|ryP	M2\TbXNCVkeHUh?=
SW837	MmXxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MmXSTWM2OD13LkO3PFc5KM7:TR?=	NF\ibXJUSU6JRWK=
U251	M{HuPGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NYDJfFJWUUN3ME21MlM6ODl4IN88US=>	NFT2ZYpUSU6JRWK=
SW1710	MoXoS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NGXXdHZKSzVyPUWuOFE2PTRizszN	NGW5eJpUSU6JRWK=
NCI-H1299	M2q2TGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NHLBRmpKSzVyPUWuOFY{OzVizszN	MlzXV2FPT0WU
RVH-421	Ml;SS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M16zTmlEPTB;NT60PVkxQCEQvF2=	NU[4XZhwW0GQR1XS
UM-UC-3	NVu3WGp7T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M1vBb2lEPTB;NT62NlY2OSEQvF2=	MmDxV2FPT0WU
MDA-MB-175-VII	Mnr2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MkTUTWM2OD13Lk[0NFQyKM7:TR?=	MVrTRW5ITVJ?
KYSE-270	NFrDfWdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M3K1RWlEPTB;NT62OlA{OSEQvF2=	NUnOW3N3W0GQR1XS
COLO-668	MmT4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M3i2[GlEPTB;NT63NVMzKM7:TR?=	MmLXV2FPT0WU
LN-405	NHTUZohIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NIfRdVVKSzVyPUWuO\|MxQDVizszN	NHvLVItUSU6JRWK=
HT-1376	NHS5U\|JIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NWT1VIR2UUN3ME21Mlc5ODV{IN88US=>	MknFV2FPT0WU
769-P	NVTxflRQT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MWjJR\|UxRTVwOE[3NVgh\|ryP	NYXId2NRW0GQR1XS
HuP-T3	MWjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M3nHZ2lEPTB;NT64PFY4PyEQvF2=	NG\qSJRUSU6JRWK=
MDA-MB-415	M2nxSmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MmPrTWM2OD13LkmyNVM6KM7:TR?=	MUHTRW5ITVJ?
MKN7	MonBS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MXnJR\|UxRTVwOUi4JO69VQ>?	NVTXe3ZrW0GQR1XS
KS-1	NYjpWJI{T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				Ml\6TWM2OD13Lkm4PFM3KM7:TR?=	Mn:4V2FPT0WU
647-V	M13QSGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NF\sPWxKSzVyPUWuPVkyPDhizszN	M{PhOHNCVkeHUh?=
COLO-679	MlrjS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MWTJR\|UxRTZwMECyOVUh\|ryP	MYfTRW5ITVJ?
AN3-CA	MkewS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MmC3TWM2OD14LkCzOFQyKM7:TR?=	NV\0U496W0GQR1XS
C32	NYPTepdUT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NYft[ZM2UUN3ME22MlE{ODN2IN88US=>	NWDLUmxUW0GQR1XS
KM12	NWO4UFQ5T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MVLJR\|UxRTZwMkSwPVkh\|ryP	MWPTRW5ITVJ?
KINGS-1	NF\FPIFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NWPQdFFmUUN3ME22MlI3OTV{IN88US=>	NUDlSlFVW0GQR1XS
KYSE-410	NVfjXWdtT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MmDkTWM2OD14LkOwOlQ2KM7:TR?=	NH\zbXNUSU6JRWK=
HPAF-II	NHLXbIhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MXzJR\|UxRTZwM{W0PEDPxE1?	NXO0[YZUW0GQR1XS
LAN-6	MmnJS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NWXNdVhjUUN3ME22MlQ6PjNzIN88US=>	M2r5XnNCVkeHUh?=
LU-99A	NG\QWItIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NULXdWp7UUN3ME22MlU2QTh7IN88US=>	NUP5WXM1W0GQR1XS
SJSA-1	M2faXWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MVTJR\|UxRTZwNU[zOFch\|ryP	MnzTV2FPT0WU
MSTO-211H	MlvXS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NIXJTI1KSzVyPU[uO\|IzOzNizszN	MWLTRW5ITVJ?
SW900	M1;mXGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NF24TFNKSzVyPU[uO\|YzOjFizszN	M133OHNCVkeHUh?=
LNCaP-Clone-FGC	MU\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MY\JR\|UxRTZwOEC0NFMh\|ryP	M{K5NHNCVkeHUh?=
OMC-1	NHLRRVBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NI\JU4JKSzVyPU[uPFU1ODJizszN	MYPTRW5ITVJ?
IST-MEL1	MUTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MWTJR\|UxRTZwOEm2Olkh\|ryP	NF3XWYZUSU6JRWK=
TE-9	M4TIcGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				Mn73TWM2OD14Lki5PFQ4KM7:TR?=	MmrzV2FPT0WU
NCI-H2030	NWjiZ\|RNT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NHK1Zm1KSzVyPU[uPVEzOjZizszN	MnnUV2FPT0WU
BFTC-909	MULHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M3PCSGlEPTB;Nz6wNFY1OSEQvF2=	M3X6bHNCVkeHUh?=
NCI-SNU-5	MorjS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NULw[GNZUUN3ME23MlAzOTV7IN88US=>	NETqWnhUSU6JRWK=
TE-5	M3XWXmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M2GzVGlEPTB;Nz6wNlg5OSEQvF2=	NI\VPFBUSU6JRWK=
SK-MES-1	MVPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MnTLTWM2OD15LkC1OFI4KM7:TR?=	NGTaOG5USU6JRWK=
SHP-77	NFPKVYdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NV\pS\|c2UUN3ME23MlE{QTV{IN88US=>	M{PObXNCVkeHUh?=
NCI-H1623	MWPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M{\y[2lEPTB;Nz6xOFA4OiEQvF2=	NFv2TGxUSU6JRWK=
TE-11	NGrRXW9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NXy3fo1xUUN3ME23MlE2OTh2IN88US=>	M1rB[3NCVkeHUh?=
EKVX	MlruS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MoTiTWM2OD15LkG5NlY4KM7:TR?=	NWn0WG9oW0GQR1XS
OVCAR-3	M2Ppcmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NX3l[md6UUN3ME23MlIyOTN\|IN88US=>	M{TYd3NCVkeHUh?=
C3A	NV71V3FvT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NHT3WoNKSzVyPUeuN\|Q2OiEQvF2=	NXj5UoQzW0GQR1XS
CFPAC-1	NHfUPJdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NGXsS3ZKSzVyPUeuN\|YzOjJizszN	NYrySYM3W0GQR1XS
MG-63	MYjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MmHXTWM2OD15LkSxPFQ6KM7:TR?=	M2r1TnNCVkeHUh?=
KYSE-140	Moi1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NF\J[m1KSzVyPUeuOFQxPjFizszN	MV;TRW5ITVJ?
MPP-89	MmXRS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MXjJR\|UxRTdwNUm3Nlkh\|ryP	MXPTRW5ITVJ?
COLO-824	NWq5Zm8yT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NGPYUG1KSzVyPUeuO\|I5PjNizszN	MoT0V2FPT0WU
SiHa	M37RXWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NXHIR4hEUUN3ME23Mlg{PzB5IN88US=>	NH32XohUSU6JRWK=
SNU-387	NH63ZlZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MWXJR\|UxRTdwOEWzOFch\|ryP	NV7OOmV3W0GQR1XS
A172	MmrkS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NXP1UGY6UUN3ME23Mlg3OTd{IN88US=>	Mm[0V2FPT0WU
COLO-680N	NGH6No1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				Ml;WTWM2OD15LkmxO\|Mh\|ryP	MWTTRW5ITVJ?
HCC1395	NGDWdVJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MkXMTWM2OD16LkC1OFUzKM7:TR?=	NV3tVHk1W0GQR1XS
NCI-H28	MnTRS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MWTJR\|UxRThwMEW5OlMh\|ryP	NXTuSG5{W0GQR1XS
LC-2-ad	NFTCRoJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NHO2Uo9KSzVyPUiuNlE6OzdizszN	MUnTRW5ITVJ?
S-117	MofsS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				Ml2yTWM2OD16LkK1N\|U{KM7:TR?=	NVPXW2RbW0GQR1XS
NCI-H1838	Ml3TS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NVTP[lBmUUN3ME24MlI2PzhzIN88US=>	NUPsXm11W0GQR1XS
PANC-10-05	NFjy[4FIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MXrJR\|UxRThwM{ewOFch\|ryP	NVPwW4hkW0GQR1XS
KALS-1	MVTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M2fnN2lEPTB;OD61NFkzQCEQvF2=	MojOV2FPT0WU
LS-1034	NXm2R4d6T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M4nj[GlEPTB;OD61O\|Q{PyEQvF2=	NH\YUpBUSU6JRWK=
TGBC1TKB	NVH5RZhuT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				Ml21TWM2OD16LkezOVM2KM7:TR?=	NVzrbIhuW0GQR1XS
OE19	MVfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NFHtV41KSzVyPUiuO\|YzPjJizszN	MomxV2FPT0WU
D-502MG	MVrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MkLHTWM2OD16Lke2PVk1KM7:TR?=	NYnXS3RKW0GQR1XS
JEG-3	MnjvS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NX\aZpZ{UUN3ME24Mlc5PjF6IN88US=>	MnvWV2FPT0WU
DBTRG-05MG	M{KzPWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MV;JR\|UxRThwOEe1OlUh\|ryP	MkH3V2FPT0WU
ME-180	M3HXWWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NUOzclhWUUN3ME25MlA3PzJ3IN88US=>	M3fDOnNCVkeHUh?=
NCI-H1573	MUfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M{DyU2lEPTB;OT6xNFU{OiEQvF2=	MVHTRW5ITVJ?
HCC2998	M{jSd2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NILzepFKSzVyPUmuNVM3QDFizszN	NFHHOlhUSU6JRWK=
ACHN	MV\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NEi2PJlKSzVyPUmuNlQ6PzVizszN	NXy5SWZYW0GQR1XS
D-392MG	Mo\RS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M3v0c2lEPTB;OT6yOVcyPSEQvF2=	Mn2xV2FPT0WU
no-11	MYHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MnnOTWM2OD17LkK2NFI5KM7:TR?=	MXHTRW5ITVJ?
KLE	M{HUXWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NH3Hc3pKSzVyPUmuN\|IzOzJizszN	NVG3OFFGW0GQR1XS
Calu-6	M3[0RWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NUDqTFNKUUN3ME25MlM4PTJ6IN88US=>	MnTjV2FPT0WU
LB831-BLC	MorPS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M4juXGlEPTB;OT60OVE4OSEQvF2=	NFrURYlUSU6JRWK=
SW684	M1\zOGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M2TBbGlEPTB;OT60OlEyPiEQvF2=	M3GxVXNCVkeHUh?=
SH-4	MX3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MmLXTWM2OD17LkS5N\|Y1KM7:TR?=	NXO2clc{W0GQR1XS
IST-MES1	NHuzWY5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NViyems2UUN3ME25MlUyPjR2IN88US=>	NEfxbGlUSU6JRWK=
Saos-2	NGO1emlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NYLocoJRUUN3ME25MlUzOTl3IN88US=>	M{DCPHNCVkeHUh?=
NCI-H2087	MoDrS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M1;SbGlEPTB;OT62O\|M2OiEQvF2=	MoCzV2FPT0WU
SCC-9	MkLpS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MojqTWM2OD17LkexPFE3KM7:TR?=	NIO2fFBUSU6JRWK=
MFE-280	M2PVT2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MWXJR\|UxRTlwN{K3PFUh\|ryP	MkfCV2FPT0WU
BEN	NFjJcXNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NH;kd49KSzVyPUmuPFIyPTlizszN	Ml3HV2FPT0WU
CP50-MEL-B	MX7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MnfRTWM2OD17LkmyOFMzKM7:TR?=	NXmwVoM5W0GQR1XS
SK-MEL-28	NVH5eYFJT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M3\RVmlEPTB;MUCuNFE6OyEQvF2=	NXjUS\|c2W0GQR1XS
NCI-H2452	Ml3sS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NWrvW5ZOUUN3ME2xNE4yPiEQvF2=	MVvTRW5ITVJ?
NCI-H1395	M4PmOmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NHPtTnJKSzVyPUGwMlE4QCEQvF2=	Mk\YV2FPT0WU
NCI-H2052	Mnm0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NWTPSXpKUUN3ME2xNE4yQDh{IN88US=>	NGrHZ3pUSU6JRWK=
A375	NFT1U3NIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NYGwfWxlUUN3ME2xNE4zPDV{IN88US=>	MX\TRW5ITVJ?
HCC38	NVzBbW04T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MW\JR\|UxRTFyLkOyNkDPxE1?	MlXVV2FPT0WU
LK-2	M{PxO2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MYfJR\|UxRTFyLkSyNFgh\|ryP	Mni2V2FPT0WU
SF126	M2Hze2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NF3nb3FKSzVyPUGwMlQ4OjdizszN	MnnyV2FPT0WU
SK-MEL-1	MX7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				Mnr4TWM2OD1zMD63PFM5KM7:TR?=	MYHTRW5ITVJ?
ACN	MYnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MXPJR\|UxRTFyLki2O\|kh\|ryP	NWjiO3hKW0GQR1XS
BB30-HNC	NYm1cGYxT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NYXLOG5CUUN3ME2xNE45PzFzIN88US=>	NU\Rbog4W0GQR1XS
NCI-H747	MYrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M3HkdWlEPTB;MUCuPFc1PiEQvF2=	NVznTYI1W0GQR1XS
KYSE-150	MUXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NYnnTYNvUUN3ME2xNU4xOzh5IN88US=>	MX7TRW5ITVJ?
D-247MG	NFf1clJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NIXPZZpKSzVyPUGxMlExODlizszN	Ml3BV2FPT0WU
BxPC-3	NYLXO2o4T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MkDrTWM2OD1zMT6zO\|Q4KM7:TR?=	Moe0V2FPT0WU
SK-MEL-30	MYDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NYrBe2pRUUN3ME2xNU41ODd7IN88US=>	MlnaV2FPT0WU
CAS-1	NFLvXIZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NWHoXXZZUUN3ME2xNU41OTB7IN88US=>	NV31XZZzW0GQR1XS
no-10	MVLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NW\zXYhpUUN3ME2xNk4yOjF5IN88US=>	NVSxT2FWW0GQR1XS
NCI-H2405	MVzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NVzGcY5ZUUN3ME2xNk4zODN4IN88US=>	NVrCXnRJW0GQR1XS
KGN	NWj3eGVvT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NF\PU\|VKSzVyPUGyMlI6ODFizszN	M4LFbHNCVkeHUh?=
BB49-HNC	NVnI[4x5T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MXPJR\|UxRTF{LkO5OVYh\|ryP	NULwb5Q5W0GQR1XS
NCI-H1693	NWXEbVhxT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NFTrdFlKSzVyPUGyMlU5OTZizszN	MYrTRW5ITVJ?
RO82-W-1	NWTSVHdYT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NHvDXpJKSzVyPUGzMlA3PDlizszN	M3PWcnNCVkeHUh?=
CAL-85-1	NUS1cplET3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MnfkTWM2OD1zMz60N\|k6KM7:TR?=	MWLTRW5ITVJ?
H-EMC-SS	M{L0TGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NF\QRVhKSzVyPUGzMlkyODRizszN	NIHtN5dUSU6JRWK=
SW1783	NF62SGlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NG\3N4tKSzVyPUG0MlI{QTFizszN	MVLTRW5ITVJ?
LB771-HNC	M335Rmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MV\JR\|UxRTF2LkSxPUDPxE1?	MYjTRW5ITVJ?
HCC70	MW\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NWfHTlJoUUN3ME2xOE41OjN\|IN88US=>	M{jRVHNCVkeHUh?=
KNS-81-FD	NGnJR3NIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MX;JR\|UxRTF2LkewOFUh\|ryP	MnvnV2FPT0WU
KYSE-520	NX3oNFI3T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MljOTWM2OD1zND65Nlch\|ryP	MmLKV2FPT0WU
TGBC24TKB	NYnRXmpHT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M3jPTGlEPTB;MUSuPVU{QSEQvF2=	NUHjW2VYW0GQR1XS
SNB75	NHL1UGxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MUPJR\|UxRTF3LkC3Nlkh\|ryP	NXvNblBSW0GQR1XS
SW872	Ml;ES5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MVXJR\|UxRTF3LkKyNVgh\|ryP	M3;qcnNCVkeHUh?=
U031	MYXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				Mle5TWM2OD1zNT64NFI5KM7:TR?=	M13FdnNCVkeHUh?=
ChaGo-K-1	NXLKbVgzT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MV3JR\|UxRTF3LkizOVkh\|ryP	MWLTRW5ITVJ?
NCI-H441	NW\tVVBvT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MofITWM2OD1zNj6wNFM6KM7:TR?=	MXfTRW5ITVJ?
TE-12	MnH3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NFfMXnVKSzVyPUG2MlE5PzNizszN	M{TKWnNCVkeHUh?=
NCI-H1755	MmHuS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MXnJR\|UxRTF4LkW3N{DPxE1?	NGDFUJhUSU6JRWK=
KNS-42	MmX0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M3:5WGlEPTB;MU[uOlU5QSEQvF2=	Mn\tV2FPT0WU
SK-PN-DW	M4TnT2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MnnPTWM2OD1zNz60NlAyKM7:TR?=	NIXvd3pUSU6JRWK=
NCI-H226	M37Lemdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M4nmd2lEPTB;MUeuPVM1PSEQvF2=	MVzTRW5ITVJ?
K-562	MoeyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M1LCZWlEPTB;MUiuOlMyPyEQvF2=	MWjTRW5ITVJ?
A388	NF3OOoZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MULJR\|UxRTF7LkCzNFMh\|ryP	M4DVeHNCVkeHUh?=
ZR-75-30	MkS3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M2GwemlEPTB;MUmuNFk3QCEQvF2=	M1jhPHNCVkeHUh?=
LU-135	M4Txdmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NHvGWo9KSzVyPUG5MlI3OzZizszN	NF;ITJpUSU6JRWK=
NCI-H2029	NH\xU4lIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M2fGV2lEPTB;MUmuOlAzOSEQvF2=	NVq5Z5NRW0GQR1XS
HT-1197	NH;vWnZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M{\VNmlEPTB;MUmuPVIzPyEQvF2=	M1v4XnNCVkeHUh?=
IGR-1	M3HSSGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NIXUXIRKSzVyPUKwMlMyOTdizszN	NX\X[2lpW0GQR1XS
U-87-MG	M3zZb2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NIfwZ4JKSzVyPUKwMlY1OTNizszN	MUDTRW5ITVJ?
NCI-H1304	M3q1Umdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MYfJR\|UxRTJyLke1NFEh\|ryP	M{PmXXNCVkeHUh?=
RCC10RGB	NFznRZJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				Mkj1TWM2OD1{MT6yPFI6KM7:TR?=	MonuV2FPT0WU
NCI-H520	NUPDPWhDT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MkLHTWM2OD1{Mj63OlEyKM7:TR?=	NIfYUoFUSU6JRWK=
SK-LU-1	M4fGXWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NWXMVXFCUUN3ME2yN{4xPzF6IN88US=>	M1\5RnNCVkeHUh?=
UACC-893	NG\oNmNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NYHIbJVTUUN3ME2yN{4yODN6IN88US=>	NFizRYdUSU6JRWK=
NCI-H2347	NEH0PVNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NHPWW3JKSzVyPUKzMlI3PzRizszN	MmW1V2FPT0WU
U-118-MG	NXzWfnVLT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M{jiW2lEPTB;MkOuO\|IyPyEQvF2=	M2rPNnNCVkeHUh?=
NCI-H596	NULnVVlTT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MV3JR\|UxRTJ\|LkmwOVUh\|ryP	M3nydXNCVkeHUh?=
MZ1-PC	Mkm3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NXPXR4RQUUN3ME2yOE43PzV7IN88US=>	NFHsdI5USU6JRWK=
SW1417	NXu5S\|FQT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MWfJR\|UxRTJ3LkK0PVgh\|ryP	M3vVO3NCVkeHUh?=
NCI-H82	MlnsS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MVXJR\|UxRTJ4LkSyPFgh\|ryP	M2jHN3NCVkeHUh?=
COLO-678	NXH5eI9XT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MWDJR\|UxRTJ5LkS5NVkh\|ryP	MmXsV2FPT0WU
KURAMOCHI	NWKwXotbT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M1jsb2lEPTB;MkiuNVI3KM7:TR?=	NY\kWosxW0GQR1XS
NCI-H1650	M3HUeWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M4r4TGlEPTB;M{CuNVkzPCEQvF2=	MX3TRW5ITVJ?
HCC1954	NH;ZWJpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MVPJR\|UxRTNzLkO2OlYh\|ryP	NXfHblVUW0GQR1XS
GAK	MkT4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NUjHWmVqUUN3ME2zNk4zPjF4IN88US=>	MXrTRW5ITVJ?
YAPC	MojHS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MlnDTWM2OD1\|Mz63OlQ5KM7:TR?=	MlPXV2FPT0WU
NCI-H2228	NVTRSVFoT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MoLHTWM2OD1\|ND6zOlA2KM7:TR?=	NGO2VoZUSU6JRWK=
VMRC-RCZ	MkXmS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NXjYSZFwUUN3ME2zOk4{ODJ{IN88US=>	MlzpV2FPT0WU
NMC-G1	NGWyNHZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M3rkWGlEPTB;M{euNFUzQSEQvF2=	M4Tvd3NCVkeHUh?=
D-336MG	M17xcWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NGq4eYtKSzVyPUSxMlg1PDJizszN	M3HDRXNCVkeHUh?=
UACC-62	NWrOfnJ6T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MniwTWM2OD12Mj61OVA2KM7:TR?=	Mkj6V2FPT0WU
C-33-A	MmfxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NXryWXBbUUN3ME20OU4{OjV4IN88US=>	NXHVRlkyW0GQR1XS
HCC1937	NHz3O2tIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NXvTO5hGUUN3ME20O{4yQTV6IN88US=>	NIX6TmdUSU6JRWK=
HDLM-2	Mn63S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NXPYWXRyUUN3ME20O{4zOjh5IN88US=>	NFnNZ5dUSU6JRWK=
NCI-H727	Mkm0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MlnWTWM2OD12Nz6yOFUyKM7:TR?=	M3nJTHNCVkeHUh?=
NY	MVXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M2ezRmlEPTB;NEmuN\|kxQCEQvF2=	NWO0XVQ6W0GQR1XS
NCI-H2291	NY\EPXNHT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				Mnm2TWM2OD12OT64N\|AyKM7:TR?=	NWX3XIlFW0GQR1XS

... Click to View More Cell Line Experimental Data

Assay

Methods	Test Index	PMID
Western blot	Ac-Histone H4 / Ac-Histone H3; PubMed: 21598070 J Neurooncol D54 and U87 glioma cells were treated with lower concentrations (1-3 µM) of vorinostat. The effects on histone acetylation was assessed by immunoblotting. phospho-CDK1; PubMed: 21598070 Changes in level of inhibitory phosphorylation of cdk1 after treatment with vorinostat was determined at 24 and 48 h (using a Tyr-15 residue phospho-specific antibody) along with total cdk1 as loading control. phospho-Cdc25c / Cdc25c; PubMed: 21598070 J Neurooncol Time course of changes in phospho-cdc25c levels after exposure to vorinostat (5 µM). Cyclin B1; PubMed: 21598070 J Neurooncol Cyclin B1 levels were determined in D54 and U87 cells after treatment with various doses of vorinostat at 24 and 48 h. c-Myc / c-Raf / Akt / Cyclin D1 / CDK4; PubMed: 19440035 Cancer Biol Ther Cell lysates from JeKo-1 and Mo2058 cells exposed to vorinostat were immunoblotted for c-Myc, c-Raf, AKT, cyclin D1, CDK4 and acetylated histone H3. The levels of β-actin served as the loading control. p-eIF2α / ATF4 / CHOP ; PubMed: 20072656 Neoplasia Western blot was performed to evaluate activated eIF2α (P-eIF2α), translational up-regulation of ATF4, and CHOP expression in U251 cells after vorinostat exposure. p21; PubMed: 21598070 J Neurooncol To determine the dose response relationship to vorinostat, cells were exposed to various higher concentrations (5–10 µM) of the agent and the levels of p21 determined by immunoblotting.	21598070 19440035 20072656
Immunofluorescence	HDAC1 / CK19; PubMed: 29917299 Cancer Sci Immunocytochemistry to detect the expression of HDAC1 and CK 19 in PDAC cells with/without Vorinostat treatment. HDAC1 and CK19 were stained red and green, respectively. The Hoechst‐stained nuclei appear blue. Scale bar: 100 μm. The CK19 expression in PSN1 and MiaPaCa2 was increased by Vorinostat treatment. Nrf2; PubMed: 20566897 Blood Vorinostat induced translocation of Nrf2 from cytosol to nucleus. U937 cells were treated with 2μM vorinostat for 18 hours and then cytospun. Cells were fixed and labeled for Nrf2 protein (red) and nucleus (blue, 4,6-diamidino-2-phenylindole) as described in “Immunofluorescence and confocal microscopy.” Images were taken by Nikon Eclipse TE2000 confocal microscope with 40×/1.30 numeric aperture oil objective lens. Ctrl indicates control cells without treatment; and Vor, vorinostat. α-SMA; PubMed: 26330748 Mol Vis Representative immunofluorescence images and the quantification graph showing the effect of vorinostat (2.5 µM), TGIF1, and TGIF2 siRNA knockdown on αSMA. Control human corneal fibroblast cultures (-TGFβ) showed no αSMA staining. Cultures treated with TGFβ1 (5 ng/ml) showed a robust αSMA staining. Vorinostat treatment markedly attenuated TGFβ-evoked αSMA staining. The knockdown of TGIF1 (+TGFβ+vorinostat+TGIF1siRNA) and TGIF2 alone (+TGFβ+vorinostat+TGIF2siRNA) or in combination (+TGFβ +vorinostat +TGIF1 +2siRNA) markedly blocked the effect of vorinostat on αSMA. Scale bar=100 μm. Ac-STAT3 / IGF2; PubMed: 27086926 Oncogene Immunofluorescence staining of Ac-STAT3 and IGF2 after vorinostat treatment.	29917299 20566897 26330748 27086926
Growth inhibition assay	Cell apoptosis; PubMed: 19440035 Cancer Biol Ther Cells were treated with indicated concentrations of vorinostat for 48 hours. Following this, the percentage of annexin-V-stained apoptotic cells was determined by flow cytometry. Values represented as bar graphs are the mean of 3 experiments plus or minus the standard error (SE) Cell viability; PubMed: 27086926 Oncogene The effects of vorinostat on the viability of the indicated NSCLC cell lines and their corresponding acquired VoR sublines. Cell viability was determined by the MTT assay (n = 3).	19440035 27086926
ELISA	IGF2; PubMed: 27086926 Oncogene Determination of vorinostat-induced IGF2 production by ELISA (n = 3). The conditioned mediums (CMs) obtained from cells treated with vorinostat (5 μM) for 2 days were used for ELISA. IL-13 / IL-10 / IL-5; PubMed: 18541724 Blood Effect of vorinostat on TH1/TH2 cytokine secretion in HL cell lines. Cells were incubated with medium or vorinostat (5 μM) for 24 hours and supernatants were examined for cytokine levels by ELISA. Each value represents a mean of 3 independent experiments done in triplicate (± SEM). M-CSF; PubMed: 23042302 Carcinogenesis Primary PyMT tumor cells were treated with SAHA (0-1000nM) for varying time points (8–48h), and supernatants were assayed by ELISA for M-CSF secretion. P < 0.05 and P < 0.001 versus control treatment. MMP-9; PubMed: 23042302 Carcinogenesis Primary PyMT tumor cells were treated with SAHA (0-1000nM) for varying time points (8–48h), and supernatants were assayed by ELISA for MMP-9 secretion. P < 0.05 and **P < 0.001 versus control treatment.	27086926 18541724 23042302

In vivo

Administration of Vorinostat (~100 mg/kg/day) significantly inhibits the growth of CWR22 human prostate xenografts in nude mice with tumor reductions of 78%, 97% and 97%, at doses of 25 mg/kg/day, 50 mg/kg/day and 100 mg/kg/day, respectively, compared with control. Vorinostat induces the accumulation of acetylated core histones and prostate-specific antigen mRNA expression in CWR22 cells, resulting in higher levels of serum prostate-specific antigen than predicted from tumor volume alone. ^[2] Oral administration of Vorinostat (0.67g/L) crosses the blood-brain barrier, increases histone acetylation in the brain, and dramatically improves the motor impairment in the R6/2 mice model of Huntington's disease. ^[5]

Protocol

Kinase Assay: ^[1]	- Collapse Immunoprecipitation-HDAC assays: The lysate of Jurkat cells is incubated for 1 hour on ice and cleared by centrifugation at 12,000 g for 10 minutes at 4 °C. Supernatants are precleared with 30 μL of 50% protein G-Sepharose slurry for 1 hour at 4 °C. Beads are pelleted by centrifugation and supernatants are incubated for 1 hour at 4 °C with 10 μg of IgG fraction from anti-HDAC1 or HDAC3 polyclonal antisera (preincubated 2 hours at room temperature with either the homologous or heterologous immunizing peptide). Both antisera are raised in rabbits against the carboxylterminal peptide of HDAC1 and HDAC3 by using synthetic peptides coupled to keyhole limpet hemocyanin. 30 μL of 50% protein G-Sepharose slurry is added for 1 hour at 4 °C. Immune complexes are pelleted by centrifugation and washed three times with 1 mL of lysis buffer. Beads are resuspended in 200 μL of HDAC buffer (20 mM Tris-HCl, pH 8.0/150 mM NaCl/10% glycerol), and the HDAC assay is performed with an ³H-acetylated peptide corresponding to amino acids 1-24 of histone H4. Released [³H]acetic acid is quantified by scintillation counting. For inhibitions studies, the immunoprecipitated complexes are preincubated with the different concentrations of Vorinostat for 30 minutes at 4 °C.
Cell Research: ^[2]	- Collapse Cell lines: LNCaP, PC-3, and TSU-Pr1 Concentrations: Dissolved in DMSO, final concentrations ~7.5 μM Incubation Time: 1, 2, 3 and 4 days Method: Cells are exposed to various concentrations of Vorinostat for 1, 2, 3 and 4 days. Cell viability is assessed by trypan blue dye exclusion. (Only for Reference)
Animal Research: ^[2]	- Collapse Animal Models: Male BALB/c nude (nu/nu) mice implanted with CWR22 tumor cells Dosages: ~100 mg/kg/day Administration: Injection i.p. (Only for Reference)

References

- Collapse

Solubility (25°C)

In vitro	DMSO	52 mg/mL (196.74 mM)
	Water	Insoluble
	Ethanol	''3 mg/mL
In vivo	Add solvents to the product individually and in order(Data is from Selleck tests instead of citations): 2% DMSO+30% PEG 300+5% Tween 80+ddH2O For best results, use promptly after mixing.	5mg/mL

* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.

Chemical Information Download Vorinostat (SAHA) SDF

Molecular Weight	264.3
Formula	C₁₄H₂₀N₂O₃
CAS No.	149647-78-9
Storage	3 years-20°C powder 2 years-80°C in solvent
Synonyms	MK0683
Smiles	C1=CC=C(C=C1)NC(=O)CCCCCCC(=O)NO

In vivo Formulation Calculator (Clear solution)

Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)

Dosage

mg/kg

Average weight of animals

Dosing volume per animal

Number of animals

Step 2: Enter the in vivo formulation (Different batches have different solubility ratios, please contact Selleck to provide you with the correct ratio)

% DMSO+ % + % Tween 80+ % ddH₂O

Calculate Reset

Calculation results:

Working concentration： mg/ml；

Method for preparing DMSO master liquid: ： mg drug pre-dissolved in μL DMSO (Master liquid concentration mg/mL， Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug. )

Method for preparing in vivo formulation：Take DMSO master liquid, next addμL PEG300， mix and clarify, next addμL Tween 80，mix and clarify, next add μL ddH₂O，mix and clarify.

Note：1.Please make sure the liquid is clear before adding the next solvent.
2.Be sure to add the solvent(s) in order. You must ensure that the solution obtained, in the previous addition, is a clear solution before proceeding to add the next solvent. Physical methods such as vortex, ultrasound or hot water bath can be used to aid dissolving.

Bio Calculators

Molarity Calculator

Calculate the mass, volume or concentration required for a solution. The Selleck molarity calculator is based on the following equation:

Mass (mg) = Concentration (mM) × Volume (mL) × Molecular Weight (g/mol)

*When preparing stock solutions, please always use the batch-specific molecular weight of the product found on the via label and MSDS / COA (available on product pages).

Dilution Calculator

Calculate the dilution required to prepare a stock solution. The Selleck dilution calculator is based on the following equation:

Concentration _(start) x Volume _(start) = Concentration _(final) x Volume _(final)

This equation is commonly abbreviated as: C1V1 = C2V2 ( Input Output )

* When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and MSDS / COA (available online).

The Serial Dilution Calculator Equation

Serial Dilutions
Concertration (start):
Dilution-folds:

Computed Result

C1=C0/X	C1:	LOG(C1):
C2=C1/X	C2:	LOG(C2):
C3=C2/X	C3:	LOG(C3):
C4=C3/X	C4:	LOG(C4):
C5=C4/X	C5:	LOG(C5):
C6=C5/X	C6:	LOG(C6):
C7=C6/X	C7:	LOG(C7):
C8=C7/X	C8:	LOG(C8):

Molecular Weight Calculator

Enter the chemical formula of a compound to calculate its molar mass and elemental composition:

Tip: Chemical formula is case sensitive. C10H16N2O2 c10h16n2o2

Instructions to calculate molar mass (molecular weight) of a chemical compound:

To calculate molar mass of a chemical compound, please enter its chemical formula and click 'Calculate'.

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molecular mass (molecular weight) is the mass of one molecule of a substance and is expressed in the unified atomic mass units (u). (1 u is equal to 1/12 the mass of one atom of carbon-12)
Molar mass (molar weight) is the mass of one mole of a substance and is expressed in g/mol.

Molarity Calculator

Clinical Trial Information (data from https://clinicaltrials.gov, updated on 2020-09-01)

NCT Number	Recruitment	interventions	Conditions	Sponsor/Collaborators	Start Date	Phases
NCT03022565	Withdrawn	Drug: Vorinostat	Uveal Melanoma	University of Miami\|University of Miami Sylvester Comprehensive Cancer Center	January 2020	Early Phase 1
NCT03167437	Recruiting	Drug: Vorinostat	Crohn''s Disease	National Institute of Allergy and Infectious Diseases (NIAID)\|National Institutes of Health Clinical Center (CC)	October 30 2017	Phase 1\|Phase 2
NCT03056495	Recruiting	Drug: N-hydroxy-N''-phenyl-octanediamide (Vorinostat)	Alzheimer Disease	German Center for Neurodegenerative Diseases (DZNE)\|University Hospital Bonn\|University of Göttingen	September 28 2017	Phase 1

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

Frequently Asked Questions

Question 1:
What’s the recommendation about reconstitution of the compound for in vivo animal study?
Answer:
We recommend the following vehicle for S1047: 2% DMSO, 40% PEG 300, 5% Propylene glycol, 1% Tween 80 at 5 mg/mL.

HDAC Signaling Pathway Map

HDAC Inhibitors with Unique Features

Selective HDAC Inhibitor

RGFP966 : HDAC3-selective, IC50=80 nM.
Selective HDAC Inhibitor

Rocilinostat (ACY-1215) : HDAC5-selective, IC50=5 nM.
Most Potent HDAC Inhibitor

Quisinostat (JNJ-26481585) : HDAC1, IC50=0.11 nM; HDAC2, IC50=0.33 nM.
FDA-approved HDAC Inhibitor

Vorinostat (SAHA, MK0683) : Approved by FDA against cutaneous T cell lymphoma.
Newest HDAC Inhibitor

RG2833 (RGFP109) ^New : Brain-penetrant HDAC inhibitor with IC50 of 60 nM and 50 nM for HDAC1 and HDAC3, respectively.

Related HDAC Products

LMK-235 ^New

LMK-235 is a selective inhibitor of HDAC4 and HDAC5 with IC50 of 11.9 nM and 4.2 nM, respectively.
CAY10603 ^New

CAY10603 is a potent and selective HDAC6 inhibitor with IC50 of 2 pM, >200-fold selectivity over other HDACs.
Domatinostat (4SC-202) ^New

4SC-202 is a selective class I HDAC inhibitor with IC50 of 1.20 μM, 1.12 μM, and 0.57 μM for HDAC1, HDAC2, and HDAC3, respectively. Also displays inhibitory activity against Lysine specific demethylase 1 (LSD1). Phase 1.
Panobinostat (LBH589)

Panobinostat (LBH589, NVP-LBH589) is a novel broad-spectrum HDAC inhibitor with IC50 of 5 nM in a cell-free assay. Panobinostat (LBH589) induces autophagy and apoptosis. Panobinostat effectively disrupts HIV latency in vivo. Phase 3.
Entinostat (MS-275)

Entinostat (MS-275, SNDX-275) strongly inhibits HDAC1 and HDAC3 with IC50 of 0.51 μM and 1.7 μM in cell-free assays, compared with HDACs 4, 6, 8, and 10. Entinostat induces autophagy and apoptosis. Phase 3.
Trichostatin A (TSA)

Trichostatin A (TSA) is an HDAC inhibitor with IC50 of ~1.8 nM in cell-free assays.
Romidepsin (FK228, Depsipeptide)

Romidepsin (FK228, depsipeptide) is a potent HDAC1 and HDAC2 inhibitor with IC50 of 36 nM and 47 nM in cell-free assays, respectively. Romidepsin (FK228/depsipeptide) controls growth and induces apoptosis in neuroblastoma tumor cells.

Features:More effective than other classical HDAC inhibitors such as TSA, TPX, and butyrate.
RGFP966

RGFP966 is an HDAC3 inhibitor with IC50 of 0.08 μM in cell-free assay, exhibits > 200-fold selectivity over other HDAC.
Tubastatin A

Tubastatin A is a potent and selective HDAC6 inhibitor with IC50 of 15 nM in a cell-free assay. It is selective against all the other isozymes (1000-fold) except HDAC8 (57-fold). Tubastatin A promotes autophagy and increases apoptosis.
Mocetinostat (MGCD0103)

Mocetinostat (MGCD0103, MG0103) is a potent HDAC inhibitor with most potency for HDAC1 with IC50 of 0.15 μM in a cell-free assay, 2- to 10- fold selectivity against HDAC2, 3, and 11, and no activity to HDAC4, 5, 6, 7, and 8. Mocetinostat (MGCD0103) induces apoptosis and autophagy. Phase 2.

Choose Your Country or Region

By Signaling Pathways

By product type

Vorinostat (SAHA)